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Abstract 
This thesis describes work focused on the use of oxetane rings as isosteres and 
incorporation of this functional group into pharmaceutically relevant scaffolds.   
 
Chapter 1 describes work directed towards the synthesis of 1,5-
dioxaspiro[2.3]hexanes via three different strategies, namely ring-closure to form the 
oxetane ring, Corey epoxidation of the corresponding 3-oxetanones, and epoxidation 
of the corresponding 3-methylene oxetane.  Nucleophilic ring-opening of substituted 
1,5-dioxaspiro[2.3]hexanes to give amino acid type isosteres is also investigated. 
 
Chapter 2 details the synthesis of novel oxetane-containing peptidomimetics.  A 
‘one-pot’ conjugate addition process from commercially available 3-oxetanone to 
give nitro dipeptide precursors in good yields was developed.  Various methods for 
the reduction of the nitro group were explored to optimise the synthesis of the 
corresponding amine.  Amide coupling, followed by deprotection, gave 
peptidomimetics containing the oxetane at the C-terminus and mid-chain in good 
yields over the 3 steps, whilst an N-terminus oxetane peptidomimetic was obtained 
in 45% yield through hydrogenation of the conjugate addition product.  X-ray 
diffraction studies, alongside molecular dynamics simulations, provided structural 
insights into these new oxetane-containing peptidomimetics. 
 
Detailed experimental procedures for the synthesis of all novel compounds are 
described in Chapter 3. 
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1.1 Introduction 
This thesis will describe the efforts made towards the incorporation of oxetane rings 
into pharmaceutically relevant scaffolds, including novel peptidomimetics.  This 
chapter provides an introduction to oxetane rings, detailing both synthetic routes 
towards them as well as their use in medicinal chemistry.  A number of 
comprehensive reviews are available on this topic, hence only relevant illustrative 
examples are included herein.  This background is followed by a discussion of the 
work we have undertaken to develop routes towards spirocyclic scaffolds, such as 1.  
Subsequent reaction of these spirocycles with various nucleophiles are also reported 
(Scheme 1.1). 
 
 
Scheme 1.1.  Proposed nucleophilic ring-opening of spirocycles. 
 
1.1.1 Trimethylene Oxide 
The oxetane moiety has been known for many years but it is only over the past few 
decades that interest in it has grown.  Indeed, Reboul was the first to synthesise the 
simplest oxetane (trimethylene oxide, 4) in 1878 via the route shown in Scheme 
1.2.1-3 
 
 
 
Scheme 1.2.  Reboul’s synthesis of trimethylene oxide.  
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Trimethylene oxide was found to have a less puckered ring compared to the 
analogous cyclobutane (Figure 1.1).3  The puckering in trimethylene oxide is 
believed to be lessened due to the replacement of a methylene group by the oxygen, 
thus reducing unfavourable eclipsing interactions.2,4-5 
 
 
 
 
 
 
 
 
 
Figure 1.1.  Comparison of ring puckering in cyclobutane and trimethylene oxide, figure reproduced 
from Process Chemistry in the Pharmaceutical Industry, Volume 2. 3 
 
1.1.2 Stability of Oxetanes 
The inherent ring strain present in oxetanes increases their susceptibility to ring-
opening reactions.  Indeed, trimethylene oxide readily undergoes acid-catalyzed 
ring-opening reactions in the presence of sulfuric or perchloric acid in aqueous 
dioxane, although base-catalyzed ring-opening occurs much more slowly.3,6  
Recently it has been discovered that 3,3-disubstituted oxetanes have ring strain 
energies (RSE) approximately 14 kJ mol-1 below that of the parent oxetane (RSE 
value of 106.3 kJ mol-1).7  These 3,3-disubstituted oxetanes undergo no reaction with 
lithium aluminium hydride at 0 °C whereas monosubstituted oxetanes are opened 
slowly by the reagent at −78 °C.  Despite this observation, 3,3-disubstituted oxetanes 
are still vulnerable to acid.8 
 
        
Cyclobutane    Trimethylene oxide 
      Ring puckering ~35°              Ring puckering ~11° 
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1.1.3 Uses of Oxetanes 
The oxetane moiety is found in a variety of natural products such as taxol, 
thromboxane A2, oxetanocin and oxetin (Figure 1.2).
3 
 
 
Figure 1.2.  The presence of oxetane in natural products. 
 
The contribution of the oxetane ring to the bioactivity of the natural products, 
however, remains unclear.  For example, the importance of the oxetane ring in taxol 
was investigated through the replacement of the oxetane by the analogous azetidine, 
thietane and selenetane rings, which all resulted in lower bioactivity for the drug.  
However, it has not yet been definitively concluded that the oxetane moiety 
contributes to the drug’s activity.  Nevertheless, computational studies on taxol have 
shown that the oxetane ring contributes to the rigidity of the molecule and can act as 
a hydrogen bond acceptor for a threonine-OH in the supposed binding pocket of the 
drug.3 
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1.1.4 Oxetanes in Drug Discovery 
Oxetanes have traditionally been overlooked in the pharmaceutical industry on 
account of their perceived instability and difficult syntheses.3  However, interest in 
them has grown rapidly over the last few years as new routes and properties have 
been discovered.  Indeed, Carreira and co-workers have hypothesised that the 
oxetane unit can be used as a gem-dimethyl surrogate, a carbonyl bond isostere and 
for modifying the molecular properties of drug molecules, making the oxetane ring 
an attractive prospect in drug discovery.9-11 
 
1.1.5 Oxetanes as Novel Bioisosteres 
Metabolically exposed sites in bioactive drug molecules have conventionally been 
blocked by the introduction of steric blocking groups such as gem-dimethyl units.   
Unfortunately, introduction of this group increases the lipophilicity of the drug 
molecule, adversely affecting its metabolic and pharmacokinetic properties.9  It has 
been proposed that a better alternative would be the introduction of a more 
metabolically robust and less lipophilic small molecular unit, which would not have 
a detrimental effect on the properties of the drug.  Such a unit is the oxetane group, 
which has been found to occupy a similar volume as the gem-dimethyl unit, based on 
calculated Van der Waals volumes.9  Introduction of the oxetane unit imparts 
improved solubility and metabolic stability with reduced lipophilicity to the drug 
candidate.  Hence oxetane can be considered analogous to a gem-dimethyl unit 
(Figure 1.3).8-9,11 
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Figure 1.3.  Oxetane as a gem-dimethyl surrogate.9 
 
As mentioned previously, oxetane rings have also been proposed as bioisosteres for 
carbonyl bonds.  The carbonyl bond is a problematic functional group for use in drug 
discovery due to its susceptibility to enzymatic attack in vivo.8,10-11  Isosteric 
replacement of the carbonyl bond by an oxetane unit could result in a drug candidate 
with a similar bioactivity, but improved stability in vivo.8  Additionally, the oxygen 
lone pairs in a carbonyl bond and a 3,3-disubstituted oxetane have been found to 
occupy the same spatial arrangement (Figure 1.4).  The oxetane ring could 
potentially also be used to improve the fit of a drug in its receptor pocket through its 
increased volume and C...O distance compared to a carbonyl bond.8,10  Furthermore, 
the hydrogen bonding capability of the oxetane moiety is comparable to aliphatic 
carbonyls such as ketones, aldehydes and esters.8,10,12-13  It does, however, remain a 
much weaker hydrogen bond acceptor than amide carbonyl bonds.8   
 
 
Figure 1.4.  Oxetane ring as a carbonyl bond bioisostere.10 
 
   metabolically at risk  metabolic attack   metabolically robust 
 
        nonpolar              polar 
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Another common ploy used in drug development, is to improve the solubility of a 
potential drug molecule through the introduction of a morpholine unit.  However, 
whilst this improves the solubility of the drug, morpholine is known to be 
susceptible to oxidative metabolism.8  It has been proposed that a spirocyclic oxetane 
unit, such as that shown in Figure 1.5, can be considered structurally analogous to 
morpholine, improving the solubility of a drug molecule whilst remaining 
metabolically stable.8,10 
 
 
Figure 1.5.  Spirocyclic oxetanes as potential morpholine replacements.10 
 
One especially desirable property of these spirocyclic analogues is the ability to 
explore and expand the chemical space around morpholine.10  With the development 
of robust synthetic routes to oxetanes that can be readily grafted or incorporated into 
drug molecules, oxetanes are a promising new scaffold in the pharmaceutical 
industry.   
 
1.1.6 Synthesis of Oxetanes 
The most common starting point for the synthesis of oxetane building blocks is 
oxetan-3-one (5), which is commercially available but very expensive.  There are 
two routes primarily used to access oxetan-3-one, one via oxetan-3-ol (6) and the 
other via 2,2-dimethoxyoxetane (7) (Scheme 1.3). 
 
Chapter 1: Towards 1,5-Dioxaspiro[2.3]hexanes 
 
19 
 
Scheme 1.3.  Retrosynthesis of oxetan-3-one. 
 
The synthesis of oxetan-3-one via oxetan-3-ol was achieved in 14% overall yield 
over 5 steps by Kozikowski and Fauq (Scheme 1.4).14 
 
 
Scheme 1.4.  Synthesis of oxetan-3-one via oxetan-3-ol.14 
 
The synthesis of oxetan-3-one via 2,2-dimethoxyoxetane was achieved in 23% 
overall yield using an improved method developed by Carreira and co-workers 
(Scheme 1.5).9  This method was used to synthesise large quantities of oxetan-3-one 
for use as a building block for incorporation into biologically active molecules.9  
However, the scalability of both routes remains problematic owing to the poor 
overall yield and multiple steps. 
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Scheme 1.5.  Preparation of oxetan-3-one from 1,3-dihydroxyacetone dimer.9 
 
Other methods for the synthesis of substituted oxetan-3-ones have been developed, 
including recent work published by Zhang and co-workers.15  These authors utilized 
a gold catalyst for the cyclisation of propargyl alcohol 15 to oxetan-3-one 17 in a 
one-pot method (Scheme 1.6).15  This method allows a wide variety of oxetan-3-ones 
substituted in the 2- and the 4-positions to be readily synthesised. 
 
 
Scheme 1.6.  One-pot gold-catalysed cyclisation of 15 to 17.15 
 
An asymmetric route towards 2-substituted oxetan-3-ones has also been developed 
within our research group.16  Metalation of the SAMP hydrazone of oxetan-3-one, 
followed by alkylation with various electrophiles yields substituted oxetan-3-ones in 
good enantiomeric excesses (Scheme 1.7). 
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Scheme 1.7.  Stereoselective synthesis of 2-substituted oxetan-3-ones.16 
 
More recently, Sharma and Williams have demonstrated the synthesis of a variety of 
mono-, di-, tri- and tetra-substituted oxetan-3-ones from allenes, as shown in Scheme 
1.8.17  Initial formation of the spirodiepoxide from allene 21 using DMDO was 
followed by either halide-induced ring-opening and subsequent base-promoted ring-
closure, or thermal rearrangement to oxetan-3-one 22.  When diastereomers were 
formed, the major diastereomer was dependent on the method employed, thus 
enabling access to either diastereomer preferentially. 
 
 
 
Scheme 1.8.  Formation of substituted oxetan-3-ones from allenes.17 
 
Another synthetic route towards substituted oxetanes is via conversion of one 
hydroxyl group of a 1,3-diol into a better leaving group, followed by ring-closure.  
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One such method, allowing the stereocontrolled synthesis of a substituted oxetane, 
has been reported by Aftab et al (Scheme 1.9).18   
 
 
 
Scheme 1.9.  Ring-closure to form an oxetane ring.18 
 
Vigo et al have recently reported two alternative syntheses for 3,3-disubstituted 
oxetanes via ring-closure.19  Using dibromide 28, they formed 3,3-disubstituted 
oxetane 29 in a good yield, with the opportunity for further functionalities to be 
introduced through displacement of the second halogen (Scheme 1.10). 
 
 
Scheme 1.10.  Synthesis of 3,3-disubstituted oxetanes using Br as leaving group.19  
 
In the second example, these authors reacted 32 with nbutyllithium and p-tosyl 
chloride to form the monotosylate before adding a further equivalent of nbutyllithium 
and heating to promote oxetane ring formation to give 33 (Scheme 1.11). 
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Scheme 1.11.  Synthesis of 3,3-disubstituted oxetanes via monotosylation.19  
 
A similar ring-closure strategy was employed by Fujishima et al20 to access oxetane-
containing analogues of 1,25-dihydroxyvitamin D3 (Scheme 1.12).  These oxetane 
analogues were postulated to have improved binding affinity for the vitamin D 
receptor, based on Carreira and co-workers’ suggestion that oxetane enables deeper 
oxygen placement in receptor pockets.8,10,20 
 
Scheme 1.12.  Synthesis of oxetane-containing 1,25-dihydroxyvitamin D3 analogue, 36.20 
  
1.1.7 Synthesis and Reactions of Spirocyclic Oxetanes 
There has been much interest shown in the synthesis of spirocyclic oxetanes, 
especially those containing 3- and 4-membered rings, as well as the reactivity of 
such systems.21  Indeed, a synthetic route towards 1,5-dioxaspiro[3.2]hexanes (39) 
(Scheme 1.13) has been developed by Ndakala and Howell.22-23  A general synthesis 
for the preparation of 2-methyleneoxetanes had previously been established within 
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the Howell group, allowing access to 1,5-dioxaspiro[3.2]hexanes by epoxidation of 
olefin 38.22-23  On account of the potential instability of 39 in acidic or basic 
conditions, the authors used DMDO as the epoxidation reagent since it can be 
employed under neutral conditions and generates inert byproducts.  Anhydrous 
“acetone free” DMDO was required for successful reactions.23  A range of 1,5-
dioxaspiro[3.2]hexanes substituted at both positions on the oxetane ring were 
successfully synthesised and isolated but the parent system 39 (R = H) was only 
observed by 1H NMR.23 
 
 
Scheme 1.13.  Synthetic route to 1,5-dioxaspiro[3.2]hexanes. 
 
Once a synthetic route to a range of 1,5-dioxaspiro[3.2]hexanes had been 
established, the reactivity of these systems was investigated.  It was discovered that 
subjection of 1,5-dioxaspiro[3.2]hexane 40 to a water/THF mixture without any acid 
present, gave the ring-opened product 41 in a 97% yield (Scheme 1.14).23 
 
 
Scheme 1.14.  Hydrolysis of 1,5-dioxaspiro[3.2]hexanes.23 
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Reactions of 1,5-dioxaspiro[3.2]hexanes with different nucleophiles were then 
investigated.  The ring-opening reactions of 1,5-dioxaspiro[3.2]hexanes can 
theoretically occur at multiple positions in the molecule (Scheme 1.15).24 
 
 
Scheme 1.15.  Potential sites of reaction in 1,5-dioxaspiro[3.2]hexanes.24 
 
Further investigation of the ring-opening revealed that the regioselectivity can be 
controlled through careful selection of both the nucleophile and the reaction 
conditions used.24-25  Neutral and anionic oxygen-, nitrogen- and sulfur-based 
nucleophiles attacked at C-6 to give the expected products, whilst lithium aluminium 
hydride appeared to react at the C-6 position before reducing the resultant β-hydroxy 
ketone.  However, DIBAL, Me3Al and TMSN3 were found to react at C-4 to give the 
unexpected oxetane product 44.24  Further investigations were carried out with a 
variety of nitrogen-containing heteroaromatic nucleophiles and it was concluded that 
the 2,2-disubstituted oxetane 44 was formed preferentially using acidic nucleophiles, 
presumably promoted through coordination of the Lewis acid to the epoxide 
oxygen.24-25  In contrast, neutral and anionic heteroatom nucleophiles appear to react 
preferentially at C-6 to give the open chain product 43.24-25 
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In addition to oxetane/oxirane ring systems, oxetane/aziridine ring systems have also 
been investigated by Hamzik and Brubaker.26  Reaction of oxetan-3-one with 
racemic 45 gave the sulfinimine 46 that was then epoxidised with a sulfur ylide to 
give the spirocycle 47 (Scheme 1.16).  The resultant activity of this spirocycle was 
then explored.26 
 
 
Scheme 1.16.  Synthesis of sulfinyl aziridine oxetane.26 
 
It was discovered that the aziridine ring could be regioselectively opened with 
carbon-, sulfur- and nitrogen-based nucleophiles (Scheme 1.17), which was 
interesting in terms of offering a useful route to 3-aminooxetanes such as 49, 51 and 
53.26  The alternative nucleophilic opening of the oxetane ring was not reported. 
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Scheme 1.17.  The ring-opening reactions of the sulfinyl aziridine oxetane.26 
 
1.1.8 Research Hypothesis and Aims 
Whilst 1,5-dioxaspiro[3.2]hexanes (39) and 5-oxa-1-azaspiro[2.3]hexanes (47) are 
known, 1,5-dioxaspiro[2.3]hexanes such as 1 have not been investigated (Figure 
1.6).  
 
Figure 1.6.  Examples of 1,5-dioxaspiro[3.2]hexanes, 5-oxa-1-azaspiro[2.3]hexanes and 1,5-
dioxaspiro[2.3]hexanes. 
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We felt that such systems would be worthy of investigation.  The opening of the 
epoxide ring of a 1,5-dioxaspiro[2.3]hexane (1) at C-2 with a nitrogen nucleophile 
would generate an amino acid isostere containing an oxetane in place of the carbonyl 
bond (Scheme 1.18).  
 
 
Scheme 1.18.  Proposed reaction of spirocycle 1. 
 
Therefore we decided to investigate routes to spirocycles such as 1, in order to 
explore their ring-opening reactions. 
 
1.2 Results and Discussion 
It was proposed that 1,5-dioxaspiro[2.3]hexane (1) could be synthesised via one of 
the three routes shown in Scheme 1.19, namely ring-closure of 55 with X as a 
leaving group (route a), epoxidation of alkene 56 (route b) or a Corey epoxidation of 
ketone 5 using a sulfur ylide (route c). 
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Scheme 1.19.  Retrosynthesis of 1. 
 
1.2.1 Attempted Synthesis of 1,5-Dioxaspiro[2.3]hexane via Ring-Closure 
The initial route we investigated for the synthesis of spirocycle 1 involved ring-
closure, as detailed in Scheme 1.20. 
 
 
Scheme 1.20.  Proposed route to 1 via ring-closure. 
 
The first task was to synthesise diol 57, which is commercially available but 
expensive, according to literature procedures.27  Initial replacement of the chlorine 
groups of commercially available 3-chloro-2-chloromethyl-1-propene (60) by 
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acetoxy groups was achieved by heating a solution of the starting material, NEt3 and 
glacial acetic acid under reflux overnight (Scheme 1.21).  After addition of 
dichloromethane and an aqueous workup, 61 was obtained in good yields with no 
need for further purification.   
 
 
Scheme 1.21.  Synthesis of 61. 
 
The second step involved the hydrolysis of the acetoxy group to give diol 57.  Using 
K2CO3, NaOH or NaOMe in methanol at rt or reflux failed to give any product, 
forming the monoacetate product preferentially.  However, NaOH in THF/water at rt 
gave diol 57 in ~44% yield (Scheme 1.22).  This yield was further improved when a 
Soxhlet extraction was used rather than an aqueous work-up.  Distillation using a 
Kugelrohr gave 57 in 55% yield.  Alternatively 57 could be taken through to the next 
step without purification. 
 
 
Scheme 1.22.  Hydrolysis of 61 to 57. 
 
Next, we sought to convert one of the hydroxyl groups of 57 into a better leaving 
group by reacting it with p-toluenesulfonyl chloride (Scheme 1.23).  The main 
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challenge with this step was preventing monotosylate 62 from reacting further to 
give ditosylate 63.  Various conditions were investigated, with only p-TsCl (1 
equiv.), NEt3 (1.1 equiv.) and DMAP (0.01 equiv.) in anhydrous CH2Cl2 giving 
monotosylate 62 in ~16% yield as well as ditosylate 63 (17% yield).  All other 
conditions explored gave either no product or predominantly 63.  Having obtained 
monotosylate 62, albeit impure, epoxidation of the double bond was attempted using 
mCPBA.  Unfortunately the desired epoxide could not be isolated. 
 
 
Scheme 1.23.  Attempted monotosylation of 57. 
 
Needing to make more material, we decided to explore an alternative to the difficult 
tosylation step.  We decided to investigate activating one of the hydroxyl groups 
with methanesulfonyl chloride.  Mesylation should proceed faster than tosylation, 
potentially minimising the chance of overreaction.  We also decided to explore 
epoxidation of diol 57 prior to the protection of the hydroxyl group, as this 
compound is reported in literature.  This modified route is shown in Scheme 1.24. 
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Scheme 1.24.  Modified route to 1. 
 
Epoxide 64 was obtained following a literature procedure, using the conditions 
shown in Scheme 1.25.28  Initial yields were poor (23%), probably due to difficulties 
in purifying epoxide 64, but were improved to 67% when the reaction was repeated 
on a larger scale. 
 
 
Scheme 1.25.  Epoxidation to give 64. 
 
With the epoxide in hand, the mesylation was investigated.  Initial attempts using 
MsCl in toluene at 0 C gave both monomesylate 65 and dimesylate 66 in poor 
yields (Scheme 1.26), possibly due to potential product loss when removing the 
toluene.  Changing the reaction solvent from toluene to CH2Cl2, and cooling the 
reaction mixture to 78 C, enabled us to isolate 65 in an improved yield of 29%, 
although a large amount of dimesylate 66 (~32%) was also formed. 
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Scheme 1.26.  Mesylation of 64. 
 
Attempts to form spirocycle 1 from monomesylate 65 using NaH in THF or DMF 
failed to provide the product, possibly due to loss into the aqueous layer in the work-
up or because of the likely volatility of the product itself.  For these reasons, direct 
reaction of the spirocycle with a nucleophile in situ was considered (Scheme 1.27).  
Benzylamine was initially used as the nucleophile but, upon irradiation in the 
microwave at 120 C for 10 minutes, only benzylamine was observed by 1H NMR.  
Dibenzylamine was then used under the same conditions but gave only an insoluble 
white solid and dibenzylamine. 
 
 
Scheme 1.27.  Attempted reaction of 1 with amine nucleophiles in situ. 
 
As dimesylate 66 was easily obtained, we decided to explore the possibility of 
opening the epoxide with water to give 69 which could then form spirocycle 1 
through a double ring-closure, as shown in Scheme 1.28.  However, whilst 69 was 
obtained, it was only in a low yield and therefore this route was not explored further. 
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Scheme 1.28.  Ring-opening of 66 with water. 
 
Owing to the difficulties in isolating 1,5-dioxaspiro[2.3]hexane 1, it was decided that 
it would be better to first establish the synthetic route using a less water-soluble 
spirocycle of higher molecular weight.  Hence, the synthesis of substituted 
spirocycles was investigated. 
 
1.2.2 Synthesis of Substituted 1,5-Dioxaspiro[2.3]hexane via Ring-Closure 
It was reasoned that putting a substituent on the epoxide ring would increase the 
molecular weight of the spirocyclic compound, making it less volatile and therefore 
easier to handle.  The proposed synthetic route to substituted spirocycle 74 is shown 
in Scheme 1.29. 
 
 
Scheme 1.29.  Proposed synthetic route to spirocycle 74. 
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The first step in the sequence involved reduction of the ester groups of commercially 
available diethyl benzylidenemalonate (70) to give diol 71, using a literature method 
(Scheme 1.30).29  The solution of 70 in toluene was cooled to 30 C before DIBAL 
(1 M in toluene) was added dropwise.  Initial attempts at the reaction gave 71 in 28% 
yield, but purification of the product by simple trituration rather than column 
chromatography gave 71 in an improved 61% yield.  The large volume of expensive 
DIBAL made this reaction suboptimal for the large scale synthesis of 71.  However, 
lithium aluminium hydride was ineffective as an alternative reducing agent. 
 
 
Scheme 1.30.  Reduction of the ester groups of 70. 
 
Having established a route to 71, the next step was to epoxidise the alkene bond.  As 
it contained allylic alcohols, use of a directed epoxidation was investigated.30  
Vanadyl acetylacetonate and tert-butyl hydroperoxide were explored for the reaction 
(Scheme 1.31).30-32  Whilst epoxide 72 was obtained, the yield was modest.  
Subsequent attempts to epoxidise the double bond with mCPBA resulted in a much 
improved yield of 73%. 
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Scheme 1.31.  Epoxidation of 71. 
 
Subjection of epoxide 72 to conventional mesylation conditions failed to isolate 
monomesylate 75, so the tosylation of 72 was investigated as an alternative (Scheme 
1.32).  Dibutyl tin oxide was initially explored for the tosylation, using a modified 
literature procedure.33-34  This provided monotosylates 76 and 77 in 28% and 22% 
yield respectively, separated by column chromatography.  Higher yields were 
obtained using nBuLi, following a recently published procedure,35 alongside a small 
amount of ditosylate 78 (11%), although the regioisomers were not separated.  The 
regioisomers showed different chemical shifts and we were therefore able to assign 
them using 1H NOE spectroscopy.  NOEs of both 76 and 77 were obtained.  For 
example, irradiation of the CH2 protons adjacent to the OTs group in 76 gave an 
enhancement of the epoxide CH signal, but no enhancement of the OH.   
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Scheme 1.32.  Two methods towards 76 and 77. 
 
When the reaction was repeated on a large scale, the two regioisomers were not 
separated as both 76 and 77 can potentially form spirocycle 74.  Next, conditions for 
the ring-closure were investigated and the results are shown in Table 1.1.  
Unfortunately, none of the conditions investigated gave 74 in good yield.  NaH in 
DMF at rt gave 74 in 6% yield (entry 1), but attempts to improve upon, or even 
replicate this reaction were unsuccessful.  Using an alternative base such as nBuLi, 
Cs2CO3, TBD or KH (entries 5-9) failed to yield any product.  A mass ion 
corresponding to [2M+Na]+ was observed (entry 10), which initially led us to believe 
spirocycle 74 had been formed.  However, after we had successfully isolated 74, it 
seems more likely that [2M+Na]+ corresponded to a dimer such as 79 (Figure 1.7), 
formed by combination of two molecules of starting material. 
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Figure 1.7.  Dimer resulting from intermolecular reaction of 76/77 with 76/77. 
 
 
 
Entry Base Solvent Conc. (M) Temp Time (h) Product (s) 
 
1 NaH DMF 0.02 0  rt 6 6% 
2 NaH DMF 0.02 0  rt 24 0%a 
3 NaH DMF 0.02 0  rt 50 Traceb 
4 NaH DMF 0.20 0  rt 24 0%a 
5 nBuLi THF 0.02 0  rt 49 Traceb 
6 Cs2CO3 MeCN 0.02 0  rt 60 0%a 
7 Cs2CO3 MeCN 0.02 0  reflux 24 0% 
8 TBD MeCN 0.02 0  rt 60 0% 
9 KH THF 0.02 0  rt 24 0% 
10 NaH DMF 0.11 0  rt o/n 79c 
 
Table 1.1.  Investigation into the ring-closure of 76/77 to form 74.  aMainly SM observed by 1H 
NMR.  bObserved by 1H NMR.  cObserved by ESI-MS. 
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As we were unable to isolate 74 in good yield, we decided to investigate the 
synthesis of spirocycle 84, with the substituent on the oxetane ring.  The proposed 
route via ring-closure is shown in Scheme 1.33. 
 
 
 
Scheme 1.33.  Proposed synthetic route to substituted spirocycle 84. 
 
The first step involved synthesis of 80 via a Baylis-Hillman reaction (Scheme 1.34).  
This was performed according to a literature procedure36 and occurred in good yield, 
despite a long reaction time. 
 
 
 
Scheme 1.34.  Baylis-Hillman reaction to give 80. 
 
Epoxidation of alkene 80 was performed using vanadyl acetylacetonate, as shown in 
Scheme 1.35, which gave (±)-81 in a relatively low yield of 32%.  The 
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stereochemistry of (±)-81 was tentatively assigned through comparison with data 
reported in the literature.37 
 
 
Scheme 1.35.  Epoxidation of 80. 
 
Reduction of the ester group of 81 was attempted using DIBAL in a 2.5-fold excess, 
but this gave mainly starting material.  As this route had low yields and there were 
difficulties reducing the methyl ester, an alternative route was sought. 
 
1.2.3 Synthesis of 1,5-Dioxaspiro[2.3]hexane via Corey Epoxidation 
A recent paper published on the synthesis of substituted oxetan-3-ones using a gold-
catalysed cyclisation provided an interesting alternative route to 1,5-
dioxaspiro[2.3]hexanes.15  The cyclisation of propargyl alcohol (87) to oxetan-3-one 
(5) could be followed by a Corey epoxidation to give 1 (Scheme 1.36). 
 
 
Scheme 1.36.  Gold-catalysed cyclisation followed by Corey epoxidation to 1. 
 
Ye et al investigated a range of gold catalysts, oxidants and acids in order to find the 
optimal conditions for the cyclisation.15  We elected to use catalyst 88, which was 
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accessed using literature methods,38 as shown in Scheme 1.37, as well as N-oxide 89 
and bis(trifluoromethane)sulfonimide as the acid source.  These were not the best 
reagents/catalysts reported by Ye et al, but they were shown by these authors to be 
effective and were more readily accessible. 
 
 
 
Scheme 1.37.  Synthesis of gold catalyst 88. 
 
Having synthesised the catalyst, the cyclisation and subsequent epoxidation in situ 
using a sulfur ylide, according to a literature procedure, was attempted (Scheme 
1.38).39  The reaction mixture was worked-up with diethyl ether, which was then 
removed by distillation.  However, only dichloroethane was observed in the distillate 
by 1H NMR.   
 
Scheme 1.38.  Attempted synthesis of 1. 
 
As attempts to obtain spirocycle 1 using this method were unsuccessful, likely due to 
the volatility and reactivity of the product, we decided to synthesise an oxetan-3-one 
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with a substituent in the 2-position.  We initially tried to synthesise oxetan-3-one 90 
from the commercially available alkyne 91, as reported by Ye et al.15  Unfortunately, 
despite exploring different conditions, we could not synthesise 90 in a good yield 
using our catalyst and N-oxide combination (Table 1.2).  In contrast, Ye et al 
synthesised 90 in 57% yield using 2-bromopyridine N-oxide and (2-
biphenyl)Cy2PAuNTf2.
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.2.  Reaction conditions explored for the formation of 90.  aMainly SM recovered. 
 
An alternative substituted oxetan-3-one was selected and the starting alkyne 93 
synthesised in 56% overall yield according to a literature method (Scheme 1.39).15  
 
 
Scheme 1.39.  Synthesis of substituted alkyne 93. 
 
 
Entry R R1 Acid Yield (%) 
 
1 H Br MsOH 0a 
2 Cl H MsOH ~16 
3 Cl H HNTf2 ~11 
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Cyclisation to 94 was achieved in reasonable yields under gold catalysis (Scheme 
1.40). 
 
 
Scheme 1.40.  Synthesis of 94 via gold-catalysed cyclisation. 
 
Before we explored the epoxidation of 94 using the Corey method, we decided to 
optimise the conditions using ketone 95, as quantities of 94 were limited. 
 
95 was synthesised following a literature method (Scheme 1.41).40  Cyclohexanone 
was added to styrene in the presence of a catalytic amount of potassium tert-
butoxide.  The reaction was performed at 40 C in order to minimise the formation 
of the disubstituted product.40  However, the low yield indicates that these conditions 
are not optimal.  
 
 
Scheme 1.41.  Synthesis of 95. 
 
Nevertheless, sufficient quantities of 95 were produced to explore its epoxidation 
and the results are shown in Table 1.3. 
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Dimethylsulfoxonium methylide, generated from trimethylsulfoxonium iodide, was 
chosen as the ylide source rather than dimethylsulfonium methylide as the latter is 
prone to spontaneous thermal decomposition.39  To begin with, we used a slight 
excess of base, but found this gave the epoxide in a fairly poor yield (Table 1.3, 
entry 1).  As we were concerned that any excess base may react with the epoxide, we 
instead explored the reaction using the sulfur ylide in excess.  This gave a marked 
improvement in yield (entry 2), which was further improved when the equivalents of 
the sulfur ylide were increased (entries 3-4).  Additionally, it was discovered that 
fresh reagents were required for best results.  Only one diastereomer of (±)-98 was 
isolated by column chromatography although it was difficult to determine from the 
crude 1H NMR if small amounts of the other diastereomer had been formed.  The 
stereochemistry is tentatively assigned as (3R*,4R*) based on work done on the 
subsequent oxetane system (p.45). 
 
 
Entrya Ylide (equiv.) NaH (equiv.) Yield (%)b 
1 1.2 1.3 27 
2 1.2 1.1 52 
3 1.6 1.5 61 
4 1.4 1.3 ~77 
 
Table 1.3.  Exploration of the Corey epoxidation of 95.  a0.5 M concentration.  bIsolated single 
diastereomer. 
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With these optimised conditions in hand, the next step was to explore the 
epoxidation of 94 (Scheme 1.42). 
 
 
Scheme 1.42.  The Corey epoxidation of 94. 
 
Dimethylsulfoxonium methylide was generated in the first step, which was then 
reacted with 94.  An aqueous work-up and purification via column chromatography 
gave (±)-99a as predominantly one diastereomer in 24% yield, although a small 
amount of the other diastereomer (~5%) was also isolated.  The stereochemistry of 
(±)-99a was tentatively assigned as (3R*,4R*) on the basis that ylide attack will 
likely arise from the opposite face to the alkyl substituent (Figure 1.8). 
 
 
Figure 1.8.  Nucleophilic attack of the sulfur ylide on 94. 
 
This epoxide slowly opened in the presence of ‘wet’ deuterated chloroform in the 
freezer over a period of 2 months to give (±)-99a and (±)-100 in a 1.9 : 1 ratio 
(Scheme 1.43).  Epoxide (±)-99a was then stirred in MeOH in the presence of an 
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acid catalyst at room temperature for 4 hours.  The crude 1H NMR suggested the 
epoxide ring was opened preferentially, although the reaction did not go to 
completion and (±)-101 was not isolated due to the small quantities involved.  The 
ring strain energies for oxiranes and oxetanes are very similar (26.3 and 24.7 kcal 
mol-1 respectively41), so it was interesting to observe selective opening of the 
epoxide ring. 
 
 
Scheme 1.43.  Ring-opening of (±)-99a. 
 
The formation of (±)-99a proved capricious and even using fresh reagents we were 
unable to improve on the 24% yield (Scheme 1.42).  As the epoxidation of ketone 94 
with a sulfur ylide was unreliable, giving inconsistent results, we decided to explore 
a different route to these spirocycles. 
 
1.2.4 Synthesis of Substituted 1,5-Dioxaspiro[2.3]hexane via Epoxidation 
An alternative route to spirocycle 99 via alkene 102 was proposed, as shown in 
Scheme 1.44. 
 
 
Scheme 1.44.  Alternative route to 99. 
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Initial attempts at Wittig reactions using standard conditions provided 102 in poor 
yields (Scheme 1.45).42-43 
 
 
 
Scheme 1.45.  Wittig reaction on 94. 
 
On account of work done by Dollinger and Howell in which 2-methyleneoxetanes 
were successfully synthesised from β-lactones,22 it was decided to try an alternative 
methylenation approach.  We decided to explore the Petasis reagent as it is milder 
and less acidic than the Tebbe reagent.22 
 
The Petasis reagent (104) was synthesised successfully from commercially available 
titanocene dichloride (103) and methyllithium in a good yield (Scheme 1.46).44  A 
0.5 M solution in toluene was prepared and stored in the dark under nitrogen as 104 
is known to be unstable in the presence of light, especially in its solid form.45 
 
 
Scheme 1.46.  Synthesis of the Petasis reagent, 104. 
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Toluene was used rather than THF as it was reported to be a superior solvent for use 
in the methylenation.22  Optimisation studies for this reaction are shown in Table 1.4.  
This investigation revealed that the best results were obtained using 1.5 equivalents 
of the Petasis reagent and performing the reaction at 75 ˚C (entry 1).22,45-46  Reducing 
the reaction time led to a decrease in yield (entry 2) whilst reducing the equivalents 
led to a slightly lower yield (entries 3 and 4).  Unfortunately, when the reaction was 
repeated on a larger scale (1.3 mmol vs 0.6 mmol) using the optimal conditions 
(entry 1), the yield of the reaction decreased to 17 – 25%.  It is known that the 
Petasis intermediate can react with the product alkene once all of the ketone has been 
consumed, thus decreasing the yield.46  Therefore the yield could potentially be 
improved by adding a sacrificial carbonyl compound, although this was not explored 
in this case.46 
 
 
Entrya Cp2TiMe2 (equiv.) Time (h) Yield (%) 
1 1.5 16 47 
2 1.5 7 30 
3 1.2 14.5 45 
4 1.05 14 45 (+ rec SM) 
5b 1.2 15 4 
 
Table 1.4.  Investigation into optimal conditions for the methylenation of 94.  aReactions performed 
on a 0.6 mmol scale.  bReaction run at 0.1 M rather than 0.5 M. 
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Having synthesised 102, the epoxidation of the double bond was investigated.  
Initially mCPBA was used as the oxidant (Scheme 1.47), despite some concern that 
the ring-opening of the spirocycle could occur in situ, due to the generation of 3-
chlorobenzoic acid during the reaction.  However, epoxidation of 102 using mCPBA 
was very slow, giving both diastereomers, as observed by 1H NMR, and the reaction 
did not go to completion.   
 
 
Scheme 1.47.  Epoxidation of 102 using mCPBA. 
 
When DMDO47 was used (Scheme 1.48), one diastereomer ((±)-99b) was observed 
preferentially, which was the opposite one to that formed via the Corey epoxidation.  
(±)-99a was observed in the crude 1H NMR (ratio (±)-99a : (±)-99b, 0.5 : 1), but was 
not isolated.  We tentatively assign (±)-99b as the (3S*,4R*)-diastereomer, arising 
from concerted epoxidation48 from the face opposite the -CH2CH2Ph group.  
Unfortunately, the yield of the epoxidation was low, possibly due to loss of product 
during purification or further reaction of the product in situ.  Another issue with the 
DMDO epoxidation is that the generation of DMDO usually occurs in poor yields, 
making scale-up of the reaction challenging. 
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Scheme 1.48.  Epoxidation of 102 using DMDO. 
 
(±)-99b, obtained from the DMDO epoxidation, was immediately reacted with 
benzylamine (Scheme 1.49) due to concerns about its stability.  Initial attempts at 
room temperature failed to give any product but, after heating under reflux overnight 
and purification via column chromatography, (±)-105 was obtained in a good yield. 
 
 
Scheme 1.49.  Nucleophilic ring-opening of (±)-99b by benzylamine. 
 
On account of the poor isolated yields of (±)-99b from the DMDO epoxidation, it 
was decided to try the epoxidation using “acetone free” DMDO23,49 followed by an 
in situ ring-opening with benzylamine, without isolating the intermediate epoxide 
(Scheme 1.50).  DMDO was generated as before, but the distillate obtained was 
diluted with water and extracted with CH2Cl2, before the combined organics were 
washed multiple times with 0.1 M phosphate buffer.  Unfortunately, this one-pot 
method failed to yield (±)-105. 
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Scheme 1.50.  DMDO epoxidation of 102 followed by in situ ring-opening with benzylamine. 
 
1.2.5 Synthesis of 1,5-Dioxaspiro[2.3]hexane-2-carboxylic Acid Ethyl Ester 
Next, the synthesis of spirocycle 107, with an ester substituent on the epoxide, via 
the proposed synthetic route shown in Scheme 1.51, was explored, primarily because 
106 is readily accessible.9,15  Specifically, we wanted to ascertain if the presence of 
an electron withdrawing group on the epoxide would influence the regioselectivity or 
reactivity of the resultant spirocycle. 
 
 
Scheme 1.51.  Proposed synthetic route to 107. 
 
Initially, a Wittig reaction between carbethoxymethylene triphenylphosphorane and 
oxetan-3-one was carried out according to a known method,15 giving 106 in 80% 
yield (Scheme 1.52). 
 
 
Scheme 1.52.  Wittig reaction using oxetan-3-one to give 106. 
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Subsequent epoxidation of the double bond, however, proved to be quite difficult, 
owing to its electron deficient nature.  Attempts to epoxidise the double bond with 
DMDO were unsuccessful and returned starting material.  Nucleophilic epoxidation 
procedures using peroxides were then investigated.50-52  Reaction of lithium tert-
butylhydroperoxide with 106 gave spirocycle 107 in 13% yield (Scheme 1.53).  
However, the reaction did not go to completion, even using extended reaction times. 
 
 
Scheme 1.53.  Epoxidation of 106 via lithium tert-butyl hydroperoxide. 
 
Difficulties were also encountered with the ring-opening of 107.  Conditions that had 
been used successfully with spirocycle 99a returned starting material at room 
temperature and, upon heating, transesterification appeared to take place and 108 
could not be isolated (Scheme 1.54). 
 
 
Scheme 1.54.  Attempted ring-opening of 107 with MeOH. 
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1.3 Conclusions 
Initial attempts to synthesise 1,5-dioxaspiro[2.3]hexane 1 were unsuccessful, 
probably due to issues with its volatility, stability and/or water solubility.  However, 
some success was noted with the preparation of substituted derivatives 74, 99a/b and 
107. 
 
Spirocycle 74 was obtained in 4 steps from 70 using a ring-closure method, although 
there were significant problems with low yields and reproducibility of the final ring 
closure. 
 
 
Scheme 1.55.  Synthetic route to 74. 
 
The synthesis of spirocycle (±)-99a was achieved in two steps through the gold-
catalysed cyclisation of alkyne 93, followed by epoxidation using a sulfur ylide 
(Scheme 1.56).  This spirocycle was shown to react readily with nucleophiles, as 
demonstrated by the ring-opening reaction occurring during storage in wet CDCl3. 
  
Chapter 1: Towards 1,5-Dioxaspiro[2.3]hexanes 
 
54 
 
 
Scheme 1.56.  Summary of route to spirocycle (±)-99a. 
 
An alternative route to spirocycle (±)-99b via the alkene was also developed that was 
complementary with respect to stereoselectivity (Scheme 1.57).  Conversion of 
ketone 94 to the corresponding alkene was realised using the Petasis reagent.  
Epoxidation of alkene 102 was then achieved with DMDO and the resultant 
spirocycle reacted successfully with benzylamine to give amine (±)-105.   
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Scheme 1.57.  Alternative route to (±)-99b and subsequent ring-opening. 
 
Spirocycle 107, containing an electron withdrawing group on the epoxide was also 
obtained, albeit in a poor yield (Scheme 1.53).   
 
Of the routes explored, the methodology described in Scheme 1.56 is the most 
attractive, although low yields deterred us from developing this chemistry further.  
Since this study was completed, an asymmetric route to 2-substituted oxetanones has 
been devised in the group (Scheme 1.7).16  Thus it might be feasible to produce 
spirocycles such as 99 as single enantiomers, and this could form the basis for future 
work. 
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2.1 Introduction 
As discussed in Chapter 1, oxetanes have become of increasing interest in medicinal 
chemistry because of their ability to act as isosteres for gem-dimethyl groups and 
carbonyl bonds.  Also of interest to medicinal chemists, are peptidomimetics.  Whilst 
there are examples of biologically active peptides being used as drugs, peptides have 
traditionally been considered to be undesirable drug candidates due to their poor 
bioavailability, susceptibility to proteolysis and rapid excretion from the body.53-57  
Peptidomimetics, however, can be designed to retain the biological activity of a 
peptide whilst having an improved bioavailability and stability, thus making them 
better drug candidates.53-59 
 
We sought to develop routes to short peptide sequences wherein one of the carbonyl 
bonds had been replaced with an oxetane ring, as illustrated in Figure 2.1.  This is 
because the amide bond in peptides is vulnerable to proteolysis and replacement of 
the C=O bond by the isosteric oxetane unit should result in novel peptidomimetics 
with increased stability.  Once a route had been established, the properties of these 
novel peptidomimetics could then be compared and contrasted with the properties of 
a peptide chain such as their preferred conformations, ability to act as receptor 
ligands, and zwitterionic character. 
 
 
 
Figure 2.1.  Peptide chain containing an aminooxetane unit as an amide bond isostere. 
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This chapter begins by introducing the concept of peptidomimetics and then details 
our work directed towards the development of routes to peptide chains containing an 
oxetane as a carbonyl bond replacement.  The structural implications of this 
replacement are also investigated using X-ray diffraction, CD and NMR 
spectroscopy, and molecular modelling. 
 
2.1.1 Introduction to Bioisosteres 
An important part of the drug discovery process is the optimisation of a lead 
molecule that has been identified from a high-throughput screening assay.  Changes 
to the molecule are usually made in order to investigate the properties of the drug 
against its target and to identify any deleterious effects.  These changes often involve 
structural modifications, of which the use of bioisosteres is an important tool.  
Functional groups present in a drug molecule can impart undesirable properties in 
vivo such as toxicity or high rates of metabolism and so the introduction of 
bioisosteres that retain the desirable properties of the original functional group, 
whilst improving the pharmacological profile of the drug can be important.60-61  
Bioisosteres can also be used to help identify the pharmacophore in a drug molecule, 
thus enabling the medicinal chemists to concentrate the optimisation of the lead 
compound on a specific set of structural features.62 
 
In 1919, Langmuir defined isosteres as compounds having the same number of 
atoms as well as the same total number of electrons that can arrange themselves in 
the same manner.63  Subsequent revisions of the definition occurred, including the 
introduction of Grimm’s Hydride Displacement Law in 1925 that states “atoms 
anywhere up to four places in the periodic system before an inert gas change their 
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properties by uniting with one to four hydrogen atoms, in such a manner that the 
resulting combinations behave like pseudoatoms, which are similar to elements in 
the groups one to four places respectively, to their right.”62  This was further built on 
by Erlenmeyer, who classified isosteres as atoms, ions and molecules whose 
outermost layers of electrons are the same.62   
 
In 1951, Friedman expanded on the definition of an isostere and introduced the term 
‘bioisostere’, stating that compounds were considered to be bioisosteric if they “fit 
the broadest definition for isosteres and have the same type of biological activity.”64  
Building on this, Thornber later gave a more flexible definition which stated that 
“bioisosteres are groups or molecules which have chemical and physical similarities 
producing broadly similar biological properties.”65 
 
Today, medicinal chemists have a broad range of bioisosteres at their disposal when 
optimising a lead compound, and these can be divided into two main types, as 
defined by Burger: classical and nonclassical bioisosteres.62,66 
 
2.1.2 Classical and Nonclassical Bioisosteres 
Classical bioisosteres are generally considered to be those that satisfy the definitions 
initially proposed by Langmuir and Grimm67 and are usually subdivided into five 
main categories: 1) monovalent atoms or groups; 2) divalent atoms or groups; 3) 
trivalent atoms or groups; 4) tetrasubstituted atoms; and 5) ring equivalents.60,62,68-69 
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There have been many successful applications of classical bioisosteres in medicinal 
chemistry, but the more general definition for bioisosteres, as developed by 
Friedman and Thornber, allowed the introduction of nonclassical bioisosteres. 
 
Nonclassical bioisosteres do not necessarily have the same number of atoms, or the 
same steric or electronic configurations as the original drug molecule and can be 
broadly divided into two main categories: 1) cyclic vs noncyclic isosteres; and 2) 
exchangeable groups.62,68 
 
2.1.3 Carbonyl Bond Bioisosteres 
Functional groups containing carbonyl bonds are not very common in drug 
discovery, due to the inherent reactivity of the carbonyl bond, especially when found 
in aldehydes and ketones.8  Examples of carbonyl bond bioisosteres are shown in 
Figure 2.2.  More recently, work done by Carreira and co-workers has identified the 
oxetane moiety as a new, nonclassical bioisostere for the carbonyl bond,10 as 
discussed in Chapter 1. 
 
 
 
Figure 2.2.  Common bioisosteres of carbonyl bonds.60 
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2.1.4 Amide Bioisosteres 
Isosteres for the amide functionality are often needed in order to improve the 
bioavailability of a drug molecule and to enhance its stability in vivo.60,62  Whilst the 
amide bond is usually stable to acidic or basic conditions, it is susceptible to 
cleavage under mild conditions by proteases and peptidases.56  Examples of amide 
isosteres are shown in Figure 2.3 and include esters, although these come with their 
own issues as drug candidates, as well as heterocyclic compounds such as 1,2,4-
oxadiazoles and triazoles. 
 
 
Figure 2.3. Amide isosteres.60 
 
The choice of bioisostere for the amide bond depends on the role that the amide 
plays in the biological activity of the drug molecule.  If, for example, the hydrogen 
bond donor and acceptor abilities of the amide are required, then the bioisostere 
needs to be able to mimic these properties in order to elicit the same biological 
response.  If, however, the amide bond merely acts as a spacer between functional 
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groups rather than being essential for the biological activity then a different isostere 
may be appropriate.62 
 
Amide bonds are omnipresent in peptides and applying bioisosteric replacements for 
these bonds led to the development of the field of peptidomimetics. 
 
2.1.5 Peptidomimetics 
There are numerous possible peptides and proteins arising from different 
combinations of the 20 natural amino acids.  However, whilst many show biological 
activity, generally speaking peptides are not suitable for application as drugs.  This is 
primarily because of their susceptibility to proteases in vivo, poor oral 
bioavailability, rapid excretion and undesirable side effects caused by the 
conformationally flexible peptides interacting with receptors other than the target.57  
These issues have led to the development of peptide isosteres, known as 
peptidomimetics.  Peptidomimetics are designed to have improved metabolic 
stability and bioavailability whilst retaining or improving the desired peptide-
receptor interactions and reducing unwanted side effects.54,57  They can be divided 
into three distinct categories: 
 
 Type I (structural) mimetics – these mimic the local topography around 
the amide bond and may utilise amide bond isosteres.  The functionalities 
responsible for the activity remain intact.55,70 
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 Type II (functional) mimetics – these peptidomimetics retain the ability to 
bind to the desired peptide receptor, but do not necessarily resemble the 
structure of the natural peptide.55,70 
 
 Type III (functional-structural) mimetics – these examples contain novel 
scaffolds unrelated to the parent peptide but containing the necessary 
functional groups arranged in the spatial orientation needed in order to 
elicit the same biological response.55,70 
 
2.1.6 Examples of Peptidomimetics 
There are many reviews covering the vast area of peptidomimetics53-57,71 and this 
section simply serves to highlight some relevant examples. 
 
One method for creating peptidomimetics is to modify the amino acid residues 
contained within the chain, either through alterations to the side chain or by altering 
the peptide backbone.  The potential modifications to the amino acid residue are 
numerous and can involve the substitution of the natural amino acid with the 
unnatural D-amino acid, use of β-, γ-, δ-amino acids, or alkylation of the α-C or the 
α-N.57  Some examples of peptide bond isosteres are shown in Figure 2.4. 
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Figure 2.4.  Examples of peptide bond isosteres. 
 
Aza-peptides are an attractive class of peptidomimetics due to the ease with which 
they can be accessed, for example through the acylation of hydrazines.53  
Sulfonamide peptidomimetics are examples of those known as “transition-state” 
isosteres,72 whereby the isostere mimics the intermediate formed during the 
hydrolysis of the amide bond.56  Other examples of these transition-state isosteres are 
phosphinates73 and hydroxyethylamines.74 
 
Simon and co-workers developed a class of peptidomimetics called peptoids75 in 
which the side chain of the amino acid has been moved onto the nitrogen of the 
amide bond (Figure 2.5).53  These peptoids can be synthesised relatively easily using 
solid-phase methods and have increased stability to proteases as well as a greater 
conformational flexibility compared to peptides.  Some peptoids also retain, or even 
exceed, the activity shown by the natural peptides.53,75 
 
Chapter 2: Synthesis of Oxetane-Containing Tripeptide Motifs 
 
65 
 
 
Figure 2.5.  Peptoids vs peptides.75 
 
Cai et al have recently reported the synthesis of ‘AApeptides’, so termed because 
they consist of N-acylated-N-aminoethyl amino acids.76  In these peptidomimetics, 
the nitrogen has been acylated whilst alternate carbonyl bonds have been removed 
from the peptide backbone (Figure 2.6).    
 
 
 
Figure 2.6.  Peptide vs AApeptide.76 
 
The synthesis of these AApeptides involves reaction of the amino ester with Fmoc-
amino ethyl aldehyde, followed by acylation with a carboxylic acid and deprotection 
to give the building block 112 (Scheme 2.1).  Initial investigations into the stability 
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of these peptidomimetics indicate an improved stability to proteolysis and good 
bioactivity.76 
 
 
Scheme 2.1.  Illustrative synthesis of an AApeptide building block.76 
 
Alterations can also be made to the peptide chain to create peptidomimetics that can 
adopt conformations mimicking the structural elements found in natural peptides.  
Hoang et al have reported the ability of cyclic tetrapeptides 113 and 114, shown in 
Figure 2.7, to mimic two of the potential nine distinct α-turn types present in protein 
structures.77 
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Figure 2.7.  Cyclic peptides mimicking α-turn types.77 
 
Vicinal disulfide constrained cyclic peptidomimetics have also been reported by 
Brust et al, synthesised by grafting an active pharmacophore onto the constrained 
cyclised scaffold.78   
 
Secondary structures of peptides, such as turns, can also be recreated by oligomers 
that do not represent traditional peptide scaffolds.  For example, Hamilton and co-
workers have developed oligomers containing aryl linkers that mimic a peptide β-
strand (Figure 2.8).79-80 
 
 
Figure 2.8.  β-strand mimics.79-80 
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The monomer 118 was initially synthesised before repeat nitro reduction and amide 
coupling using HBTU as the coupling reagent, followed by heating in basic 
phosgene solution gave the mimetic 123 (Scheme 2.2).79 
 
 
Scheme 2.2.  Synthetic route towards the β-strand mimetic 123.79 
 
2.1.7 Oxetane-Containing Peptidomimetics 
In 1984, Matsumoto and co-workers81 identified and isolated a new antibiotic from 
Streptomyces sp. OM-2317 that showed activity against Bacillus subtilis and 
Pyricularia oryzae in minimal media, as well as demonstrating a herbicidal effect.  
This antibiotic was oxetin (Figure 2.9) and was the first reported natural product 
containing an oxetane ring that is also a β-amino acid.81-82 
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Figure 2.9.  The antibiotic oxetin. 
 
Like α-amino acids, β-amino acids can form chains (known as β-peptides) that 
contain amide bonds along the backbone, potentially allowing them to form stable 
secondary structures and thereby classifying them as foldamers.83  These β-peptides 
are consequently examples of peptidomimetics and, as such, have potential for 
application in medicinal chemistry.  Indeed, Porter et al demonstrated that a β-
peptide analogue of a known antibiotic had comparable antimicrobial activity to that 
of the natural antibiotic itself.84  Fleet and co-workers have developed a route to 
oxetane β-amino acids as scaffolds for the synthesis of new foldamers that form the 
hexamers 125, 126 and 127 (Figure 2.10).82   
 
 
Figure 2.10.  Hexamers from cis-β-azidoesters.82 
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NMR studies showed that hexamers 125 and 126, which have the same absolute 
configuration at C-2 and C-3 as oxetin, form a left-handed helix stabilised by inter-
residue hydrogen bonds between the amide and carbonyl groups, to form ten-
membered rings.82,85  In contrast, hexamer 127 has the opposite absolute 
configuration at C-2 and C-3 compared to oxetin and forms a right-handed helix.82,85   
 
Johnson et al utilised similar methodology to synthesise dipeptide isosteres of D/L-
alanine-D-serine and glycine-L-serine based on oxetane δ-amino acid scaffolds,86 as 
shown in Schemes 2.3 and 2.4.  L-Rhamnose (128) was converted into 129 through 
sequential reaction with bromine water then benzaldehyde to form the lactone, which 
was then esterified with triflic anhydride and reacted with potassium carbonate in 
methanol to provide 129.82,87  Once 129 had been obtained, various conditions were 
employed to introduce the azide functionality, either with retention of configuration 
at C-5 to give 132 and 133 as conformationally restricted mimetics of L-Ala-D-Ser, 
or with inversion of configuration to give 130 and 131 as mimetics of D-Ala-D-Ser 
(Scheme 2.3).86 
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Scheme 2.3.  Synthetic strategy for D/L-alanine-D-serine dipeptide isosteres derived from L-
rhamnose.86 
 
A similar strategy was employed to access 134 from D-xylose (Scheme 2.4).  
Bromination of 134 allows the introduction of the azide functionality to give 136.  
Hydrolysis of the benzoate ester of 136 with NaOH also removed the methyl ester, 
which was readily reinstated using methanol and hydrochloric acid.  
Transesterification of 137 to the isopropyl ester was required to prevent in situ 
oligomerisation after reduction of the azide to the amine.  Formation of triflate 139, 
followed by SN2 displacement gave 140, which can be considered to be a 
conformationally restricted mimetic of Gly-L-Ser. 
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Scheme 2.4.  Synthetic strategy for glycine-L-serine dipeptide isosteres derived from D-xylose.86 
 
This methodology allowed the synthesis of cis- and trans-oxetane δ-amino acids of 
the type shown in Figure 2.11 to be realised.  Interestingly, 1H NMR and IR 
experiments showed that oligomers (dimers, tetramers and hexamers) of δ-2,4-trans-
oxetane amino acids such as 143, 144 and 145 displayed no regular secondary 
structure in solution whilst the oligomers of 141 and 142 showed ordered 
conformations, primarily due to the steric bulk of the TBDMS group.88  Tetramers 
and hexamers of δ-2,4-cis-oxetane amino acid 146, on the other hand, had defined 
secondary structures in solution due to the formation of 10-membered rings through 
intramolecular hydrogen bonds.89   
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Figure 2.11.  δ-cis- and δ-trans-oxetane amino acids.89 
 
2.1.8 Oxetane Replacement of Carbonyl Bonds in Drug Molecules 
The effect that the presence of the oxetane ring has on the activity of known drug 
molecules has been investigated.  Burkhard et al synthesised an oxetane-containing 
analogue of the known drug thalidomide, as well as an analogue of the closely 
related lenalidomide, which is being investigated for the treatment of various cancers 
(Schemes 2.5 and 2.6).90 
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Scheme 2.5.  Synthesis of oxetane-containing thalidomide analogue, 151.90 
 
 
 
Scheme 2.6.  Synthesis of oxetane-containing lenalidomide analogue, 156.90 
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The authors discovered that the introduction of the oxetane as a replacement for one 
of the carbonyl bonds resulted in little change in the physicochemical and in vitro 
metabolic profiles of the compounds.  However, oxetane thalidomide is much more 
stable than thalidomide itself in human plasma.90 
 
2.1.9 Research Hypothesis and Aims 
These results lend credence to the idea that an oxetane-containing peptidomimetic 
could potentially form defined secondary structures in solution, retain the bioactivity 
of the analogous parent peptide, and be more stable.   
 
2.2 Results and Discussion 
A route towards the synthesis of a peptidomimetic containing an oxetane ring as a 
replacement for the carbonyl bond in the middle of a tripeptide chain was initially 
proposed (Scheme 2.7). 
 
 
Scheme 2.7.  Proposed synthetic route towards oxetane-containing peptidomimetics.  
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This was inspired by work by Carreira and co-workers, who demonstrated that 
oxetane-containing Michael acceptors, 162 and 164, are readily accessible from 
commercially available 3-oxetanone.9,91  Moreover, Burkhard et al demonstrated the 
ease with which 164 reacts with benzylamine (Scheme 2.8),91 suggesting that 
conjugate addition to form 159 should be facile. 
 
 
 Scheme 2.8.  The synthesis and reactions of 162 and 164.9,91  
 
Whilst this synthetic route appeared promising, several questions would need to be 
addressed in order to develop a general route to oxetane-containing peptidomimetics.  
What substituents and protecting groups can be tolerated in the sequence?  Can the 
conjugate addition to 157 be achieved with stereocontrol when R ≠ H?  Can the 
reduction of the nitro group be achieved with control?  Can further coupling (160 → 
161) be achieved without protection of the secondary amine?  What protecting 
groups are optimal in this sequence? 
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Initially, we elected to focus on the synthesis of peptidomimetics containing oxetane 
mimetics of glycine and phenylalanine, as 162 and 164 were known and readily 
accessible. 
 
2.2.1 Conjugate Additions to ‘Phe’ via a Two-Step Method 
As we perceived 164 to be easier to handle than 162, we decided to explore the 
synthesis of mimetics containing an oxetane ‘Phe’ residue first since this would also 
allow us to investigate the potential for a stereoselective conjugate addition to 164. 
 
Whilst our initial target was to develop a route towards pseudo-tripeptides containing 
an oxetane instead of a carbonyl bond in the mid-chain position, the potential for 
incorporation of the oxetane at the N- or C-terminus was also of interest.  During the 
synthesis of 164, 166 is formed as an intermediate, which could be used as a 
precursor for the synthesis of a peptidomimetic containing an oxetane at the C-
terminus.  Therefore, nitroalkane 163 was reacted with 3-oxetanone in the presence 
of catalytic NEt3 according to a literature procedure,
91 to give 166 in excellent yield 
after purification by column chromatography (Scheme 2.9).  To our knowledge, this 
intermediate has not been isolated previously. 
 
 
Scheme 2.9.  Henry addition of 163 to 3-oxetanone to give 166. 
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To obtain nitroalkene 164, the Henry addition was repeated using 3-oxetanone and 
nitroalkane 163, followed by mesylation and elimination of the resulting mesylate, 
according to the method reported by Burkhard et al (Scheme 2.10).91  Nitroalkene 
164 was obtained in a similar yield to that reported and the rearranged product, 167, 
was also observed.91   
 
 
Scheme 2.10.  Synthesis of 164. 
 
Isoxazole 167 is formed through deprotonation of the oxetane ring of 164, leading to 
the rearrangement shown in Scheme 2.11, which is promoted by secondary or 
tertiary amines.91  Unfortunately 167 cannot be completely removed from 164 using 
column chromatography. 
 
 
Scheme 2.11. Rearrangement of 164 to form isoxazole 167.91 
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Having obtained 164 in reasonable yield, the next step was to explore the conjugate 
addition with commercially available amino esters, which are generally sold as their 
hydrochloride or p-toluenesulfonate salts.  Glycine methyl ester hydrochloride was 
investigated initially, due to the lack of steric hindrance.  On account of the 
propensity of 168 to polymerise, it was used in the conjugate addition immediately 
after it had been free based according to literature methods (Scheme 2.12).92-93  168 
was used in a 2-fold excess to compensate for loss due to polymerisation in situ and 
reacted smoothly with 164 at rt in THF to give 169 in 88% yield.  Formation of 169 
was indicated by the appearance of a proton at 5.12 ppm in the 1H NMR, which was 
found to be adjacent to the benzyl group based on 2-D NMR experiments. 
 
 
Scheme 2.12.  Conjugate addition of 168 to 164. 
 
We were also interested in exploring the conjugate addition of a dipeptide ester such 
as 172 to give a tripeptide precursor containing an oxetane at the N-terminus 
(Scheme 2.13).  Reaction of N-Z-glycine (170) with 168 using standard amide 
coupling conditions gave protected dipeptide ester 171 in which the N-protecting 
group could be selectively removed by hydrogenation.  The moderate yield for the 
synthesis of 171 could be attributed to polymerisation of 168 in the reaction mixture. 
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Dipeptide ester 171 was hydrogenated in THF, then filtered through Celite® before 
the filtrate was added immediately to a solution of 164 in THF.  The reaction was 
stirred at rt for 11.5 days and followed by TLC.  However, after work-up, the crude 
1H NMR showed 173 and unreacted 164 in a 1 : 2 ratio despite the dipeptide ester 
being used in a 2.5-fold excess.  Purification by column chromatography gave 173 in 
23% yield.  The presence of unreacted starting material suggested that 172 had 
potentially cyclised in situ before it could react with 164, a known issue with 
dipeptide esters, particularly those containing glycine residues.94 
 
 
Scheme 2.13.  Conjugate addition of dipeptide ester 172 to 164. 
 
In order to prevent the possible cyclisation of 172, we decided to use a bulkier ester 
protecting group, in this case the tert-butyl ester as they are known to be more stable 
to cyclisation due to the steric bulk inhibiting nucleophilic attack.95 
 
Dipeptide ester 175 was synthesised using the same amide coupling conditions in a 
much higher yield (Scheme 2.14).  Deprotection, followed by conjugate addition 
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afforded 177 in 28% yield.  However, a large proportion of the starting material was 
recovered, possibly due to cyclisation of the dipeptide ester still occurring. 
 
 
Scheme 2.14.  Conjugate addition of dipeptide ester 176 to 164. 
 
Whilst using a tert-butyl ester rather than a methyl ester did not significantly 
improve the yields for the conjugate addition, we hypothesised that a tert-butyl ester 
may prove beneficial when reducing the nitro group of peptidomimetic precursors 
such as 159, on account of the propensity of dipeptides to undergo cyclisation.96-97 
 
Therefore we investigated the conjugate addition of glycine tert-butyl ester to 164 
and found the reaction proceeded smoothly to give 178 in 88% yield (Scheme 2.15). 
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Scheme 2.15.  Conjugate addition of 174 to 164. 
 
Having demonstrated that the conjugate addition occurred readily, albeit in varying 
yields, with unsubstituted amino and dipeptide esters, we wanted to explore the 
reaction using an amino ester containing a substituent on the α-carbon.  We elected 
to investigate L-valine methyl ester, since it is a branched-chain amino ester and 
would provide a good indication of whether steric hindrance might slow the 
conjugate addition.  Additionally, it would also allow us to probe if a chiral amino 
ester might influence the diastereoselectivity of the conjugate addition.  Immediately 
before the conjugate addition, L-valine methyl ester hydrochloride was free based92 
and reacted with 164.   
 
The reaction of L-Val-OMe and 164 in THF at rt was followed by TLC and, after no 
reaction was observed, the reaction mixture was heated under reflux (Table 2.1, 
entry 1).  The crude 1H NMR showed both diastereomers 180a/180b, as well as 
starting material 164 and isoxazole 167.  Observation of 167 suggested that the 
rearrangement of 164 can occur with primary amines under more forcing conditions 
such as heating.  Alternative solvents were then investigated.  Using methanol, a 
mixture of products were formed, including isoxazole 167 as well as the product 
resulting from conjugate addition of methanol to 164, as indicated by ESI-MS (entry 
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2).  When DMSO was used as the solvent, and the reaction was heated at 85 C, only 
isoxazole 167 was observed (entry 3).  Finally it was discovered that the reaction 
proceeded well in THF at rt, but required a longer reaction time than for glycine 
methyl ester (entry 4).  Unfortunately the two diastereomers 180a and 180b were 
inseparable by column chromatography and were isolated in near equal quantities 
(55 : 45). 
 
 
 
Entry 
 
Reaction Conditions 
 
Product(s) 
 
1 
 
THF, rt  reflux, 72 h 
 
164, 167, 180a/180ba 
2 MeOH, rt  reflux, 51 h 167 and unknown productsa 
3 DMSO, rt  85 C, 120 h 167a 
4 THF, rt, 64 h 180a/180b (80%)b 
 
Table 2.1.  Optimisation of the conjugate addition of L-valine methyl ester to 164.  aObserved in 
crude 1H NMR.  bIsolated as a 55 : 45 mixture, as determined by 1H NMR. 
 
Based on these results, we had established that the conjugate addition occurred 
readily with substituents on the nitroalkene and/or the amino ester α-carbon.  
However, poor diastereoselectivity was observed in the addition to 164.  Next, we 
were interested in investigating if stereocontrol could be achieved in the conjugate 
addition using a chiral catalyst. 
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2.2.1.1   Control of Stereoselectivity in Conjugate Addition 
It was hypothesised that the diastereoselectivity of the conjugate addition could be 
improved by addition of a chiral catalyst during the reaction.  There are few reported 
examples of asymmetric aza-Michael additions to nitroalkenes98-99 and of these, the 
majority involve the use of an enantiopure nucleophile to control the selectivity of 
the reaction, rather than a chiral catalyst.  For example, Enders and Wiedemann 
developed a route towards the diastereo- and enantioselective synthesis of protected 
vicinal diamines, by addition of ADMP, as a chiral equivalent of ammonia, to 
various nitroalkenes (Scheme 2.16).100 
 
 
Scheme 2.16.  Diastereo- and enantioselective route towards protected vicinal diamines.100 
 
Similarly, Lucet et al added (R)- or (S)-4-phenyl-2-oxazolidinone (186) to 
monosubstituted nitroalkenes in the presence of 18-crown-6 and potassium t-
butoxide to give a single diastereomer of the conjugate product that could then be 
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reacted further as required (Scheme 2.17).101  Indeed, Mioskowski and co-workers 
expanded on this chemistry to develop routes towards the synthesis of various α,α-
disubstituted amines.102 
 
 
Scheme 2.17.  Diastereoselective aza-Michael reaction of Lucet et al.101 
 
However, examples of asymmetric organocatalytic aza-Michael additions involving 
nitroalkenes had not been established until Wang et al’s work in 2006, which 
demonstrated the reaction using N-heterocycles as nucleophiles.103  Whilst examples 
of asymmetric organocatalytic aza-Michael additions are still relatively rare, a 
method published by Lykke et al99 interested us because of its potential applicability 
to this project.  Using benzophenone imine (189) as an ammonia equivalent, the 
authors added it to a range of nitroalkenes in the presence of various chiral catalysts.  
They found that thiourea-based catalysts, used to activate nitroalkenes towards 
nucleophilic attack, gave the most promising results.99,104  Optimal results were 
obtained when 10 mol% of 190 was used in n-heptane at 24 C.99  Application of 
these conditions enabled the isolation of β-amino nitro compounds as their 
hydrochloride salts in good yields and enantioselectivities (Scheme 2.18).99 
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Scheme 2.18.  Organocatalysed aza-Michael addition to nitroalkenes.99 
 
Based on their investigations, we decided to explore their optimised conditions for 
the conjugate addition of L-valine methyl ester to 164, as changes in 
diastereoselectivity would be readily observed by 1H NMR.  Entry 1 in Table 2.2 
was performed according to the optimal conditions developed by Lykke et al99 and 
showed a preference for the opposite diastereomer to that observed under the 
standard conjugate addition conditions.  As the conjugate additions were 
traditionally performed with an excess of L-valine methyl ester rather than an excess 
of nitroalkene 164, we decided to explore the catalysed reaction using a 1 : 2 ratio of 
164 : 179.  The control reaction (entry 7), performed in the absence of any catalyst, 
showed that the solvent choice, and/or the temperature, has some effect on the ratio 
of the diastereomers, increasing the selectivity for 180a over 180b compared to the 
reaction in THF at rt.  In the presence of catalyst 190, the ratios of the diastereomers 
did change, decreasing the selectivity for 180a compared to 180b.  However, the 
results were rather inconsistent (entries 2 vs 3, entries 4 vs 5), which could be in part 
due to issues of solubility in n-heptane.  When the reaction was performed in toluene 
(entry 6), there were no solubility issues and the amount of the minor diastereomer 
increased, although there was still very little diastereoselectivity. 
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Table 2.2.  Investigation into the diastereoselectivity of the addition of 179 to 164.  aReaction 
repeated under the same conditions.  bReaction repeated under the same conditions. 
 
These results suggest that an organocatalyst can influence the diastereoselectivity of 
the conjugate addition, however, there is much to be done to optimise this process. 
 
Due to the acidic nature of the proton on the carbon adjacent to the nitro group, we 
decided to explore whether the ratio of the diastereomers is changed by equilibration 
Entry 
 
Ratio of 
164 : 179 
 
Catalyst 
Loading 
Solvent 
 
Ratio of 
diastereomers 
Conversion 
 
1 2 : 1 10 mol% Heptane 0.68 : 1 ~99% 
2a 1 : 2 10 mol% Heptane 0.76 : 1 >99% 
3a 1 : 2 10 mol% Heptane 1.15 : 1 >99% 
4b 1 : 2 20 mol% Heptane 1.08 : 1 86% 
5b 1 : 2 20 mol% Heptane 0.98 : 1 ~94% 
6 1 : 2 10 mol% Toluene 1.06 : 1 >99% 
7 1 : 2 N/A Heptane 1.43 : 1 98% 
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via deprotonation/protonation (Scheme 2.19).  Reaction of 180a/b (180a : 180b, 1 : 
2.5) with NaOMe led to the consumption of the starting material and the formation 
of unknown products alongside 164.  However, using a milder base such as DBU, 
the diastereoselectivity did change (1 : 2.5 → 1.6 : 1), although elimination of L-
valine methyl ester from 180a/b to give 164 (19%) was also observed. 
 
 
Scheme 2.19.  Deprotonation of 180a/b to alter the diastereomeric ratio. 
 
Based on these early investigations, it is possible to affect the stereoselectivity of the 
conjugate addition to nitroalkene 164, but the optimal conditions have not yet been 
found.  Similarly, the diastereomeric ratio can be altered by deprotonation with a 
weak base, but there is a competing elimination reaction.  Lack of stereocontrol in 
this conjugate addition led us to turn our attention to the reactions of unsubstituted 
nitroalkene 162. 
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2.2.2   Conjugate Additions to ‘Gly’ via a Two-Step Method 
We were interested in developing a route towards peptidomimetics containing an 
oxetane ‘Gly’ residue as this would allow us to establish the methodology without 
the need to address the issue of stereocontrol in the conjugate addition. 
 
Nitroalkene 162 was prepared according to the literature procedure9 (Scheme 2.20).  
However, 162 was isolated in a much lower yield than reported, probably due to its 
volatility and difficulties identified in purifying it. 
 
 
Scheme 2.20.  Synthesis of 162. 
 
162 was taken through and reacted with both L-valine methyl ester and glycine tert-
butyl ester.  The amino esters were free based from their hydrochloride salts as 
described previously then immediately reacted with 162 to give 192 and 193 in good 
yields (Scheme 2.21). 
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Scheme 2.21.  Conjugate addition of 174 and 179 to 162. 
 
Whilst the conjugate additions to 162 occurred in good yields, the difficulties 
encountered in obtaining 162 cleanly led to a poor yield over the 2 steps.  Therefore 
an alternative method of obtaining the addition products was sought. 
 
2.2.3 Conjugate Additions via a One-Pot Method 
The limiting step in the synthesis of the nitro amino esters, was the formation of 
Michael acceptors 162 and 164.  On the basis that these compounds were formed in 
low yields because of their volatility and/or susceptibility to rearrangement, we 
decided to investigate the potential for generating them in situ.  Our initial reaction 
conditions involved using the nitroalkene as the limiting reagent and the results are 
shown in Table 2.3.  Encouragingly, (S)-193 was formed in a higher yield of 47% 
compared to the 22% overall yield achieved with the two step method (entry 1).  
High yields were also obtained with L-valine benzyl ester (entry 2, 83%) and L-
phenylalanine benzyl ester (entry 3, 73%), whilst moderate to good yields were 
obtained with other amino esters.  Good yields were also obtained for 199 and 200, 
which suggests that reacting 164 in situ may help prevent the rearrangement to 
isoxazole 167. 
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Entrya,b R Amino ester salt Product Yield (%) 
1 H H-L-Val-OMe.HCl 
 
(S)-193 
47 
2 H H-L-Val-OBn.TsOH 
194 
83 
3 H H-L-Phe-OBn.HCl 
195 
73 
4 H H-L-Ser-OMe.HCl 
 196 
48 
5 H H-Gly-OiPr.HCl 
 
197 
61 
6 H H-Gly-OBn.TsOH 
198 
64 
7 Bn H-Gly-OBn.TsOH 
199 
58 
8 Bn 
H-Gly-Gly-
OBn.TsOH 
 
64 
 
Table 2.3.  One-pot reactions to form nitro amino esters.  aMethod for entries 1-6: CH3NO2 (1 eq), 3-
oxetanone (1.3 eq), NEt3 (0.2 eq), 30 min; NEt3 (2 eq), MsCl (1 eq) 30 – 40 min; amino ester salt (2 
eq), NEt3 (2 eq), 16 – 25 h.  bMethod for entries 7-8: BnCH2NO2 (1 eq), 3-oxetanone (1.3 eq), NEt3 
(0.2 eq), 90 min; NEt3 (2 eq), MsCl (1 eq), 90 min; amino ester salt (2.2 eq), NEt3 (2 eq), o/n. 
200 
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Whilst the yields were generally good, close-running impurities were often formed 
that were difficult to remove by column chromatography.  It was postulated that one 
of these impurities could have been 202, resulting from the reaction of the amino 
ester anion 201 with excess 3-oxetanone (Scheme 2.22), due to the presence of extra 
peaks in the oxetane region of the 1H NMR. 
 
 
Scheme 2.22.  Potential over-reaction of 201. 
 
In order to minimise this possible side reaction, we investigated the one-pot reaction 
using 3-oxetanone as the limiting reagent.  The results are shown in Table 2.4.  With 
3-oxetanone as the limiting reagent, the yield for (S)-193 increased from 47% to 65% 
(entry 1) and the reaction conditions gave the products from a range of amino and 
dipeptide esters in generally good yields.  The synthesis of (S)-193 using reduced 
equivalents of the amino ester (entry 2), gave (S)-193 in a lower yield of 40%.  
Therefore the amino ester was used in a 2-fold excess in all subsequent additions. 
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Entrya Amino ester salt Product Yield (%) 
1 H-L-Val-OMe.HCl 
 
 (S)-193 
65 
2 H-L-Val-OMe.HCl 
 
 (S)-193 
40b 
3 H-D-Val-OMe.HCl 
 (R)-193 
68 
4 H-L-Leu-OBn.TsOH 
 203 
59 
5 H-L-Ile-OBn.TsOH 
 204 
52 
6 H-L-Thr-OBn.HCl 
 205 
56 
7 H-Gly-Gly-OBn.TsOH 
  
57 
8 H-L-Val-Gly-OBn.HCl 
 
62 
 
Table 2.4.  One-pot reactions to form nitro amino esters using 3-oxetanone as the limiting reagent.  
aMethod: CH3NO2 (1.4 eq), 3-oxetanone (1 eq), NEt3 (0.2 eq), 30 min; NEt3 (2 eq), MsCl (1 eq) 40 – 
120 min; amino ester salt (2 eq), NEt3 (2 eq), 20 h.  bMethod as above with 1.2 eq of L-Val-OMe.   
206 
207 
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A variety of amino esters, including polar and hydrophobic examples, have been 
successfully used in these one-pot reactions, as well as dipeptide esters, which 
provide easy access to longer chain oxetane-containing peptidomimetics.  
Importantly, chiral HPLC analysis of (R)-193 and (S)-193 (synthesised from D- and 
L-valine methyl ester respectively), indicated that no detectable racemisation 
occurred during the conjugate additions (Appendix I).  Thus this methodology 
appears promising for the synthesis of enantiopure peptidomimetics. 
 
Having developed a reliable method for the synthesis of nitro peptide precursors in 
good yields, with the reaction conditions tolerated by a range of substituents and 
protecting groups, we next focused our attention on progressing the synthesis of the 
target peptidomimetics by reduction of the nitro group. 
  
2.2.4 Reduction of the Nitro Group 
Whilst there is much literature precedent for the reduction of aromatic nitro groups 
to the corresponding amine, the reduction of nitroalkanes is generally more 
challenging. 
 
We initially chose to explore the reduction of 169 to discover if the methyl ester 
would be susceptible to cyclisation, or if the presence of the oxetane and the benzyl 
group would inhibit this potential side reaction.  Initial attempts to reduce the nitro 
group using hydrogenation or transfer hydrogenation failed to yield amine 208.9,105  
Reduction of the nitro group with samarium(II) iodide (Scheme 2.23) gave only the 
cyclised oxetane-containing diketopiperazine (209), whose structure was confirmed 
by X-ray crystallography (Figure 2.12). 
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Scheme 2.23.  Reduction of the nitro group of 169. 
 
Figure 2.12. Crystal structure of 209. 
 
As feared, these results indicated that the methyl ester is susceptible to the 
cyclisation.97  Oxetane-containing diketopiperazine 209, however, was itself of 
interest as diketopiperazines are often regarded as peptidomimetics and are also 
present in various natural products.96,106  Therefore, we decided to try to optimise 
this cyclisation.  
 
Generally, acidic conditions promoted the cyclisation, even in the presence of 
bulkier protecting groups such as benzyl esters.  Indeed, diketopiperazine synthesis 
often involves heating in acidic medium.96,106  Even in the absence of acid, the 
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cyclisation still occurs to give 210 in a reasonable yield under standard 
hydrogenation conditions (Table 2.5, entry 1).  Interestingly, the reduction and in 
situ cyclisation of 194 (entry 2) did not go to completion despite longer reaction 
times being investigated and the amine was observed in the crude 1H NMR, along 
with 210 (2 : 1 amine : 210).  In this example, the isopropyl substituent did not 
prevent nucleophilic attack onto the methyl ester.  It is believed that the 
unsubstituted example, 198, (entry 5) most likely cyclised but the resultant product 
was not isolated on account of its potential water solubility. 
 
 
Entry Substrate R R1 R2 Methoda Product(s) 
1 (S)-193 H iPr Me B, 17 h 210 (45%) 
2 194 H iPr Bn A, 67 h 210 (22%) 
3 195 H Bn Bn A, 67 h 211 (68%) 
4 196 H CH2OH Me A, 72 h
 0%b 
5 198 H H Bn A, 67 h 0%b 
6 199 Bn H Bn A, 24 h 209 (35%) 
 
Table 2.5.  Optimisation of the cyclisation.  aMethod A: Zn (35 eq), AcOH, THF, rt;107 Method B: 
Pd/C (50% by wt), H2, MeOH, rt.  b1H NMR of crude product was inconclusive.   
 
Our results indicate that both the choice of ester protecting group and the amino ester 
itself can affect the efficiency of the cyclisation.  Heating the reaction in acid may 
encourage complete conversion to the cyclised product.   
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Investigations into the reduction of the nitro group indicated that whilst the 
corresponding amines can be obtained, there is a strong propensity for cyclisation to 
the diketopiperazine-like structure.  The extent of this cyclisation is dependent on the 
nature of the ester group, α-carbon substituents and reaction conditions.  Zn in AcOH 
generally promoted cyclisation with various α-carbon substituents, even when a 
benzyl ester was used, and heating the reaction may result in full conversion to the 
cyclised product.  Hydrogenation when the ester was a methyl group also gave the 
cyclised product despite the isopropyl substituent on the α-carbon.  To minimise loss 
of the amine through cyclisation, we decided to investigate the reduction of the nitro 
group, followed by immediate coupling to the next amino acid (Scheme 2.7, p.75). 
 
2.2.5 Nitro Reduction and Amide Couplings 
Efforts focused on the reduction and subsequent coupling of compounds with either 
a substituent on the α-carbon of the amino ester, a bulky ester group, or both. 
 
2.2.5.1 Synthesis of Protected Mid-Chain Peptidomimetics 
Reduction of 180a/b, as a 55 : 45 mixture of diastereomers, with samarium(II) iodide 
in MeOH gave the corresponding amine (212), which was coupled with N-Z-glycine, 
using DCC as the coupling reagent, to give a mixture of 213a and 213b in 71% 
yield.  These were subsequently separated by chiral HPLC to give one diastereomer 
in 26% isolated yield and the other diastereomer in 19% isolated yield, although the 
relative stereochemistry of each diastereomer was not determined.   
 
Chapter 2: Synthesis of Oxetane-Containing Tripeptide Motifs 
 
98 
 
Scheme 2.24.  Reduction and coupling of 180a/b. 
 
As the samarium(II) iodide reduction and in situ DCC coupling had been successful 
with 180a/b, we decided to examine these conditions with a range of nitro 
compounds, the results of which are shown in Table 2.6.  When a tert-butyl ester was 
used, amide 214 was isolated in 50% yield (entry 1).  This was promising as, 
traditionally, the presence of glycine residues facilitates diketopiperazine formation 
due to the lack of an obstructive side chain.97  Attempts to improve this yield using 
EDC as the coupling reagent instead of DCC gave 214 in 35% yield (entry 2).  
Unsurprisingly, the reduction of 197, containing two glycine residues, yielded no 
amide product, despite the presence of the isopropyl ester group (entry 3).  
Interestingly, the reduction of 195 gave only diketopiperazine 211 (entry 4).  Benzyl 
esters are generally believed to be less reactive to cyclisation than other esters, based 
on a study using H-Gly-Gly-OR.97  The reduction of (S)-193 on the other hand, gave 
215 in ~17% yield containing the cyclised product 210 as well (entry 5).  This 
indicates that a benzyl ester, in conjunction with a branched substituent on the α-
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carbon of the amino ester, enables some of the intermediate amine to react before it 
cyclises.  Similarly, the reduction of 194 allowed the isolation of 216 containing 
trace cyclised product (entry 6).  These results implied that the choice of ester group 
may not be as important as the α-carbon substituent with respect to suppressing the 
cyclisation.  Reduction and coupling of 200 demonstrated the ability to access longer 
chain peptidomimetics (entry 7).  Under the conditions employed, however, 
transesterification of the ester group occurred, giving the final amide product as the 
methyl ester rather than the expected benzyl ester.  As samarium(II) iodide is highly 
oxophilic and can be used as a Lewis acid, the transesterification likely occurred in 
the reduction step.108-109  Indeed, samarium(II) iodide has been used to catalyse the 
transesterification of dimethylcarbonate and phenol.110  
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Entry Substrate R R1 R2 Product(s) 
1 178 Bn H OtBu 214 (50%)a 
2b 178 Bn H OtBu 214 (35%) 
3 197 H H OiPr 0 
4 195 H Bn OBn 211 (~88%) 
5 (S)-193 H iPr OMe 215 (~17%)c  
6 194 H iPr OBn 216 (~41%) 
7 200 Bn H  217 (45%)d 
 
Table 2.6.  Investigation of sequential nitro reduction and amide coupling.  aYield calculated for 
amide coupling step due to crude amine used in excess.  bCoupling conditions: EDC·HCl, HOBt, 
NMM, EtOH, rt.  cAs a 2.5 : 1 mixture of 215 : 210.  dMethyl ester amide isolated due to 
transesterification. 
 
We decided to investigate the reduction of 200 with Zn in AcOH/THF as an 
alternative to samarium(II) iodide and applied these conditions to the synthesis of 
220 (Scheme 2.25).  We discovered that these reduction conditions did not reduce 
the nitro group completely and the intermediate hydroxylamine also underwent 
amide coupling to Z-Gly-OH.  Unfortunately this product was inseparable from 220.   
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Scheme 2.25.  Reduction and coupling of 200 using Zn in AcOH. 
 
We then decided to try the reduction in pure acetic acid, without a co-solvent, and 
left it for a much longer reaction time (Scheme 2.26).  200 was initially subjected to 
the reaction conditions for 84 h, after which 1H NMR indicated the presence of both 
amine 218 and hydroxylamine 219 in an approximately 1 : 1 ratio.  The crude 
material was resubjected to the reaction conditions for a further 72 h.  Unfortunately, 
whilst there was a slight increase in conversion to amine 218, the reaction did not go 
to completion, implying the need for more forcing conditions.  The low yield 
suggests 218 was being lost, either through cyclisation or on work-up. 
 
 
Scheme 2.26.  Reduction of 200 with Zn in AcOH. 
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As samarium(II) iodide reduction had been successful for 200, despite 
transesterification occurring, we decided to attempt the reduction of 206 using 
tBuOH as the proton source rather than MeOH (Scheme 2.27).  When the reduction 
was performed in tBuOH no transesterification was observed but 223 was only 
isolated in a 24% yield over the 2 steps.  The low yield may be attributed to the 
presence of the glycine residues encouraging DKP formation.  Attempts to reduce 
206 with indium, followed by an EDC coupling failed to give any product. 
 
 
Scheme 2.27.  Reduction and coupling of 206 using samarium(II) iodide and EDC. 
 
Based on our earlier results, we decided to focus on optimising the reduction of 194.  
This substrate was chosen on the theory that the combination of benzyl ester and the 
isopropyl group of L-valine would inhibit the cyclisation enough to enable the amide 
coupling to proceed.  Additionally, the use of the benzyl ester group would allow the 
concomitant deprotection of the N- and C-termini in the final step of the sequence.  
We chose EDC as the coupling reagent rather than DCC due to the comparative ease 
of removing the urea by-product. 
Chapter 2: Synthesis of Oxetane-Containing Tripeptide Motifs 
 
103 
A screen of various conditions for the reduction of 194, followed by an amide 
coupling with Z-Gly-OH was performed and the results are shown in Table 2.7.  The 
reduction of 194 with nickel boride, generated in situ, and sodium borohydride 
returned mainly starting material (entry 1).  Reduction of 194 with tin chloride in 
methanol (entry 3) showed no reaction at rt, as judged by TLC, whilst heating the 
mixture under reflux for 2 hours showed consumption of starting material.  After the 
subsequent amide coupling, the main product isolated was amide 224, shown in 
Figure 2.13.  Clearly, heating the reaction mixture had resulted in the elimination of 
the amino ester from 194 to yield L-valine benzyl ester and nitroalkene 162.  
Reduction using samarium(II) iodide in tBuOH gave 216 in 35% yield whereas 
reduction with indium in aqueous HCl improved the yield to 49% (entries 2 and 4).  
Changing the acid from HCl to HCO2NH4 or AcOH had a detrimental effect on the 
yield of 216 (entries 5 and 6).  Shorter reaction times had no effect (entry 7).  
 
 
Figure 2.13.  Amide from reaction of L-Val-OBn with Z-Gly-OH. 
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Entry Reduction Conditions Yield (%) 
1 NiCl2.6H2O (0.5 eq), NaBH4 (5 eq), MeOH, rt, 24 h
111 0 
2 SmI2 (0.1 M in THF, 14 eq), 
tBuOH, rt, 25 min 35 
3 SnCl2.2H2O (5 eq), MeOH, rt, 24 h then reflux, 2 h
112 0 
4 In (4 eq), 6 M HCl (6 eq), THF/H2O, rt, 3 h
112 49 
5 In (4 eq), HCO2NH4 (6 eq), THF/H2O, rt, 24 h then 80 C, 4 h113 0 
6 In (4 eq), AcOH (6 eq), THF/H2O, rt, 3 h
113 37 
7 In (4 eq), 6 M HCl (6 eq), THF/H2O, rt, 90 min  49 
 
Table 2.7.  Investigation of sequential nitro reduction and EDC coupling of 194. 
 
With good reduction conditions in hand, the amide coupling conditions were varied 
to determine if the yield of 216 could be improved (Table 2.8).  This involved 
varying the solvent used (entry 1), the equivalents of Z-Gly-OH (entry 2), the 
coupling reagent employed (entry 3) and using Et2O rather than EtOAc in the work-
up (entry 4).  However, no further improvements were realised and the optimal 
conditions were reduction with indium in aqueous HCl, followed by an amide 
coupling using EDC, as for entry 7 in Table 2.7.  The similar yields obtained from 
investigating the amide coupling conditions indicate the nitro reduction is the 
limiting step. 
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Entry Coupling Conditions Yield (%) 
1 
 
Z-Gly-OH (1.03 eq), HOBt (0.15 eq), NMM (2.2 eq), 
EDC.HCl (1.2 eq), CH2Cl2, rt, 18 h 
 
45 
2 
Z-Gly-OH (1.2 eq), HOBt (0.15 eq), NMM (2.6 eq), 
EDC.HCl (1.4 eq), EtOH, rt, 18 h 
 
47 
3 
Z-Gly-OH (1.03 eq), HOBt (0.15 eq), DIEA (2.2 eq), 
PyBOP (1.2 eq), CH2Cl2, rt, 18 h
114 
 
47 
4 
Z-Gly-OH (1.03 eq), HOBt (0.15 eq), NMM (2.2 eq), 
EDC.HCl (1.2 eq), EtOH, rt, 18 ha 
42 
 
Table 2.8.  Optimisation of indium reduction and amide coupling of 194.  aWorked-up with Et2O 
rather than EtOAc. 
 
The next step was to apply these reduction and coupling conditions to a range of 
nitro compounds.  The reduction of amino esters 194, 203, 204 and 205, followed by 
coupling with a range of N-carboxybenzyl protected amino acids afforded protected 
oxetane-containing peptidomimetics (Table 2.9).  Interestingly, the highest yields 
were obtained when Z-L-Phe-OH was coupled with both the L-valine analogue 194 
(entry 1) and the L-isoleucine analogue 204 (entry 2), but no product was observed 
with the L-leucine or L-threonine analogues 203 and 205 (entries 8 and 9).  The lack 
of product from the L-threonine example (entry 9) may be due to the presence of the 
free hydroxyl group, which could make it more difficult to extract from the aqueous 
reaction mixture or compete in the coupling.  Attempts to reduce 205 with 
samarium(II) iodide in tBuOH, followed by coupling with Z-L-Phe-OH, were also 
Chapter 2: Synthesis of Oxetane-Containing Tripeptide Motifs 
 
106 
unsuccessful.  One solution to this would be to protect the free hydroxyl with a 
benzyl group, which would still allow all protecting groups to be removed 
concomitantly (vide infra). 
 
 
Entry Oxetane R R1 Product Yield (%) 
1 194 iPr Bn 225 60 
2 204 CH(Me)Et Bn 226 58 
3 194 iPr Me 227 44 
4 194 iPr iPr 228 47 
5 204 CH(Me)Et CH2
 iPr 229 54 
6 194 iPr CH2(indole) 230 20 
7 194 iPr CH2CH2SCH3 231 37 
8 203 CH2
 iPr Bn 232 0 
9 205 CH(OH)Me Bn 233 0 
 
Table 2.9.  Synthesis of 225-233. 
 
Having established a route towards the synthesis of protected peptidomimetics 
containing the oxetane mid-chain, we applied the reaction conditions to the reduction 
of 207 in order to access the protected tetrapeptide 235 (Scheme 2.28).  235 was 
Chapter 2: Synthesis of Oxetane-Containing Tripeptide Motifs 
 
107 
isolated in a low yield of 19% despite the presence of the valine residue in 207 to 
help minimise cyclisation.  As cyclisation onto an amide bond should be much 
slower (compared to the ester), this suggests there are other issues with this 
chemistry.  Whilst this example demonstrates feasibility, further work is clearly 
required to optimise this sequence. 
  
 
Scheme 2.28.  Reduction and coupling of 207 to make protected tetrapeptide 235. 
 
The reduction and amide coupling conditions, whilst not optimal, do allow the nitro 
group of the conjugate addition products to be reduced and coupled with another N-
protected amino acid.  The best overall yields were achieved using indium or 
samarium(II) iodide for the reduction step. 
 
2.2.5.2 Synthesis of Protected C-Terminus Peptidomimetics 
The synthesis of C-terminus peptidomimetics involves the reduction of the nitro 
group in 166, followed by amide coupling and deprotection, as for the mid-chain 
examples.  Various conditions for the reduction and immediate amide coupling of 
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166 were investigated (Table 2.10).  Reduction using Zn in AcOH and coupling with 
DCC gave 236 in ~46% yield (entry 1), but this was contaminated with the 
hydroxylamine derived by-product.  Samarium(II) iodide reduction, combined with 
DCC coupling, gave impure product in a low yield (entry 2).  Hydrogenation of 166 
in AcOH, followed by amide coupling with either EDC or DCC gave 236 in similar 
yields (entries 3 and 4).  Finally, changing the hydrogenation solvent from AcOH to 
methanol gave 236 in the highest yield (entry 5).   
 
 
Entry Reduction Conditions Coupling Methoda Yield (%) 
1 Zn (35 eq), AcOH, rt, 96 h A, 18 h ~46b 
2 SmI2 (0.1 M, 14 eq), MeOH, rt, 20 min A, 21 h ~15 
3 Pd/C (50% by wt), H2, AcOH, rt, 20 h
115 A, 18 h 44 
4 Pd/C (50% by wt), H2, AcOH, rt, 20 h
115 B, 5.5 h 42 
5 Pd/C (50% by wt), H2, MeOH, rt, 22 h B, 17 h 65 
 
Table 2.10.  Reduction and coupling of 166.  aMethod A: Z-Gly-OH (1 eq), DCC (1.1 eq), HOBt (1.1 
eq), DIEA (1.1 eq), CH2Cl2, 0 ˚C, 1 h then rt; Method B: Z-Gly-OH (1.03 eq), EDC·HCl (1.2 eq), 
HOBt (0.15 eq), NMM (2.2 eq), EtOH, rt.  bHydroxylamine product co-eluted. 
 
These optimised reaction conditions were also used to provide C-terminus oxetane 
tripeptide mimetic 238 in 74% yield (Scheme 2.29). 
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Scheme 2.29.  Reduction and coupling of 166 to give tripeptide mimic 238. 
 
2.2.6 Deprotection to Free Peptidomimetics 
With routes developed for the synthesis of peptidomimetics containing the oxetane 
ring at different positions along the peptide chain, the next step was to investigate the 
removal of the terminal protecting groups. 
 
2.2.6.1 Attempted Removal of the tert-Butyl Ester 
We focused our initial investigations into the hydrolysis of the tert-butyl ester group 
of 214.  From the outset, we were concerned about the potential susceptibility of the 
oxetane ring to the acidic conditions that might be needed to cleave this ester 
group.11,116  Traditionally tert-butyl esters are removed using acids such as TFA117 
and, as 3,3-disubstituted oxetanes are thought to be relatively stable to TFA at lower 
temperatures,116 we decided to initially explore these conditions (Table 2.11, entries 
1 and 2).  When the reaction was performed at 0 C, the starting material was not 
consumed (according to TLC), but at rt a mixture of unknown products was formed.  
During the cleavage of the tert-butyl ester, a tert-butyl cation is formed that can 
potentially alkylate any nucleophilic sites within the molecule.118  As the 
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peptidomimetic contained a secondary amine we decided to perform the deprotection 
with TFA in the presence of triethylsilane (TES) as a carbocation scavenger.119  
Unfortunately these conditions failed to give 239 either at 0 C or rt (entries 3 and 4).  
As carboxybenzyl groups are reported to be removed under acidic conditions, we 
were concerned that the TFA could be opening the oxetane ring and/or removing the 
N-protecting group.  Therefore, the next step was to try the deprotection using milder 
conditions.  Using formic acid, only 214 and unknown products were observed 
(entry 5).  Work done in the group has demonstrated that the oxetane ring is stable to 
heating in AcOH120 and so we decided to explore the use of this acid (entry 6).121  
Deprotection in acetic acid at rt gave no reaction, as determined by TLC, but upon 
heating the starting material was fully consumed.  However, it was determined 
through mass spectrometry (m/z = 480 [M+H]+) and NOE experiments that the 
product observed was not 239, but 240, resulting from cyclisation of the secondary 
amine onto the carbonyl group of the amide bond (Scheme 2.30).  Heating the 
reaction obviously promotes this cyclisation as 240 was not formed at rt.  Attempts 
to remove the tert-butyl group with silica gel in refluxing toluene122 (entry 7) gave 
214 as well as 240 (2.6 : 1).  Finally, we investigated the use of phosphoric acid to 
deprotect the tert-butyl ester at rt (entry 8).123  Unfortunately, 214 had poor solubility 
in toluene so a mixture of CH2Cl2 and MeOH had to be added to the reaction 
mixture.  ESI-MS indicated possible product formation (m/z = 464 [M+Na]+), but the 
crude 1H NMR was messy and inconclusive.   
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Entry Reaction Conditions Product(s) 
1 TFA/CH2Cl2 (1 : 1), rt, 5 h
124 0%a 
2 TFA/CH2Cl2 (1 : 4), 0 C  rt, 5 h125 0% a 
3 TES (10 eq), TFA/CH2Cl2 (1 : 2.5), 0 C  rt, 5 h119 0%
 a 
4 TES (11 eq), TFA/CH2Cl2 (1 : 1), 0 C, 48 h119 0%a 
5 HCO2H, rt, o/n
126 214 and unknown 
6 AcOH, 70 C, 5.5 h121 240 (~68%)b 
7 Silica gel (1 eq), toluene, reflux, 90 min122 214 and 240c 
8 H3PO4 (5 eq), toluene, CH2Cl2/MeOH (5 : 1), rt, 17 h
123 239 and unknownd 
 
Table 2.11.  Investigation into the hydrolysis of the tert-butyl ester group of 214.  aUnknown products 
formed.  bObserved in crude 1H NMR.  c214 : 240 in 2.6 : 1.0 ratio according to 1H NMR.  dBased on 
ESI-MS. 
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Scheme 2.30.  Proposed mechanism for the formation of 240. 
 
Evidence for 240 was primarily based on NOE experiments that showed irradiation 
of H-1 caused an enhancement of the oxetane H-2, whilst irradiation of the CH2 
protons (H-5/H-6) gave an enhancement of the oxetane protons (H-3 and H-4) as 
well as H-7 and H-8 (Figure 2.14).  The enhancement of H-7 and H-8, caused by 
irradiation of H-5 and H-6 is particularly indicative of the formation of 240, as this 
would not be expected if the compound was 214 or 239. 
 
 
Figure 2.14.  NOE enhancements in 240. 
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These results showed that the tert-butyl ester was not a suitable protecting group, 
despite an improved resistance towards cyclisation, as it was difficult to remove in 
the presence of the oxetane ring and the secondary amine.  Therefore we decided to 
focus our attentions on the deprotection of the methyl ester of 213a and 213b 
instead. 
 
2.2.6.2 Attempted Removal of the Methyl Ester 
Basic conditions for the hydrolysis of the methyl ester of 213b were investigated and 
the results are shown in Table 2.12.  The hydrolysis of the methyl ester using 
different bases failed to give 241b.  Even conditions that had been successfully used 
previously to remove a methyl ester from an N-carboxybenzyl protected Gly-Gly 
dipeptide failed to give 241b (entry 2).  One possible explanation for this is the steric 
bulk of the isopropyl group blocking nucleophilic attack.   
 
 
Entry Reaction Conditions Producta 
1 LiOH.H2O (6 eq), THF/MeOH/H2O (3 : 1 : 1), 0 C  rt, 89 h
127 
 
Unknown 
2 LiOH (2 eq), H2O2 (5 eq), THF/H2O (3 : 1), 0 C  rt, 17 h
128-129 
 
213b 
3 K2CO3 (1.5 eq), MeOH/H2O (1 : 1), rt, 20 h
130 
 
Unknown 
4 LiOH.H2O (5 eq), THF/H2O (1 : 1), reflux, 15 h Unknown 
 
Table 2.12.  Investigation into the hydrolysis of the methyl ester of 213b.  aAccording to crude 1H 
NMR. 
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Attempts to hydrolyse the other diastereomer, 213a, with NaOH also failed (Scheme 
2.31). 
 
 
Scheme 2.31.  Attempted hydrolysis of the methyl ester group in 213a. 
 
Removing the N-protecting group before attempted hydrolysis of the methyl ester 
failed to generate 243, despite ESI-MS evidence to suggest the amine 242 (m/z = 364 
[M+H]+, 386 [M+Na]+) had been successfully formed (Scheme 2.32). 
 
 
Scheme 2.32.  Attempted hydrogenation and hydrolysis of 213b. 
 
The difficulties encountered removing the methyl ester protecting group, as well as 
the tendency of the methyl ester analogues to undergo cyclisation, led us to 
ultimately discount the use of this ester. 
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2.2.6.3 Hydrogenation of Nitro and Benzyl Ester Groups 
Next, the hydrogenation of oxetane 199 was explored with a view to providing 
dipeptide derivatives.  The results are presented in Table 2.13.  It was demonstrated 
that hydrogenation could be used to reduce the nitro group and remove the benzyl 
ester concurrently.  However, the cyclised side-products, 245 and 209, were often 
observed in the crude 1H NMR, sometimes along with 244.  This suggested that the 
nitro group was being reduced faster than the benzyl ester was cleaved.  
Diketopiperazine 209 could arise from further reduction of 245, or alternatively, 
arise from cyclisation of amine 244.  Resubjecting 245 to the reaction conditions led 
to 209, suggesting that the former pathway may be in operation. 
 
The hydrogenations were initially performed in the presence of acid, in order to 
prevent the amine poisoning the palladium catalyst.131  However, ring-closure was 
observed when acid was present (Table 2.13, entries 1-4).  When methanol was used 
as the solvent, a mixture of products was obtained, including 244 (entries 5-6).  
When no acid was present, a larger proportion of Pd/C was required to compensate 
for inhibition by the amine.  Attempts to purify 244 using reverse-phase HPLC gave 
a mixture of 244 and increased amounts of 209, likely due to the use of formic acid 
in the eluent.  Unfortunately, on account of these difficulties, the dipeptide 
derivatives were not isolated. 
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Entry Reaction Conditions Product(s)a 
1 
 
Method A, Pd/C (50% by wt), 2 M, 20 h 
 
245 and 209 (3.2 : 1) 
2 Method A, Pd/C (75% by wt), 0.2 M, 21 h 
 
245 and 209 (3.3 : 1) 
3 Method B, Pd/C (30% by wt), 0.01 M, 17 h 
 
245 and 209 (2.7 : 1) 
4 Method B, Pd/C (50% by wt), 0.1 M, 20 h 
 
245 and 209 (1.1 : 1) 
5 Method C, Pd/C (100% by wt), 0.05 M, 22 h 244 and 209 (1.4 : 1) 
6 Method C, Pd/C (50% by wt), 0.1 M, 21 h 
 
244, 245 and 209 (4.5 : 1 : 1.2) 
 
Table 2.13.  Hydrogenation conditions to access dipeptide isosteres.  aAs observed by 1H NMR.  
Method A: H2, Pd/C, AcOH, rt. 115  Method B: H2, Pd/C, AcOH/EtOAc/MeOH (1 : 2 : 1), rt.132  
Method C: H2, Pd/C, MeOH, rt.133 
 
Next, we explored the hydrogenation of longer chain nitro compounds to access N-
terminus peptidomimetics.  Initial attempts to hydrogenate 206, a Gly-Gly-Gly 
analogue, resulted in a poor mass recovery and a mixture of 2 compounds, believed 
to be 246 and 247, as judged by the 1H NMR (Scheme 2.33). 
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Scheme 2.33.  Hydrogenation of 206. 
 
As the glycine residues in 206 could promote the cyclisation, we decided to explore 
the hydrogenation of analogues containing substituents at different positions on the 
chain.  Hydrogenation of 200 under standard conditions gave primarily 248, as 
observed by crude 1H NMR, as well as some impurities (Scheme 2.34).  Purification 
by reverse-phase HPLC, however, resulted in conversion of 248 to 209, catalysed by 
the presence of formic acid in the eluent.  This implied the amine had cyclised onto 
the amide bond, eliminating glycine.  Based on our previous work optimising the 
reduction of the nitro group, we decided to introduce an L-valine residue into the 
tripeptide in order to minimise this cyclisation. 
 
 
Scheme 2.34.  Hydrogenation of 200. 
 
Pleasingly, hydrogenation of 207 gave peptidomimetic 249 in 72% yield (Scheme 
2.35).  The presence of the isopropyl group presumably providing sufficient steric 
hindrance to minimise cyclisation.  This chemistry could therefore provide easy 
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access to a range of N-terminus peptidomimetics, of varying chain length, provided 
the amide bond is protected from nucleophilic attack by adjacent substituents. 
 
 
Scheme 2.35.  Hydrogenation of 207. 
 
This work demonstrated that the benzyl ester is readily cleaved without harsh 
conditions that could affect the oxetane ring.  Once we had established a route to 
tripeptides containing an oxetane at the N-terminus, we focused our attention on the 
concomitant removal of the N-carboxybenzyl and benzyl ester groups to furnish mid-
chain oxetane-containing peptidomimetics. 
 
2.2.6.4 Concomitant Removal of Cbz and Benzyl Ester Groups 
Deprotection of compounds 216, 225–229 proceeded smoothly using standard 
hydrogenolysis conditions134 to give the oxetane peptidomimetics in excellent yields 
(Table 2.14).  
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Entry Substrate R1 R Product Yield (%) 
1 216 H iPr 250 84 
2 225 Bn iPr 251 96 
3 226 Bn CH(Me)Et 252 96 
4 227 Me iPr 253 100 
5 228 iPr iPr 254 94 
6 229 CH2
iPr CH(Me)Et 255 99 
 
Table 2.14.  Deprotection to give peptidomimetics 250-255. 
 
The high yields obtained from the removal of the N-carboxybenzyl and benzyl ester 
protecting groups led us to consider these as the optimal protecting groups for this 
chemistry, especially when sterically bulky amino esters were used. 
 
2.2.6.5 Removal of Cbz Group to afford C-Terminus Peptidomimetics 
The final step in the synthesis of the C-terminus oxetane-containing peptidomimetics 
was the removal of the N-carboxybenzyl protecting group.  This was achieved under 
standard hydrogenolysis conditions to give dipeptide 256 and tripeptide 257 in high 
yields (Scheme 2.36). 
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Scheme 2.36.  Deprotection of 236 and 238. 
 
Therefore an easy route to peptidomimetics containing an oxetane at the C-terminus 
has been developed.  Longer chain peptide isosteres should be readily accessible via 
standard homologation of the N-terminus using conventional peptide chemistries. 
 
2.2.7 Structural Investigations 
In collaboration with Dr Rebecca Notman of the University of Warwick, molecular 
dynamics simulations of 255 were run, along with simulations of the parent peptide 
258 (Figure 2.15).  This model system was chosen as 258 has shown activity as an 
angiotensin I-converting enzyme (ACE) inhibitor and it would be interesting to 
compare the effect of the oxetane on its properties.135  
 
 
Figure 2.15.  Peptidomimetic 255 and its parent peptide 258. 
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We were interested in exploring how the replacement of an sp2 hybridised carbon 
centre in the natural peptide with an sp3 hybridised 3-aminooxetane unit would affect 
the conformation of the peptidomimetic.  We were also concerned as to whether the 
presence of the secondary amine within the peptide backbone might influence the 
behaviour of the molecule, for example by competitive protonation in the 
zwitterionic form (Scheme 2.37). 
 
 
Scheme 2.37.  Competitive protonation in 255. 
 
CHARMM-compatible forcefield parameters for the 3-aminooxetane residue were 
first derived from quantum mechanical calculations.  Each peptide was then 
simulated for 100 ns in water at 500 K and from this trajectory 10 distinct 
conformations of each peptide were selected for an additional 100 ns of simulation at 
300 K, to yield a total simulation time of 1 s per peptide. Cluster analysis was 
performed using 100000 structures extracted from the trajectories at 10 ps intervals. 
 
The simulations showed that there were eleven distinct structures for the 
peptidomimetic 255 compared to seven for the peptide 258.  These results suggested 
that the oxetane-containing peptidomimetic has greater conformational flexibility 
than the traditional peptide, as might be expected on account of the substitution of a 
rigid amide bond with a 3-aminooxetane unit. 
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Snapshots of the two most populated clusters for 255 and 258 are shown in Figure 
2.16.   
 
 
 
Figure 2.16. Snapshots of the two most populated clusters of 258 (top) and 255 (bottom) showing the 
percentage of total structures accounted for by the cluster. Hydrogen atoms have been omitted for 
clarity. Snapshots were generated using the Visual Molecular Dynamics software.136 
 
The natural tripeptide 258 adopts conformations in which the C and N termini are 
separated by > 7 Å. In contrast, the oxetane peptidomimetic spends more time in a 
folded conformation with a C-N separation distance of 3-4 Å, presumably driven by 
the electrostatic interaction of the terminal –CO2- and –NH3+ ions in this arrangement 
(Figure 2.17).  The flexibility of the peptidomimetic, arising from the change in 
hybridisation, allows formation of these folded conformations, which could in turn 
give rise to turn-like behaviour in longer chain peptidomimetics.  
 
258 
255 
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Figure 2.17.  Normalised distribution of the distance between the C-terminal C atom and the N-
terminal N atom obtained from MD simulations in solution. 
 
Having synthesised these oxetane peptidomimetics, we also wanted to determine 
their conformations in solution, to compare them to the results of the molecular 
dynamics simulations.  Consequently, NOESY and ROESY experiments of 253, 254 
and 255 were run.  The NOESY and ROESY spectra for 255 are presented in Figures 
2.18 and 2.19, whilst those for 253 and 254 are in Appendix II.  However, there was 
no discernible interaction between the two side chains present in the molecules.  This 
means that the molecules are likely not, in solution, spending appreciable amounts of 
time in folded conformations where these side chains would be in close contact. 
 
 
 
 
 
 
258 
255 
C-N distance (Ǻ) 
Number of 
occurrences 
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Figure 2.18.  NOESY spectrum of 255. 
 
 
Figure 2.19.  ROESY spectrum of 255. 
 H1 H2 
H3 H4 
H5 
H6 H7 
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Fortunately, we were able to grow crystals of 252 and 255 from methanol and 
determine the solid state structure of these peptidomimetics using X-ray 
crystallography (Figures 2.20 and 2.21).   
 
 
 
Figure 2.20.  Crystal structure of 252. 
 
 
 
Figure 2.21.  Crystal structure of 255. 
 
The crystal structures confirmed that both 252 and 255 were zwitterionic and the 
secondary amine was not protonated in the solid state.  Both peptidomimetics also 
showed an antiparallel sheet-like arrangement, which was interesting as molecular 
dynamics simulations had shown the peptidomimetic adopting a folded 
conformation, to a significant extent, in water (Figures 2.22 and 2.23).  The 
antiparallel sheet arises from hydrogen bonds between the amides, carboxylates, 
ammonium ions and secondary amines in the antiparallel oxetane tripeptide mimics.  
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The oxetane oxygen, however, is approximately orthogonal to this hydrogen-bonded 
sheet and is involved in hydrogen bonding outside of the plane of the sheet. 
 
 
 
Figure 2.22.  Antiparallel sheet arrangement of 252 in the solid state. 
 
 
 
Figure 2.23.  Antiparallel sheet arrangement of 255 in the solid state. 
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The presence of the oxetane ring also had a notable effect on the C-N-Cox-C torsional 
angle in the pseudo-tripeptides due to the pyramidal nature of the nitrogen atom 
(Figure 2.24).  For 252,  = 55.7 and for 255, the C-N-Cox-C torsional angle was 
60.2 (values derived from the average of all molecules in the unit cell).  This is in 
comparison to a traditional peptide that has a trigonal nitrogen and  = ~180. 
 
 
Figure 2.24.  Torsional angle () in oxetane-containing peptidomimetics. 
 
CD spectroscopy on the oxetane-containing peptidomimetics in water (Figure 2.25) 
showed that when the oxetane was in the mid-chain position (250–255), there was no 
evidence of conventional peptide secondary structure elements, such as α-helices, β-
sheets or turns.56  In fact, secondary structures such as α-helices are not seen in 
tripeptides as they are stabilised by a hydrogen bond between the carbonyl oxygen of 
one residue (n) and the nitrogen of the amide four residues along the chain (n+4).137  
However, when the oxetane was at the N-terminus, as in 249, the peptidomimetic 
showed indications of β-sheet formation.  This is because the negative peak that 
occurs near 217 nm and the positive peak at around 195 nm are characteristic of β-
sheets spectra.138-139  As there are two sequential amino acid residues present in 249, 
it could be that these impart rigidity to the peptide chain, decreasing its flexibility 
compared to the peptidomimetics containing the oxetane in the mid-chain position 
and therefore enabling it to adopt a sheet-like structure normally seen in a traditional 
peptide.  If any of the peptidomimetics formed α-helices in solution, two negative 
- 
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peaks of similar intensity would be observed at ~222 nm and ~208 nm, as well as a 
positive peak at ~192 nm of higher intensity.138-139 
 
 
Figure 2.25.  CD spectroscopy of oxetane peptidomimetics 249–255. 
 
Our initial structural investigations indicate that replacement of a carbonyl bond with 
an oxetane ring in a tripeptide does have a significant effect on the properties.  The 
increased flexibility resulting from the change in hybridisation of the carbon from 
sp2 to sp3 allows the oxetane peptidomimetic to adopt a wider range of 
conformations in water, as evidenced by molecular dynamics simulations.  However, 
the peptidomimetic remains zwitterionic like a natural tripeptide and can produce 
antiparallel sheet-like structures in the solid state, along similar lines to conventional 
peptides. 
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2.3 Conclusions 
In summary, we have developed routes towards the synthesis of peptidomimetics 
containing an oxetane as a carbonyl bond isostere at the N-terminus, C-terminus and 
mid-chain from commercially available 3-oxetanone.140 
 
A range of peptidomimetics containing different amino acid residues have been 
synthesised.  The initial conjugate addition between a nitroalkene (162 or 164) and 
an amino ester has been successfully demonstrated, as well as more efficient, higher 
yielding one-pot reactions to give the conjugate addition product directly from 3-
oxetanone.  This one-pot reaction has been performed with a range of amino and 
dipeptide esters, including polar and hydrophobic amino esters, in moderate to good 
yields (Schemes 2.38 and 2.39). 
 
The optimal ester protecting group for the synthesis of mid-chain oxetane-containing 
peptidomimetics was found to be the benzyl ester.  The reduction of the nitro group 
proceeded best when a branched substituent was present on the α-carbon of the 
amino ester in order to minimise competitive cyclisation to the DKP derivatives.  
Nitro reduction using indium in aqueous HCl, followed immediately by an amide 
coupling gave the best results and, using this method, a range of protected 
peptidomimetics were synthesised in good yields (Table 2.9, p.106).  Hydrogenation 
to remove the protecting groups gave the final peptidomimetics in excellent yields 
(Table 2.14, p.119). 
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Scheme 2.38.  Routes to mid-chain oxetane peptidomimetics using the benzyl ester protecting group. 
 
 
Scheme 2.39.  Route to N-terminus oxetane peptidomimetic 249. 
 
Where there was no potential for cyclisation, reduction of the nitro group occurred 
readily under standard hydrogenation conditions and amide coupling to give the 
protected C-terminus peptidomimetic 257 in good yield (Scheme 2.40).   
 
 
Scheme 2.40.  Route to C-terminus oxetane peptidomimetic 257. 
 
Cyclisation to the oxetane-containing diketopiperazine was promoted in acidic 
conditions and examples of these pharmaceutically interesting molecules have been 
synthesised (Scheme 2.41).   
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Scheme 2.41.  Routes developed to oxetane-containing diketopiperazines. 
 
Exploration of the structures of these oxetane peptidomimetics using X-ray 
crystallography, CD spectroscopy and molecular dynamics simulations provided 
interesting insights.  When the oxetane is in the middle of a tripeptide chain, CD 
spectroscopy indicated that there is no dominant structure in solution, although in the 
solid state they appear to form antiparallel sheet-like arrangements, as evidenced by 
the crystal structures of 252 and 255.  The crystal structures also showed the 
formation of conventional zwitterions rather than by protonation of the secondary 
amine.  Molecular dynamics simulations indicate that these oxetane peptidomimetics 
have a greater flexibility than their analogous tripeptides and favour folded 
conformations, presumably driven by electrostatic interactions and the change in 
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hybridisation at the central “peptide” bond.  Interestingly, when the oxetane is at the 
N-terminus, CD spectroscopy provided some evidence of β-sheet formation. 
 
The development of oxetane-containing peptidomimetics is a rapidly evolving area 
of research.  Recently, appearing in print shortly after our initial findings had been 
published,140 Carreira and co-workers have demonstrated a strategy to accessing 
protected oxetane-containing peptidomimetics closely related to that described in 
this thesis.141   These authors established a similar synthetic route to oxetane-
containing pseudo-dipeptides such as 260 through conjugate addition of the amino 
ester in DMSO to 162, followed by nitro reduction with Raney Ni and immediate 
protection of the resultant amine.  As well as polar and lipophilic side chains, these 
authors also had success using protected amino esters, including derivatives of L-
tyrosine, L-serine, L-glutamic acid, and L-asparagine.  Interestingly, they reported 
that the use of the n-propyl esters gave higher yields than the corresponding methyl 
or benzyl esters.  The reaction also worked with unprotected amino acids, proceeding 
in similar yields.  Similar strategies have been developed to access oxetane 
peptidomimetics such as 262, although the ability to separate the diastereomers was 
dependent on the substrate.  Subsequent cleavage of either the N-protecting group or 
the ester, followed by a standard amide coupling to elongate the peptide chain was 
further established.  Carreira did not report any structural insights into the folding of 
the resulting  peptidomimetics.141   
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Scheme 2.42.  Synthetic routes to oxetane-containing peptidomimetics developed by Carreira et al.141 
 
This complementary work can only help to expand our knowledge of, and access to, 
oxetane-containing peptidomimetics. 
 
2.4 Future Work 
Due to time constraints, we were unable to investigate fully the potential for a  
diastereoselective conjugate addition of amino esters to the substituted nitroalkene 
164.  Optimisation of the reaction in the presence of a chiral catalyst to preferentially 
form one diastereomer is of the utmost interest, as it would allow access to many 
different oxetane-containing peptidomimetics, and not just ‘Gly’ or racemic ‘Phe’ 
examples produced herein.  Alternative routes such as chiral protonation strategies 
also merit investigation. 
 
Having established routes towards these oxetane peptidomimetics, it would be of 
interest to expand the chemistry further to longer peptide chains, and to remove the 
need for the presence of branched-chain substituents at the residue downstream of 
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the oxetane.  It would be of great interest to see the impact of the oxetane unit on the 
flexibility and secondary structure of longer peptidomimetics (4 amino acids or 
longer).  
 
Finally, the impact of the oxetane unit on a peptide’s biological activity and stability 
needs to be investigated.  In particular, enantiopure peptidomimetics containing the 
oxetane ‘Phe’ residue could be exposed to chymotrypsin assays in order to compare 
their stability and reactivity to the natural peptides.  Additionally, the peptide Leu-
Gly-Ile has been shown to have activity as an angiotensin I-converting enzyme 
(ACE) inhibitor.135  As our structural studies have shown that the oxetane analogue 
255 has more rotational freedom than the parent peptide, it would be interesting to 
explore the activity of the peptidomimetic in such an assay.  Another tripeptide of 
interest, is the neuropeptide, Pro-Leu-Gly-NH2 (PLG), a modulator of the dopamine 
D2 receptor.
142  Studies have shown that PLG forms a type II β-turn and it would be 
interesting to explore the impact of the introduction of the oxetane on both the 
secondary structure of the peptide chain and its bioactivity.143 
 
 
  
135 
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3.1 General Information 
All reactions were performed under an atmosphere of dry nitrogen in flame- or oven- 
dried glassware unless otherwise stated.  Anhydrous solvents were purchased from 
Sigma-Aldrich or Fisher Scientific in Sure-Seal™ bottles for use as reaction 
solvents.  All other solvents were reagent grade and used as received or purified by 
standard protocols where stated.  Petrol refers to the petroleum ether fraction which 
boils in the range 40 – 60 oC for column chromatography.   
 
Commercially available starting materials were used without further purification 
unless otherwise stated.  Thin layer chromatography was performed on pre-coated 
aluminium-backed plates (Merck Silicagel 60 F254), visualised by UV 254 nm then 
stained with potassium permanganate or ceric ammonium molybdate solution.  Flash 
chromatography was performed using Fluorochem LC60A 40-63 micron silica.  
Chiral HPLC was performed using an Agilent 1100 series or an Agilent 1260 
Infinity system.  Melting points were recorded on a Gallenkamp MPD350 apparatus 
or a Büchi B-545 Melting Point Apparatus and are reported as observed.  Single 
crystal X-ray diffraction data were obtained using a Siemens SMART XRD system 
or an Oxford Diffraction Gemini XRD system.  Infrared spectra were recorded on a 
Perkin Elmer Spectrum 100 FT-IR spectrometer, Thermo Nicolet Avatar 370 FT-IR 
or a Bruker Alpha Platinum ATR spectrometer with internal calibration and are 
given in cm-1.   
 
Low resolution mass spectra were recorded on an Esquire 2000 platform with 
electrospray ionisation or on a Waters Alliance Micromass ZQ / CapLC.  High 
resolution mass spectra were obtained using a Bruker MicroTOF spectrometer or a 
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Thermo Accela CTC – LTQ FT.  Optical rotations were measured using an AA-1000 
Polarimeter from Optical Activity Ltd.  Warwick Analytical Service carried out all 
elemental analysis.   
 
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker DPX (300, 
400, 500 or 600 MHz) or AV (400 or 700 MHz) spectrometers.  Chemical shifts are 
reported in parts per million relative to the standard tetramethylsilane.  The peak 
multiplicities were specified as singlet (s), doublet (d), triplet (t), quartet (q), quintet 
(quint). Coupling constants (J) are reported in Hertz.  
 
2-Methylenepropane-1,3-diyl diacetate (61)144 
This known compound was prepared according to a literature 
procedure.27  To a solution of 3-chloro-2-chloromethyl-1-propene (5.57 
g, 44.6 mmol) in glacial acetic acid (40 mL) at 0 C was added NEt3 (12.5 mL, 89.7 
mmol) and the reaction mixture was heated under reflux overnight.  On cooling, the 
solution was diluted with CH2Cl2 (50 mL) and washed with water (3 x 50 mL).  The 
organic extracts were dried over MgSO4, filtered and concentrated in vacuo to give 
61 (6.48 g, 84%) as an orange liquid.  Data in agreement with literature values.144  IR 
(film) 1735, 1370, 1214, 1026, 917 cm-1; δH (300 MHz, CDCl3) 5.18 (2H, t, J = 1.0, 
=CH2), 4.50 (4H, t, J = 1.0, CH2), 1.99 (6H, s, CH3); δC (100 MHz, CDCl3) 170.4 
(C=O), 138.7 (C), 116.6 (=CH2), 64.4 (CH2), 20.7 (CH3); MS (ES
+) m/z 195 
[M+Na]+; HRMS (ES+) calcd. for C8H12NaO4 [M+Na]
+: 195.0628; found: 195.0626. 
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2-Methylenepropane-1,3-diol (57)145 
This known compound was prepared as follows.  To a solution of 61 
(11.66 g, 67.7 mmol) in THF (36 mL) and H2O (36 mL) at 0 C was 
added NaOH (6.01 g, 150.3 mmol) and the reaction mixture was stirred at rt for 72 h.  
The mixture was concentrated in vacuo and the resultant solid extracted with diethyl 
ether by Soxhlet extraction.  The ether solution was concentrated in vacuo and the 
resulting oil distilled (110 C, 0-1 mbar) to give 57 (3.30 g, 55%) as a colourless 
liquid.  Data in agreement with literature values.145  IR (film) 3286, 2919, 1662, 908 
cm-1; δH (300 MHz, CDCl3) 5.14 (2H, t, J = 0.9, =CH2), 4.24 (4H, s, CH2), 1.94 (2H, 
br s, OH); δC (75 MHz, CDCl3) 147.6 (C), 112.6 (=CH2), 64.8 (CH2). 
 
(2-Hydroxymethyloxiranyl)-methanol (64)28 
This known compound was prepared according to a literature 
procedure.28  To a stirred solution of 57 (3.6 g, 40.9 mmol) in anhydrous 
CH2Cl2 (100 mL) was added mCPBA (77% in water, 11.1 g, 49.5 mmol).  The 
reaction mixture was stirred at rt for 5 h then concentrated in vacuo.  Purification by 
column chromatography (100% EtOAc) provided 64 (2.86 g, 67%) as a colourless 
liquid.  Data in agreement with literature values.28  Rf = 0.25 (100% EtOAc); δH (300 
MHz, CDCl3) 3.90 (2H, dd, J = 12.4, 5.6, CHH), 3.72 (2H, dd, J = 12.4, 7.2, CHH), 
2.89 (2H, s, epoxide CH2), 2.64 (2H, dd, J = 7.2, 5.6, OH); δC (100 MHz, CDCl3) 
62.5 (CH2), 60.6 (C), 49.0 (CH2).  
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[2-(Hydroxymethyl)oxiran-2-yl]methyl methanesulfonate (65) 
This novel compound was prepared using a modified literature 
procedure.146  To a solution of 64 (126 mg, 1.21 mmol) and NEt3 (0.19 
mL, 1.36 mmol) in anhydrous toluene (3 mL) at 0 C was added a solution of MsCl 
(0.1 mL, 1.29 mmol) in anhydrous toluene (2 mL) dropwise.  The reaction mixture 
was stirred at 0 C for 90 min then filtered and concentrated in vacuo.  Purification 
by column chromatography (67  80% EtOAc in petroleum ether) provided 
dimesylate 66 (15 mg, 5%), followed by the more polar 65 (20 mg, 9%) as a 
colourless oil.  Rf = 0.2 (75% EtOAc in petroleum ether); δH (400 MHz, CDCl3) 4.43 
(1H, d, J = 11.6, CHHOMs), 4.35 (1H, d, J = 11.6, CHHOMs), 3.88 (1H, dd, J = 
12.5, 5.9, CHHOH), 3.80 (1H, dd, J = 12.5, 7.2, CHHOH), 3.08 (3H, s, CH3), 2.96 
(1H, d, J = 4.4, epoxide CHH), 2.89 (1H, d, J = 4.4, epoxide CHH), 1.91 (1H, dd, J 
= 7.2, 5.9, OH); δC (100 MHz, CDCl3) 69.3 (CH2), 61.5 (CH2), 57.5 (C), 49.5 (CH2), 
37.9 (CH3).  Dimesylate 66: δH (400 MHz, CDCl3) 4.42 (2H, d, J = 11.8, CHHOMs), 
4.34 (2H, d, J = 11.8, CHHOMs), 3.10 (6H, s, CH3), 2.98 (2H, s, CH2); δC (100 
MHz, CDCl3) 68.3 (CH2), 55.1 (C), 50.2 (CH2), 38.0 (CH3). 
 
2-Hydroxy-2-(hydroxymethyl)propane-1,3-diyl dimethanesulfonate (69) 
This novel compound was prepared as follows.  To 66 (180 mg, 0.69 
mmol) and p-toluenesulfonic acid monohydrate (18 mg, 0.09 mmol) 
was added THF (5 mL) and water (5 mL).  The reaction mixture was stirred at rt 
overnight then heated under reflux for 20 h.  On cooling, the reaction mixture was 
concentrated in vacuo.  The residue was extracted with EtOAc (3 x 30 mL) and the 
combined organic extracts washed with water (30 mL), dried over MgSO4, filtered 
and concentrated in vacuo.  Purification by column chromatography (83% EtOAc in 
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petroleum ether) provided 69 (24 mg, 12%) as a white solid.  Rf = 0.27 (100% 
EtOAc); M.p. 80 – 81 C; IR (film) 3489, 3424, 1411, 1332, 1166, 1122, 1062 cm-1; 
δH (300 MHz, MeOD) 4.25 (4H, s, CH2OMs), 3.58 (2H, s, CH2OH), 3.13 (6H, s, 
CH3), OHs not observed; δC (75 MHz, MeOD) 73.7 (C), 70.9 (CH2), 63.2 (CH2), 
37.1 (CH3); MS (ES
+) m/z 301 [M+Na]+; HRMS (ES+) calcd. for C6H14NaO8S2 
[M+Na]+: 301.0022; found: 301.0024. 
 
2-Benzylidenepropane-1,3-diol (71)  
This known compound was prepared according to a literature 
procedure.29  To a solution of diethyl benzylidenemalonate (2.21 g, 8.90 
mmol) in anhydrous toluene (4 mL) at ˗30 C was added DIBAL (1 M in 
toluene, 40.0 mL, 40.0 mmol) dropwise.  The reaction mixture was stirred at ˗30 C 
for 3 h then quenched with methanol (10 mL).  Potassium sodium tartrate (36 g) in 
water (100 mL) was added to the solution, which was stirred at rt for 1 h before it 
was extracted with EtOAc (3 x 100 mL).  The combined organic extracts were 
washed with brine (2 x 100 mL), dried over MgSO4, filtered and concentrated in 
vacuo.  Resultant solid was washed with petroleum ether, filtered and dried to give 
71 (890 mg, 61%) as a white solid.  Rf = 0.23 (75% EtOAc in petroleum ether); δH 
(400 MHz, DMSO-d6) 7.37 – 7.30 (4H, m, ArH), 7.26 – 7.21 (1H, m, ArH), 6.56 
(1H, br s, =CH), 4.89 (1H, t, J = 5.6, OH), 4.81 (1H, t, J = 5.2, OH), 4.15 (2H, dd, J 
= 5.6, 1.4, CH2), 4.07 (2H, d, J = 5.2, CH2); δC (100 MHz, DMSO-d6) 142.6 (C), 
136.9 (C, Ar), 128.6 (CH, Ar), 128.1 (CH, Ar), 126.5 (CH, Ar), 124.7 (CH), 63.0 
(CH2), 57.3 (CH2); MS (ES
+) m/z 187 [M+Na]+; HRMS (ES+) calcd. for C10H12NaO2 
[M+Na]+: 187.0730; found: 187.0736. 
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(3-Phenyloxirane-2,2-diyl)dimethanol (72) 
This novel compound was prepared using a modified literature 
procedure.31-32  To a solution of 71 (160 mg, 0.97 mmol) and vanadyl 
acetylacetonate (29 mg, 0.11 mmol) in anhydrous toluene (15 mL) at 
˗25 C was added anhydrous t-butyl hydroperoxide (5-6 M in decane, 0.4 mL, 1.95 
mmol).  The reaction mixture was stirred at 0 C for 23 h before water (50 mL) was 
added and the solution extracted with EtOAc (3 x 100 mL).  The combined organic 
extracts were washed with water (2 x 50 mL) then brine (50 mL) before being dried 
over MgSO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (75% EtOAc in petroleum ether) provided 72 (80 mg, 46%) as a 
white solid.  Rf = 0.27 (75% EtOAc in petroleum ether); M.p. 99 - 100 C; IR (film) 
3242, 2925, 1602, 1498, 1450, 1244, 953, 862 cm-1; δH (400 MHz, CDCl3) 7.40 – 
7.28 (5H, m, ArH), 4.27 (1H, s, CH), 4.11 (1H, d, J = 12.4, CHH), 3.95 (1H, d, J = 
12.4, CHH), 3.59 (2H, s, CH2), 2.15 (1H, br s, OH), 1.72 (1H, br s, OH); δC (75 
MHz, acetone-d6) 136.8 (C, Ar), 128.9 (CH, Ar), 128.2 (CH, Ar), 127.2 (CH, Ar), 
66.5 (C), 63.0 (CH2), 60.9 (CH), 60.1 (CH2); MS (ES
+) m/z 203 [M+Na]+; HRMS 
(ES+) calcd. for C10H12NaO3 [M+Na]
+: 203.0679; found: 203.0684. 
 
(3-Phenyloxirane-2,2-diyl)dimethanol (72) 
To a solution of 71 (888 mg, 5.41 mmol) in anhydrous CH2Cl2 (35 mL) 
was added mCPBA (77% in water, 1.86 g, 8.30 mmol) and the reaction 
mixture stirred at rt for 4.5 h.  EtOAc (100 mL) was added to the 
solution, which was washed with saturated aqueous Na2S2O3 solution (100 mL) then 
saturated aqueous NaHCO3 solution (100 mL).  The combined organic extracts were 
dried over MgSO4, filtered and concentrated in vacuo.  Purification by column 
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chromatography (75% EtOAc in petroleum ether) provided 72 (715 mg, 73%) as a 
white solid.  Data as previously reported. 
 
[2-(Hydroxymethyl)-3-phenyloxiran-2-yl]methyl 4-methylbenzenesulfonate (76 
and 77) 
These novel compounds were prepared using a modified 
literature procedure.33-34  A solution of 72 (103 mg, 0.57 
mmol) and dibutyltin(IV) oxide (4 mg, 0.02 mmol) in 
anhydrous CH2Cl2 (2 mL) was stirred at rt for 1 h.  Diisopropyl ethylamine (0.12 
mL, 0.69 mmol) was added and the reaction mixture stirred for 5 min, before p-
toluenesulfonyl chloride (115 mg, 0.60 mmol) was added.  The reaction mixture was 
stirred at rt for 21 h before 1 M HCl (20 mL) was added.  The solution was extracted 
with EtOAc (3 x 30 mL) before the combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo.  Purification by column chromatography 
(11  33% EtOAc in petroleum ether) provided the less polar 76 (54 mg, 28%) as a 
colourless oil.  Rf = 0.24 (33% EtOAc in petroleum ether); IR (film) 3568, 1359, 
1265, 1175, 968, 815, 733, 700, 666 cm-1; δH (400 MHz, CDCl3) 7.84 (2H, d, J = 
8.3, ArH), 7.40 – 7.26 (7H, m, ArH), 4.39 (1H, d, J = 11.0, CHHOTs), 4.30 (1H, d, J 
= 11.0, CHHOTs), 4.15 (1H, s, CH), 3.51 (2H, s, CH2OH), 2.46 (3H, s, CH3), 1.62 
(1H, br s, OH); δC (100 MHz, CDCl3) 145.4 (C, Ar), 133.6 (C, Ar), 132.7 (C, Ar), 
130.2 (CH, Ar), 128.5 (CH, Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 126.4 (CH, Ar), 
69.8 (CH2OTs), 62.9 (C), 61.7 (CH), 59.4 (CH2OH), 21.8 (CH3); MS (ES
+) m/z 357 
[M+Na]+; HRMS (ES+) calcd. for C17H18NaO5S [M+Na]
+: 357.0767; found: 
357.0766.  Followed by the more polar 77 (42 mg, 22%) as a colourless oil.  Rf = 
0.27 (40% EtOAc in petroleum ether); IR (film) 3546, 1362, 1270, 1176, 973, 814, 
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735, 701, 667 cm-1; δH (400 MHz, CDCl3) 7.58 (2H, d, J = 8.3, ArH), 7.29 – 7.24 
(5H, m, ArH), 7.19 – 7.15 (2H, m, ArH), 4.25 (1H, s, CH), 3.99 – 3.88 (2H, m, 
CH2OH), 3.98 (1H, d, J = 10.9, CHHOTs), 3.86 (1H, d, J = 10.9, CHHOTs), 2.44 
(3H, s, CH3), 1.92 (1H, t, J = 6.0, OH); δC (100 MHz, CDCl3) 145.2 (C, Ar), 133.5 
(C, Ar), 132.2 (C, Ar), 130.0 (CH, Ar), 128.5 (CH, Ar), 128.3 (CH, Ar), 128.1 (CH, 
Ar), 126.3 (CH, Ar), 67.2 (CH2OTs), 62.8 (C), 61.7 (CH2OH), 60.4 (CH), 21.8 
(CH3); MS (ES
+) m/z 357 [M+Na]+; HRMS (ES+) calcd. for C17H18NaO5S [M+Na]
+: 
357.0767; found: 357.0767.  The regioisomers were identified using NOE 
experiments. 
 
[2-(Hydroxymethyl)-3-phenyloxiran-2-yl]methyl 4-methylbenzenesulfonate (76 
and 77) 
These novel compounds were prepared using a modified 
literature procedure.35  To a solution of 72 (505 mg, 2.80 
mmol) in anhydrous THF (24 mL) at 0 C was added nBuLi 
(1.6 M in hexanes, 1.8 mL, 2.88 mmol) dropwise and the reaction mixture stirred at 
0 C for 30 min.  A solution of p-toluenesulfonyl chloride (538 mg, 2.82 mmol) in 
anhydrous THF (11 mL) was added dropwise to the reaction mixture, which was 
stirred at 0 C for 5 h before it was quenched with saturated aqueous NH4Cl solution 
(20 mL).  The aqueous layer was extracted with EtOAc (3 x 50 mL) before the 
combined organic extracts were washed with brine (50 mL), dried over MgSO4, 
filtered and concentrated in vacuo.  Purification by column chromatography (22%  
29% EtOAc in hexane) provided a mixture of 76 and 77 (654 mg, 70%) as a pale, 
viscous liquid.  Ratio of 76 : 77 was 1.7 : 1.  Data as previously reported. 
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2-Phenyl-1,5-dioxaspiro[2.3]hexane (74) 
This novel compound was prepared as follows.  To a stirred suspension of 
NaH (60% in mineral oil, 20 mg, 0.50 mmol) in anhydrous DMF (7 mL) at 
0 C, was added a solution of 76 and 77 (103 mg, 0.31 mmol) in anhydrous 
DMF (8.4 mL).  The reaction mixture was stirred at 0 C for 1 h then warmed to rt 
and stirred for a further 6 h.  Saturated aqueous NH4Cl solution (15 mL) was added 
to the solution, which was extracted with EtOAc (3 x 30 mL).  The combined 
organic extracts were washed with brine (20 mL), dried over Na2SO4, filtered and 
concentrated in vacuo.  Purification by column chromatography (17  25% EtOAc 
in petroleum ether) provided 74 (3 mg, 6%) as a colourless oil.  Rf = 0.24 (25% 
EtOAc in petroleum ether); δH (300 MHz, CDCl3) 7.52 – 7.46 (2H, m, ArH), 7.41 – 
7.35 (3H, m, ArH), 5.41 (1H, s, CH), 4.71 (1H, d, J = 7.0, OCHH), 4.65 (1H, d, J = 
7.0, OCHH), 4.54 (1H, d, J = 7.4, OCHH), 4.48 (1H, d, J = 7.4, OCHH).   
 
Methyl 2-[hydroxy(phenyl)methyl]acrylate (80)147 
This known compound was prepared according to a literature 
procedure.36  A solution of methyl acrylate (5.1 mL, 56.6 mmol), 
benzaldehyde (4.8 mL, 47.3 mmol) and 1,4-diazobicyclo[2.2.2]octane (5.4 g, 48.1 
mmol) were added together at 0 C then stirred at rt for 52 h.  Diethyl ether (80 mL) 
was added to the solution, which was washed with 1 M HCl (2 x 50 mL), saturated 
aqueous NaHCO3 solution (2 x 50 mL), water (50 mL) and brine (50 mL).  The 
organic extracts were dried over Na2SO4, filtered and concentrated in vacuo.  
Purification by column chromatography (10  20% EtOAc in petroleum ether) 
provided 80 (7.02 g, 77%) as a white solid.  Data in agreement with literature 
values.147  Rf = 0.2 (20% EtOAc in petroleum ether); δH (400 MHz, CDCl3) 7.32 – 
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7.24 (4H, m, ArH), 7.23 – 7.17 (1H, m, ArH), 6.26 (1H, s, =CHH), 5.76 – 5.74 (1H, 
m, =CHH), 5.51 – 5.47 (1H, m, CH), 3.64 (3H, s, CH3), 2.93 (1H, d, J = 4.9, OH); δC 
(100 MHz, CDCl3) 166.8 (C=O), 142.1 (C), 141.4 (C, Ar), 128.5 (CH, Ar), 127.9 
(CH, Ar), 126.7 (CH, Ar), 126.1 (CH2), 73.2 (CH), 52.0 (CH3); MS (ES
+) m/z 215 
[M+Na]+; HRMS (ES+) calcd. for C11H12NaO3 [M+Na]
+: 215.0679; found: 
215.0680.   
 
Methyl (S*)-2-((R*)-hydroxy(phenyl)methyl)oxirane-2-carboxylate ((±)-81)37 
This known compound was prepared using a modified literature 
procedure.32  To a solution of 80 (507 mg, 2.64 mmol) and vanadyl 
acetylacetonate (69 mg, 0.26 mmol) in anhydrous toluene (25 mL) at ˗20 C, was 
added anhydrous t-butyl hydroperoxide (5-6 M in decane, 0.95 mL, 5.20 mmol).  
The reaction mixture was stirred at 0 C for 25 h before water (25 mL) was added 
and the solution was extracted with EtOAc (3 x 50 mL).  The combined organic 
extracts were washed with brine (2 x 25 mL) then dried over Na2SO4, filtered and 
concentrated in vacuo.  Purification by column chromatography (17  50% EtOAc 
in petroleum ether) provided (±)-81 (176 mg, 32%) as a colourless oil.  Data in 
agreement with literature values.37  Rf = 0.27 (40% EtOAc in petroleum ether); δH 
(400 MHz, CDCl3) 7.41 (2H, d, J = 7.5, ArH), 7.37 – 7.27 (3H, m, ArH), 5.18 (1H, 
s, CH), 3.71 (3H, s, CH3), 3.14 (1H, br s, OH), 3.10 (1H, d, J = 5.8, CHH), 2.83 (1H, 
d, J = 5.8, CHH); δC (100 MHz, CDCl3) 169.9 (C=O), 138.4 (C, Ar), 128.4 (CH, Ar), 
127.1 (CH, Ar), 71.8 (CH), 59.0 (C), 52.8 (CH3), 49.8 (CH2); MS (ES
+) m/z 231 
[M+Na]+; HRMS (ES+) calcd. for C11H12NaO4 [M+Na]
+: 231.0628; found: 
231.0625.   
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[Bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I) (88)38 
This known compound was prepared according to 
literature procedures.38  Silver carbonate (470 mg, 1.70 
mmol) and bis(trifluoromethane)sulfonimide (980 mg, 
3.49 mmol) were dissolved in water (17 mL) and the 
reaction mixture was heated under reflux for 3 h.  On cooling, the reaction mixture 
was concentrated in vacuo to give silver bis(trifluoromethanesulfonyl)imide as a 
white solid, which was immediately taken through to the next step. 
 
Meanwhile, chloro(dimethylsulfide)gold(I) (498 mg, 1.69 mmol) and 
triphenylphosphine (445 mg, 1.70 mmol) were dissolved in anhydrous CH2Cl2 (42 
mL) and the reaction mixture was stirred at rt for 15 min.  The reaction mixture was 
concentrated in vacuo and the resultant solid washed with hexane, filtered and dried 
to give chloro(triphenylphosphine)gold(I) as a white solid, which was immediately 
taken through to the next step. 
 
A solution of chloro(triphenylphosphine)gold(I) in anhydrous CH2Cl2 (9 mL) was 
added to a solution of silver bis(trifluoromethanesulfonyl)imide in anhydrous 
CH2Cl2 (10 mL) and the reaction mixture was stirred at rt for 15 min.  The solution 
was then filtered through Celite®, washed with CH2Cl2 and concentrated in vacuo to 
afford 88 (1.25 g, 100%) as a white solid.  Data in agreement with literature values.38  
δH (300 MHz, CDCl3) 7.63 – 7.44 (15H, m, ArH); 31P NMR (121.5 MHz, CDCl3) δP 
29.8.   
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5-Phenylpent-1-yn-3-ol (93)15 
This known compound was prepared according to a literature 
procedure.15  To a solution of trimethylsilylacetylene (3.2 mL, 
22.6 mmol) in anhydrous THF (56 mL) at ˗78 C, was added nBuLi (1.6 M in 
hexanes, 14.9 mL, 23.8 mmol) and the reaction mixture was stirred for 15 min.  A 
solution of 3-phenylpropionaldehyde (2.0 mL, 15.2 mmol) in anhydrous THF (56 
mL) was added dropwise and the reaction mixture was stirred at ˗78 C for 3.5 h 
before saturated aqueous NH4Cl solution (20 mL) was added.  The aqueous layer 
was extracted with diethyl ether (4 x 50 mL) then the combined organic extracts 
were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in 
vacuo.  Purification by repeat column chromatography (13% EtOAc in petroleum 
ether; 11  13% EtOAc in petroleum ether) provided the TMS-protected alkyne.  
To a stirred solution of this alkyne (2.46 g, 10.6 mmol) in anhydrous THF (93 mL) at 
0 C, was added a solution of tetrabutylammonium fluoride (1 M in THF, 12.7 mL, 
12.7 mmol) and the reaction mixture was stirred for 30 min.  Saturated aqueous 
NH4Cl solution (30 mL) was added to the reaction mixture and the aqueous layer 
was extracted with diethyl ether (3 x 75 mL).  The combined organic extracts were 
washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo.  
Purification by column chromatography (13  17% EtOAc in petroleum ether) 
provided 93 (1.29 g, 76%) as a pale yellow liquid.  Data in agreement with literature 
values.15  Rf = 0.23 (17% EtOAc in petroleum ether); IR (film) 3485, 3283, 2931, 
1604, 1496, 1042, 746, 698 cm-1; δH (400 MHz, CDCl3) 7.33 – 7.27 (2H, m, ArH), 
7.25 – 7.18 (3H, m, ArH), 4.37 (1H, t, J = 5.8, CHOH), 2.81 (2H, t, J = 7.8, CH2), 
2.50 (1H, d, J = 2.0, CH), 2.32 (1H, br s, OH), 2.12 – 1.97 (2H, m, CH2); δC (100 
MHz, CDCl3) 141.2 (C, Ar), 128.6 (CH, Ar), 128.6 (CH, Ar), 126.1 (CH, Ar), 84.8 
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(CH), 73.5 (C), 61.6 (CHOH), 39.1 (BnCH2), 31.3 (PhCH2); MS (ES
+) m/z 178 
[M+NH4]
+.148 
 
2-Phenethyloxetan-3-one (94)15 
This known compound was prepared according to a literature 
procedure.15  To a solution of 93 (707 mg, 4.41 mmol) in anhydrous 
DCE (62 mL) was added 3,5-dichloropyridine N-oxide (1.48 g, 9.02 mmol), 
bis(trifluoromethane)sulfonimide (1.52 g, 5.41 mmol) and 88 (169 mg, 0.23 mmol).  
The reaction mixture was stirred at rt for 4 h in the absence of light before saturated 
aqueous NaHCO3 solution (50 mL) was added and the solution extracted with 
CH2Cl2 (3 x 50 mL).  The combined organic extracts were washed with brine (20 
mL), dried over MgSO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (0  15% EtOAc in petroleum ether) provided 94 (485 mg, 62%) 
as a colourless oil.  Data in agreement with literature values.15  Rf = 0.22 (17% 
EtOAc in petroleum ether); δH (400 MHz, CDCl3) 7.32 – 7.27 (2H, m, ArH), 7.23 – 
7.17 (3H, m, ArH), 5.48 – 5.42 (1H, m, CH), 5.29 (1H, dd, J = 15.1, 1.3, OCHH), 
5.24 (1H, dd, J = 15.1, 4.0, OCHH), 2.85 – 2.73 (2H, m, CH2), 2.23 - 2.06 (2H, m, 
CH2); δC (100 MHz, CDCl3) 203.2 (C=O), 140.4 (C, Ar), 128.7 (CH, Ar), 128.6 
(CH, Ar), 126.4 (CH, Ar), 102.9 (CH), 89.0 (OCH2), 32.9 (CH2), 30.3 (CH2); MS 
(ES+) m/z 199 [M+Na]+.   
 
2-Phenethylcyclohexan-1-one (95)40 
This known compound was prepared according to a literature 
procedure.40  To a stirred suspension of potassium t-butoxide (558 
mg, 4.97 mmol) in anhydrous DMSO (52 mL) was added cyclohexanone (5.13 mL, 
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49.5 mmol) and styrene (1.9 mL, 16.5 mmol).  The reaction mixture was heated at 40 
C for 16 h then cooled to 0 C and diluted with water (50 mL).  The solution was 
extracted with CH2Cl2 (3 x 100 mL) and the combined organic extracts washed with 
brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo.  Purification 
by column chromatography (0  10% EtOAc in petroleum ether) provided 95 (1.06 
g, 32%) as a pale yellow liquid.  Data in agreement with literature values.40  Rf = 
0.29 (10% EtOAc in petroleum ether); δH (400 MHz, CDCl3) 7.24 – 7.18 (2H, m, 
ArH), 7.15 – 7.09 (3H, m, ArH), 2.63 – 2.49 (2H, m, CH2), 2.40 – 2.30 (1H, m, CH), 
2.27 – 2.17 (2H, m, CH2), 2.13 – 2.03 (2H, m, CH2), 2.02 – 1.91 (1H, m, CH), 1.85 – 
1.74 (1H, m, CH), 1.68 – 1.52 (2H, m, CH2), 1.49 – 1.31 (2H, m, CH2); δC (100 
MHz, CDCl3) 213.2 (C=O), 142.3 (C, Ar), 128.5 (CH, Ar), 128.4 (CH, Ar), 125.9 
(CH, Ar), 50.0 (CH), 42.2 (CH2), 34.1 (CH2), 33.3 (CH2), 31.3 (CH2), 28.2 (CH2), 
25.0 (CH2); MS (ES
+) m/z 225 [M+Na]+.   
 
(3R*,4R*)-4-Phenethyl-1-oxaspiro[2.5]octane ((±)-98) 
This novel compound was prepared using a modified literature 
procedure.39  Anhydrous DMSO (1.2 mL) was added to NaH (60% 
in mineral oil, 76 mg, 1.90 mmol) and trimethylsulfoxonium iodide (395 mg, 1.79 
mmol).  After 15 – 20 min, a solution of 95 (300 mg, 1.49 mmol) in anhydrous 
DMSO (1.8 mL) was added and the reaction mixture was stirred at rt for 20 min 
before being heated at 50 C for 3 h.  After cooling, water (10 mL) was added to the 
solution, which was extracted with diethyl ether (4 x 25 mL).  The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo.  Purification by 
column chromatography (6  10% EtOAc in petroleum ether) provided (±)-98 (88 
mg, 27%) as a colourless oil.  Rf = 0.26 (2% EtOAc in petroleum ether); IR (film) 
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2931, 2859, 1604, 1496, 1240, 922, 845, 734, 698 cm-1; δH (400 MHz, CDCl3) 7.31 – 
7.25 (2H, m, ArH), 7.21 – 7.15 (3H, m, ArH), 2.74 – 2.64 (1H, m, CHH), 2.70 (1H, 
dd, J = 4.8, 0.9, OCHH), 2.61 – 2.49 (1H, m, CHH), 2.52 (1H, d, J = 4.8, OCHH), 
1.85 – 1.34 (11H, m, CH2, CH); δC (100 MHz, CDCl3) 142.7 (C, Ar), 128.5 (CH, 
Ar), 128.4 (CH, Ar), 125.8 (CH, Ar), 61.5 (C), 53.7 (OCH2), 40.2 (CH), 33.9 (CH2), 
32.0 (CH2), 30.6 (CH2), 29.5 (CH2), 25.2 (CH2), 22.4 (CH2); MS (ES
+) m/z 239 
[M+Na]+; HRMS (ES+) calcd. for C15H20NaO [M+Na]
+: 239.1406; found: 239.1408. 
 
(3R*,4R*)-4-Phenethyl-1,5-dioxaspiro[2.3]hexane ((±)-99a) 
This novel compound was prepared using a modified literature 
procedure.39  Anhydrous DMSO (1.45 mL) was added to NaH 
(60% in mineral oil, 53 mg, 1.33 mmol) and trimethylsulfoxonium iodide (319 mg, 
1.45 mmol) and the reaction mixture was stirred at rt for 20 min.  A solution of 94 
(182 mg, 1.03 mmol) in anhydrous DMSO (0.7 mL) was then added and the reaction 
mixture was stirred at rt for 20 min before being heated at 50 C for 2.5 h.  After 
cooling, water (20 mL) was added to the solution, which was extracted with diethyl 
ether (4 x 20 mL).  The combined organic extracts were washed with brine (20 mL), 
dried over MgSO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (13  22% EtOAc in petroleum ether) provided one diastereomer, 
(±)-99a (47 mg, 24%) as a colourless oil.  Rf = 0.25 (20% EtOAc in petroleum 
ether); IR (film) 2944, 1604, 1496, 1454, 962, 864 cm-1; δH (400 MHz, CDCl3) 7.27 
– 7.21 (2H, m, ArH), 7.17 – 7.12 (3H, m, ArH), 5.01 (1H, ddd, J = 7.3, 5.9, 1.1, 
CH), 4.89 (1H, d, J = 7.9, OCHH), 4.78 (1H, d, J = 7.9, OCHH), 2.80 (1H, d, J = 
4.3, epoxide CHH), 2.75 – 2.70 (1H, m, CHH), 2.68 (1H, d, J = 4.3, epoxide CHH), 
2.66 – 2.57 (1H, m, CHH), 2.19 – 2.09 (1H, m CHH), 2.02 – 1.93 (1H, m, CHH); δC 
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(100 MHz, CDCl3) 141.4 (C, Ar), 128.6 (CH, Ar), 128.5 (CH, Ar), 126.1 (CH, Ar), 
87.1 (CH), 76.0 (OCH2), 61.4 (C), 48.8 (epoxide CH2), 33.4 (CH2), 30.3 (CH2); MS 
(ES+) m/z 213 [M+Na]+; HRMS (ES+) calcd. for C12H14NaO2 [M+Na]
+: 213.0886; 
found: 213.0887.  A small amount of the other diastereomer (99b) was also obtained 
impure (9 mg, ~ 5%).  
 
3-(Hydroxymethyl)-2-phenethyloxetan-3-ol ((±)-100) 
This novel compound was prepared as follows.  (±)-99a was 
left in the freezer with residual CDCl3 over a period of 2 
months.  Purification by column chromatography (25  70% EtOAc in petroleum 
ether) provided (±)-100 (18 mg, 35%) as a colourless oil.  Rf = 0.39 (70% EtOAc in 
petroleum ether); IR (film) 3380, 2881, 1601, 1496, 1454, 1067, 954, 751, 698 cm-1; 
δH (400 MHz, CDCl3) 7.24 – 7.18 (2H, m, ArH), 7.15 – 7.09 (3H, m, ArH), 4.43 
(1H, dd, J = 8.2, 5.9, CH), 4.41 – 4.37 (2H, m, OCH2), 3.79 – 3.71 (2H, m, OHCH2), 
2.72 – 2.64 (2H, m, OH, CHH), 2.59 – 2.51 (1H, m, CHH), 2.16 – 1.95 (3H, m, CH2, 
OH); δC (100 MHz, CDCl3) 141.6 (C, Ar), 128.6 (CH, Ar), 126.1 (CH, Ar), 88.4 
(CH), 78.5 (OCH2), 74.6 (C), 67.5 (CH2OH), 32.5 (CH2), 30.8 (CH2); MS (ES
+) m/z 
231 [M+Na]+; HRMS (ES+) calcd. for C12H16NaO3 [M+Na]
+: 231.0992; found: 
231.0993. 
 
Dimethyl titanocene (Petasis reagent) (104)44 
This known compound was prepared according to a literature 
procedure.44  To a stirred solution of bis(cyclopentadienyl)titanium (IV) 
dichloride (2.02 g, 8.11 mmol) in anhydrous Et2O (20 mL) at 0 C in the dark, was 
added methyl lithium (1.6 M in diethyl ether, 11.0 ml, 17.6 mmol) dropwise.  The 
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reaction mixture was stirred at rt for 1 h then cooled to 0 C and quenched with 
water (30 mL).  The solution was extracted with Et2O (3 x 50 mL) and the combined 
organic extracts washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give 104 (1.66 g, 98%) as a bright orange solid.  A 0.5 M 
solution was made up using anhydrous toluene.  Data in agreement with literature 
values.44  δH (400 MHz, CDCl3) 6.06 (10H, s, Cp), -0.15 (6H, s, CH3); δC (100 MHz, 
CDCl3) 113.2 (CH, Cp), 45.6 (CH3).   
 
3-Methylene-2-phenethyloxetane (102) 
This novel compound was prepared using a modified literature 
procedure.22  A stirred solution of 94 (101 mg, 0.57 mmol) and 104 
(0.5 M solution in toluene, 1.72 mL, 0.86 mmol) was heated at 75 C for 16 h then 
cooled to rt.  Petroleum ether (2 mL) was added and the cloudy solution formed was 
filtered through Celite® repeatedly until the filtrate was clear.  The filtrate was 
concentrated in vacuo and subsequent purification by column chromatography (5  
20% Et2O in petroleum ether) provided 102 (47 mg, 47%) as a colourless liquid.  Rf 
= 0.36 (20% EtOAc in petroleum ether); IR (film) 3026, 2930, 2860, 1699, 1602, 
1495, 1454, 1073, 956, 885, 746, 697 cm-1; δH (400 MHz, acetone-d6) 7.34 – 7.28 
(2H, m, ArH), 7.25 (2H, d, J = 7.8, ArH), 7.20 (1H, t, J = 7.3, ArH), 5.26 – 5.20 (1H, 
m, CH), 5.10 – 5.04 (1H, m, OCHH), 5.04 – 4.98 (1H, m, OCHH), 4.92 (1H, d, J = 
1.1, =CHH), 4.86 (1H, d, J = 1.1, =CHH), 2.85 – 2.69 (2H, m, CH2), 2.13 – 1.98 
(2H, m, CH2); δC (100 MHz, acetone-d6) 149.8 (C=), 142.7 (C, Ar), 129.2 (CH, Ar), 
129.2 (CH, Ar), 126.6 (CH, Ar), 103.6 (=CH2), 89.4 (OCH), 76.3 (OCH2), 38.5 
(CH2), 30.9 (CH2); MS (ES
+) m/z 197 [M+Na]+; HRMS (ES+) calcd. for C12H14NaO 
[M+Na]+: 197.0937; found: 197.0937. 
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(3S*,4R*)-4-Phenethyl-1,5-dioxaspiro[2.3]hexane ((±)-99b) 
DMDO was generated according to a literature procedure.47  A 
solution of NaHCO3 (12 g), water (20 mL) and acetone (13 mL) 
was stirred at 0 C and equipped with distillation apparatus cooled with dry ice.  
Oxone (25 g) was added and the reaction mixture was stirred at rt under a slight 
vacuum for 1 h.  The DMDO solution collected was added to a solution of (±)-102 
(46 mg, 0.26 mmol) in CH2Cl2 (1 mL) at 0 C.  The reaction mixture was warmed to 
rt and stirred overnight before it was concentrated in vacuo.  Purification by column 
chromatography (0  10% Et2O in petroleum ether + 0.5% NEt3) provided 99b (11 
mg, 22%) as a colourless oil.  δH (400 MHz, acetone-d6) 7.30 – 7.25 (2H, m, ArH), 
7.24 – 7.15 (3H, m, ArH), 4.90 (1H, dd, J = 8.0, 4.3, CH), 4.75 (1H, dd, J = 7.8, 1.3, 
OCHH), 4.67 (1H, d, J = 7.8, OCHH), 2.92 (1H, d, J = 4.4, epoxide CHH), 2.80 – 
2.72 (1H, m, CHH), 2.77 (1H, d, J = 4.4, epoxide CHH), 2.69 – 2.60 (1H, m, CHH), 
2.10 – 2.00 (1H, m, CHH), 1.94 – 1.85 (1H, m, CHH).  The compound was taken 
through to the next step immediately due to its instability. 
 
3-[(Benzylamino)methyl]-2-phenethyloxetan-3-ol ((±)-105) 
This novel compound was prepared as follows.  To a 
stirred solution of (±)-99b (10 mg, 52.6 µmol) in 
anhydrous ethanol (2 mL), was added benzylamine (6.9 µL, 63.1 µmol).  The 
reaction mixture was heated under reflux for 16 h then cooled to rt and concentrated 
in vacuo.  Purification by column chromatography (80% EtOAc in petroleum ether 
 10% MeOH in EtOAc) provided (±)-105 (12 mg, 77%) as a colourless oil.  Rf = 
0.41 (10% MeOH in EtOAc); IR (film) 3337, 3027, 2944, 2871, 1603, 1496, 1454, 
1329, 964, 746, 698 cm-1; δH (400 MHz, CDCl3) 7.36 – 7.25 (7H, m, ArH), 7.22 – 
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7.15 (3H, m, ArH), 4.74 (1H, dd, J = 9.5, 4.3, CH), 4.49 (1H, d, J = 6.3, OCHH), 
4.23 (1H, d, J = 6.3, OCHH), 3.81 (2H, s, PhCH2NH), 3.01 – 2.94 (2H, m, 
BnNHCH2), 2.80 – 2.50 (4H, m, CH2, OH, NH), 1.98 – 1.79 (2H, m, CH2); δC (125 
MHz, CDCl3) 141.4 (C, Ar), 138.6 (C, Ar), 128.8 (CH, Ar), 128.6 (CH, Ar), 128.5 
(CH, Ar), 128.4 (CH, Ar), 127.8 (CH, Ar), 126.2 (CH, Ar), 90.9 (CH), 79.4 (OCH2), 
73.9 (C), 54.1 (PhCH2NH), 51.2 (BnNHCH2), 33.3 (CH2), 31.4 (CH2); MS (ES
+) m/z 
298 [M+H]+, 320 [M+Na]+; HRMS (ES+) calcd. for C19H24NO2 [M+H]
+: 298.1802; 
found: 298.1802.   
 
Ethyl 2-(oxetan-3-ylidene)acetate (106)15 
This known compound was prepared according to a literature 
procedure.15  To a stirred solution of 3-oxetanone (390 mg, 5.41 mmol) 
in anhydrous CH2Cl2 (90 mL) at rt was added carbethoxymethylene 
triphenylphosphorane (2.84 g, 8.15 mmol).  The reaction mixture was stirred at rt for 
5.5 h and then concentrated in vacuo.  Purification by column chromatography (10 
 20% EtOAc in petroleum ether) provided 106 (615 mg, 80%) as a colourless 
liquid.  Data in agreement with literature values.15  Rf = 0.33 (30% EtOAc in 
petroleum ether); IR (film) 2913, 2860, 1727, 1703, 1471, 1370, 1343, 1296, 1252, 
1200, 1096, 958, 862, 831 cm-1; δH (400 MHz, CDCl3) 5.61 – 5.58 (1H, m, CH), 
5.48 – 5.44 (2H, m, OCH2), 5.28 – 5.24 (2H, m, OCH2), 4.12 (2H, q, J = 7.2, CH2), 
1.23 (3H, t, J = 7.2, CH3); δC (100 MHz, CDCl3) 165.3 (C=O), 159.3 (C), 111.2 
(CH), 81.1 (OCH2), 78.5 (OCH2), 60.4 (CH2), 14.3 (CH3); GC-MS (EI) m/z 142 
[M]+, 84, 68, 55. 
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Ethyl 1,5-dioxaspiro[2.3]hexane-2-carboxylate (107) 
This novel compound was prepared using a modified literature 
procedure.52  To a stirred solution of anhydrous THF (4 mL) at ˗78 C was 
added t-BuOOH (~ 5.5 M in decane, 0.19 mL, 1.05 mmol), followed by 
nBuLi (2.5 M in hexane, 0.31 mL, 0.78 mmol).  The reaction mixture was stirred at 
˗78 C for 5 min before a solution of 106 (97 mg, 0.68 mmol) in anhydrous THF (2 
mL) was added.  The reaction mixture was stirred at ˗78 C for 5 min then warmed 
to 0 C and maintained at this temperature for 23 h before sodium sulfite (0.5 g) was 
added.  The reaction mixture was warmed to rt and stirred for 20 min then diluted 
with Et2O (15 mL), filtered through Celite
®, washed with Et2O and concentrated in 
vacuo.  Purification by column chromatography (0  50% EtOAc in petroleum 
ether) provided 107 (14 mg, 13%) as a colourless oil.  Rf = 0.27 (30% EtOAc in 
petroleum ether); IR (film) 2953, 2878, 1738, 1452, 1339, 1291, 1198, 1026 cm-1; δH 
(400 MHz, acetone-d6) 4.96 – 4.93 (1H, m, OCHH), 4.87 – 4.84 (1H, m, OCHH), 
4.79 (2H, d, J = 8.5, OCHH), 4.27 – 4.14 (2H, m, CH2CH3), 3.63 (1H, s, epoxide 
CH), 1.26 (3H, t, J = 7.2, CH3); δC (100 MHz, acetone-d6) 168.0 (C=O), 78.0 
(OCH2), 78.0 (OCH2), 64.3 (C), 62.2 (CH2), 54.5 (epoxide CH), 14.5 (CH3); GC-MS 
(CI) m/z 159 [M+H]+; HRMS (ES+) calcd. for C7H11O4 [M+H]
+: 159.0652; found: 
159.0653. 
 
3-(1-Nitro-2-phenylethyl)oxetan-3-ol (166) 
This novel compound was prepared using a modified literature 
procedure.91  (2-Nitroethyl)benzene (194 mg, 1.28 mmol), 3-
oxetanone (107 µL, 1.67 mmol) and NEt3 (36 µL, 0.26 mmol) were 
stirred at rt for 90 min, giving a pale yellow solid.  Purification by column 
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chromatography (40  50% EtOAc in hexane) provided 166 (246 mg, 86%) as a 
white solid.  M.p. 96 – 97 °C; Rf = 0.32 (50% EtOAc in hexane); IR (film) 3354, 
2955, 2884, 1602, 1548, 1497, 1455, 1369, 1274, 1079, 971, 744, 699 cm-1; δH (400 
MHz, CDCl3) 7.36 – 7.23 (5H, m, ArH), 5.20 (1H, t, J = 7.5, CH), 4.63 (1H, d, J = 
7.4, OCHH), 4.59 (1H, d, J = 7.4, OCHH), 4.39 (1H, d, J = 7.7, OCHH), 4.03 (1H, 
d, J = 7.7, OCHH), 3.50 (1H, s, OH), 3.43 (1H, dd, J = 14.1, 8.0, CHHPh), 3.27 (1H, 
dd, J = 14.1, 7.0, CHHPh); δC (100 MHz, CDCl3) 134.5 (C, Ar), 129.2 (CH, Ar), 
129.1 (CH, Ar), 128.0 (CH, Ar), 92.4 (CH), 81.6 (OCH2), 79.7 (OCH2), 74.3 (C), 
35.0 (CH2Ph); MS (ES
+) m/z 246 [M+Na]+; HRMS (ES+) calcd. for C11H13NNaO4 
[M+Na]+: 246.0737; found: 246.0738; CHN calcd. for C11H13NO4: C, 59.19 H, 5.87 
N, 6.27%; found: C, 59.08 H, 5.86 N, 6.23%. 
 
3-(1-Nitro-2-phenylethylidene)oxetane (164)91 
This known compound was prepared according to a literature 
procedure.91  (2-Nitroethyl)benzene (630 mg, 4.17 mmol), 3-
oxetanone (0.35 mL, 5.46 mmol) and NEt3 (0.12 mL, 0.86 mmol) were stirred at rt 
for 90 min then diluted with anhydrous CH2Cl2 (24.5 mL) and cooled to ˗78 C.  
NEt3 (1.74 mL, 12.5 mmol) was added, followed by MsCl (0.35 mL, 4.52 mmol).  
The reaction mixture was stirred at ˗78 C for 30 min then gradually warmed to ˗20 
C over 1 h and quenched with saturated aqueous NH4Cl solution (20 mL).  The 
solution was diluted with water (10 mL) and CH2Cl2 (30 mL) and extracted with 
CH2Cl2 (3 x 50 mL).  The combined organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo.  Purification by column chromatography (10  
30% Et2O in petroleum ether) provided 164 (359 mg, 42%) in an inseparable mixture 
with its rearrangement product 167 (~25 : 1) as a white solid.  Data in agreement 
Chapter 3: Experimental 
 
157 
with literature values but full data had not been reported.91  Rf = 0.18 (20% EtOAc in 
petroleum ether); M.p. 51 – 52 C; IR (film) 2915, 2850, 1602, 1513, 1496, 1454, 
1337, 1305, 960, 770, 699 cm-1; δH (400 MHz, CDCl3) 7.36 – 7.28 (3H, m, ArH), 
7.24 – 7.20 (2H, m, ArH), 5.60 – 5.57 (2H, m, OCH2), 4.92 – 4.88 (2H, m, OCH2), 
3.82 (2H, s, CH2); δC (100 MHz, CDCl3) 151.3 (C), 140.0 (C), 134.8 (C, Ar), 129.2 
(CH, Ar), 129.0 (CH, Ar), 127.7 (CH, Ar), 79.9 (OCH2), 75.5 (OCH2), 34.0 (CH2); 
MS (ES+) m/z 228 [M+Na]+; HRMS (ES+) calcd. for C11H11NNaO3 [M+Na]
+: 
228.0631; found: 228.0634.   
 
Methyl glycinate (168) 
This known compound was prepared according to a literature 
procedure.92  To a stirred solution of glycine methyl ester 
hydrochloride (1.06 g, 8.44 mmol) in anhydrous chloroform (6 mL) was added a 
solution of NEt3 (1.18 mL, 8.47 mmol) in anhydrous chloroform (6 mL).  The 
reaction mixture was stirred at rt for 5 h then at 70 C for 1 h before it was cooled to 
rt and concentrated in vacuo.  The white solid formed was diluted with Et2O and 
filtered under vacuum.  The filtrate was concentrated in vacuo to give 168 (352 mg, 
47%) as a pale yellow liquid, which was used without further purification.  Data in 
agreement with literature values.149  δH (400 MHz, CDCl3) 3.72 (3H, s, CH3), 3.43 
(2H, s, CH2), 1.42 (2H, br s, NH2); MS (ES
+) m/z 112 [M+Na]+.150 
 
Methyl [3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycinate (169) 
This novel compound was prepared using a modified 
literature procedure.91  To a stirred solution of 164 (357 mg, 
1.74 mmol) in anhydrous THF (16 mL) was added a solution 
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of 168 (311 mg, 3.49 mmol) in anhydrous THF (10.5 mL).  The reaction mixture 
was stirred at rt for 4 h then concentrated in vacuo.  Resultant solid was 
recrystallised (EtOH) to give 169 (450 mg, 88%) as white crystals.  M.p. 102 - 104 
C; IR (film) 3339, 2955, 2885, 1738, 1606, 1550, 1497, 1456, 1437 1368, 1213, 
1181, 981, 747, 699 cm-1; δH (400 MHz, CDCl3) 7.35 – 7.21 (5H, m, ArH), 5.12 (1H, 
dd, J = 9.8, 4.5, CH), 4.65 (1H, d, J = 7.5, OCHH), 4.62 (1H, d, J = 7.5, OCHH), 
4.51 (1H, d, J = 8.0, OCHH), 4.48 (1H, d, J = 8.0, OCHH), 3.78 (3H, s, CH3), 3.72 
(1H, dd, J = 17.3, 6.0, CHHCO2Me), 3.61 (1H, dd, J = 17.3, 6.0, CHHCO2Me), 3.52 
(1H, dd, J = 14.6, 9.8, CHHPh), 3.29 (1H, dd, J = 14.6, 4.5, CHHPh), 2.47 (1H, br t, 
J = 5.9, NH); δC (100 MHz, acetone-d6) 173.1 (C=O), 137.2 (C, Ar), 129.9 (CH, Ar), 
129.5 (CH, Ar), 128.0 (CH, Ar), 92.7 (CH), 77.6 (OCH2), 77.2 (OCH2), 63.1 (C), 
52.2 (CH3), 45.0 (CH2CO2Me), 35.2 (CH2Ph); MS (ES
+) m/z 295 [M+H]+, 317 
[M+Na]+; HRMS (ES+) calcd. for C14H18N2NaO5 [M+Na]
+: 317.1108; found: 
317.1108.   
 
Methyl [(benzyloxy)carbonyl]glycylglycinate (171) 
This known compound was prepared using a modified 
literature procedure.151  To a stirred solution of Z-Gly-OH 
(73 mg, 0.35 mmol), DCC (79 mg, 0.38 mmol), HOBt (59 mg, 0.38 mmol) and 
DIEA (66.4 µL, 0.38 mmol) in anhydrous CH2Cl2 (2 mL) was added a solution of 
168 (34 mg, 0.38 mmol) in anhydrous CH2Cl2 (3 mL).  The reaction mixture was 
stirred at rt overnight then filtered through Celite®, washed with CH2Cl2 and 
concentrated in vacuo.  Purification by column chromatography (70  75% EtOAc 
in petroleum ether + 0.5% NEt3) provided 171 (37 mg, 38%) as a white solid.  Data 
was not fully reported in the literature.  M.p. 64 – 66 °C; Rf = 0.23 (70% EtOAc in 
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petroleum ether); IR (film) 3317, 3037, 2955, 2851, 1733, 1688, 1655, 1533, 1495, 
1235, 1209, 997, 733, 694 cm-1; δH (400 MHz, CDCl3) 7.35 – 7.27 (5H, m, ArH), 
6.87 – 6.81 (1H, m, NH), 5.76 – 5.70 (1H, m, NH), 5.11 (2H, s, PhCH2O), 4.01 (2H, 
d, J = 5.0, CH2), 3.90 (2H, d, J = 4.5, CH2), 3.72 (3H, s, CH3); δC (100 MHz, CDCl3) 
170.3 (C=O), 169.6 (C=O), 156.8 (C=O), 136.2 (C, Ar), 128.6 (CH, Ar), 128.3 (CH, 
Ar), 128.2 (CH, Ar), 67.3 (PhCH2O), 52.5 (CH3), 44.4 (CH2), 41.2 (CH2); MS (ES
+) 
m/z 281 [M+H]+, 303 [M+Na]+; HRMS (ES+) calcd. for C13H16N2NaO5 [M+Na]
+: 
303.0951; found: 303.0952.   
 
Methyl [[3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycyl]glycinate (173) 
This novel compound was prepared using modified 
literature procedures.91,134  A suspension of 171 (307 
mg, 1.10 mmol) and 10% Pd/C (66 mg) in 
anhydrous THF (9 mL) was stirred under an atmosphere of hydrogen at rt for 4.5 h, 
then filtered through Celite® and washed with anhydrous THF (10 mL).  This 
solution was added to a stirred solution of 164 (92 mg, 0.45 mmol) in anhydrous 
THF (1 mL).  The reaction mixture was stirred at rt for 11.5 days then concentrated 
in vacuo.  Purification by column chromatography (85  100% EtOAc in petroleum 
ether) provided 173 (37 mg, 23%) as a pale yellow oil.  Rf = 0.38 (100% EtOAc); IR 
(film) 3368, 2955, 1746, 1669, 1595, 1550, 1545, 1498, 1456, 1371, 1209, 1183, 
733, 699 cm-1; δH (300 MHz, CDCl3) 7.40 – 7.20 (6H, m, ArH, NH), 5.18 (1H, dd, J 
= 10.4, 3.8, CH), 4.71 – 4.61 (3H, m, OCHH, OCHH), 4.56 (1H, d, J = 7.9, OCHH), 
4.16 (1H, dd, J = 18.3, 5.8, CHHCO2Me), 4.01 (1H, dd, J = 18.3, 5.3, CHHCO2Me), 
3.76 (3H, s, CH3), 3.72 – 3.51 (3H, m, CH2, CHHPh), 3.30 (1H, dd, J = 14.7, 3.8, 
CHHPh), 2.40 (1H, br s, NH); δC (75 MHz, CDCl3) 171.3 (C=O), 170.3 (C=O), 
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135.1 (C, Ar), 129.2 (CH, Ar), 128.8 (CH, Ar), 127.9 (CH, Ar), 93.2 (CH), 76.9 
(OCH2), 76.5 (OCH2), 62.4 (C), 52.6 (CH3), 46.0 (CH2), 40.9 (CH2CO2Me), 34.7 
(CH2Ph); MS (ES
+) m/z 352 [M+H]+, 374 [M+Na]+; HRMS (ES+) calcd. for 
C16H21N3NaO6 [M+Na]
+: 374.1323; found: 374.1326.   
 
tert-Butyl glycinate (174)152 
This known compound was prepared according to a literature 
procedure.92  To a stirred solution of glycine tert-butyl ester 
hydrochloride (878 mg, 5.24 mmol) in anhydrous chloroform (6.1 mL) was added a 
solution of NEt3 (0.73 mL, 5.24 mmol) in anhydrous chloroform (6.1 mL).  The 
reaction mixture was stirred at rt for 3 h then at 70 C for 1 h before it was cooled to 
rt and concentrated in vacuo.  The white solid formed was diluted with Et2O and 
filtered under vacuum.  The filtrate was concentrated in vacuo to give 174 (642 mg, 
93%) as a pale yellow liquid, which was used without further purification.  Data in 
agreement with literature values.152  δH (400 MHz, CDCl3) 3.27 (2H, s, CH2), 1.88 
(2H, br s, NH2), 1.41 (9H, s, CH3); δC (100 MHz, CDCl3) 173.3 (C=O), 81.2 (C), 
44.5 (CH2), 28.1 (CH3); MS (ES
+) m/z 132 [M+H]+, 154 [M+Na]+. 
 
tert-Butyl [(benzyloxy)carbonyl]glycylglycinate (175)153  
This known compound was prepared using a modified 
literature procedure.154  To a stirred solution of Z-Gly-OH 
(512 mg, 2.45 mmol), DCC (550 mg, 2.67 mmol), HOBt (410 mg, 2.67 mmol) and 
DIEA (0.46 mL, 2.64 mmol) in anhydrous CH2Cl2 (15 mL) at 0 °C was added a 
solution of 174 (351 mg, 2.68 mmol) in anhydrous CH2Cl2 (10 mL).  The reaction 
mixture was stirred at rt for 40 h, then filtered through Celite®, washed with CH2Cl2 
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and concentrated in vacuo.  Purification by column chromatography (45  60% 
EtOAc in petroleum ether + 0.5% NEt3) provided 175 (674 mg, 85%) as a pale 
yellow oil.  Data in agreement with literature values.153  Rf = 0.29 (60% EtOAc in 
petroleum ether); IR (film) 3323, 2979, 1725, 1667, 1527, 1368, 1224, 1153, 737, 
697 cm-1; δH (400 MHz, CDCl3) 7.36 – 7.28 (5H, m, ArH), 6.61 – 6.53 (1H, m, NH), 
5.60 – 5.52 (1H, m, NH), 5.12 (2H, s, PhCH2O), 3.95 – 3.89 (4H, m, CH2), 1.46 (9H, 
s, CH3); δC (100 MHz, CDCl3) 169.2 (C=O), 168.9 (C=O), 156.7 (C=O), 136.2 (C, 
Ar), 128.7 (CH, Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 82.6 (C), 67.4 (PhCH2O), 44.5 
(CH2), 42.0 (CH2), 28.1 (CH3); MS (ES
+) m/z 345 [M+Na]+. 
 
tert-Butyl [[3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycyl]glycinate (177) 
This novel compound was prepared using modified 
literature procedures.91,134  A suspension of 175 
(250 mg, 0.78 mmol) and 10% Pd/C (51 mg) in 
anhydrous THF (4 mL) was stirred under an atmosphere of hydrogen at rt for 6 h 
before it was filtered through Celite® and washed with anhydrous THF (4 mL).  This 
crude solution was added to a stirred solution of 164 (96 mg, 0.47 mmol) in 
anhydrous THF (0.5 mL).  The reaction mixture was stirred at rt for 72 h then 
concentrated in vacuo.  Purification by column chromatography (75  90% EtOAc 
in petroleum ether) provided 177 (52 mg, 28%) as a colourless oil as well as 
recovered 164 (68 mg).  Rf = 0.27 (90% EtOAc in petroleum ether); IR (film) 3323, 
2981, 1738, 1671, 1596, 1553, 1537, 1457, 1369, 1230, 1157, 985, 701 cm-1; δH (400 
MHz, CDCl3) 7.36 – 7.20 (6H, m, ArH, CONH), 5.21 – 5.15 (1H, m, CH), 4.69 – 
4.65 (1H, m, OCHH), 4.63 – 4.57 (2H, m, OCHH, OCHH), 4.56 – 4.52 (1H, m, 
OCHH), 4.08 – 3.99 (1H, m, CHHCO2tBu), 3.95 – 3.86 (1H, m, CHHCO2tBu), 3.68 
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– 3.52 (3H, m, NHCH2CO, CHHPh), 3.34 – 3.26 (1H, m, CHHPh), 2.52 (1H, br s, 
NH), 1.47 (9H, s, CH3); δC (100 MHz, CDCl3) 171.0 (C=O), 168.9 (C=O), 135.2 (C, 
Ar), 129.2 (CH, Ar), 128.8 (CH, Ar), 127.9 (CH, Ar), 93.3 (CH), 82.6 (C, tBu), 77.0 
(OCH2), 76.7 (OCH2), 62.4 (C, oxetane), 46.1 (NHCH2CO), 41.8 (CH2CO2
tBu), 34.8 
(CH2Ph), 28.2 (CH3); MS (ES
+) m/z 394 [M+H]+, 416 [M+Na]+; HRMS (ES+) calcd. 
for C19H27N3NaO6 [M+Na]
+: 416.1792; found: 416.1796.   
 
tert-Butyl [3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycinate (178) 
This novel compound was prepared using a modified 
literature procedure.91  To a stirred solution of 164 (27 mg, 
0.13 mmol) in anhydrous THF (2 mL) was added a solution 
of 174 (26 mg, 0.20 mmol) in anhydrous THF (0.5 mL).  The reaction mixture was 
stirred at rt overnight then concentrated in vacuo.  Purification by column 
chromatography (30% EtOAc in petroleum ether) provided 178 (39 mg, 88%) as a 
white solid.  M.p. 124 – 125 °C; Rf = 0.35 (30% EtOAc in petroleum ether); IR 
(film) 3334, 2977, 1729, 1605, 1552, 1497, 1455, 1367, 1237, 1153, 983, 749, 699 
cm-1; δH (400 MHz, CDCl3) 7.34 – 7.20 (5H, m, ArH), 5.12 (1H, dd, J = 10.0, 4.3, 
CH), 4.64 (1H, d, J = 7.3, OCHH), 4.61 (1H, d, J = 7.3, OCHH), 4.52 – 4.48 (2H, m, 
OCH2), 3.60 (1H, d, J = 17.4, NHCHH), 3.53 (1H, dd, J = 14.7, 10.0, CHHPh), 3.49 
(1H, d, J = 17.4, NHCHH), 3.27 (1H, dd, J = 14.7, 4.3, CHHPh), 2.46 (1H, br s, 
NH), 1.49 (9H, s, CH3); δC (100 MHz, CDCl3) 171.3 (C=O), 135.5 (C, Ar), 129.1 
(CH, Ar), 128.9 (CH, Ar), 127.7 (CH, Ar), 93.1 (CH), 82.2 (C, tBu), 77.3 (OCH2), 
77.3 (OCH2), 62.4 (C, oxetane), 45.5 (NHCH2), 34.5 (CH2Ph), 28.2 (CH3); MS (ES
+) 
m/z 337 [M+H]+, 359 [M+Na]+; HRMS (ES+) calcd. for C17H24N2NaO5 [M+Na]
+: 
359.1577; found: 359.1582.   
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Methyl L-valinate (179)155 
This known compound was prepared according to a literature 
procedure.92  To a stirred solution of L-valine methyl ester 
hydrochloride (151 mg, 0.90 mmol) in anhydrous chloroform (1 mL) was added a 
solution of NEt3 (0.12 mL, 0.86 mmol) in anhydrous chloroform (1.5 mL).  The 
reaction mixture was stirred at rt for 2 h then at 70 C for 1 h before it was cooled to 
rt and concentrated in vacuo.  The white solid formed was diluted with Et2O and 
filtered under vacuum.  The filtrate was concentrated in vacuo to give 179 (88 mg, 
74%) as a pale yellow liquid, which was used without further purification.  Data in 
agreement with literature values.155  δH (400 MHz, CDCl3) 3.72 (3H, s, CO2CH3), 
3.32 (1H, d, J = 5.0, CHiPr), 2.08 – 1.98 (1H, m, CHMe2), 1.83 (2H, br s, NH2), 0.97 
(3H, d, J = 6.8, CH3), 0.91 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 176.1 
(C=O), 60.0 (CHiPr), 51.8 (CH3), 32.2 (CHMe2), 19.3 (CH3), 17.3 (CH3); MS (ES
+) 
m/z 132 [M+H]+. 
 
Methyl [3-(1-nitro-2-phenylethyl)oxetan-3-yl]-L-valinate (180a/b) 
This novel compound was prepared using a modified 
literature procedure.91  To a stirred solution of 164 (105 mg, 
0.51 mmol) in anhydrous THF (4 mL) was added a solution 
of 179 (130 mg, 0.99 mmol) in anhydrous THF (4 mL).  The reaction mixture was 
stirred at rt for 64 h then concentrated in vacuo.  Purification by repeat column 
chromatography (10  25% EtOAc in petroleum ether; 50  80% CH2Cl2 in 
petroleum ether) provided 180a/b (137 mg, 80%) as a 55 : 45 mixture of 
diastereoisomers as an oily white solid.  Rf = 0.28, 0.36 (30% EtOAc in petroleum 
ether); IR (film) 3336, 2962, 2882, 1729, 1552, 1496, 1455, 1366, 1200, 1153, 985, 
Chapter 3: Experimental 
 
164 
744, 699 cm-1; δH (400 MHz, CDCl3) 7.35 – 7.20 (9.3H, m, ArH D1 and D2), 5.17 
(1H, dd, J = 10.0, 4.3, CHBn D1), 5.10 (0.86H, dd, J = 10.3, 3.8, CHBn D2), 4.72 
(0.86H, d, J = 7.7, OCHH D2), 4.59 (0.86H, d, J = 7.7, OCHH D2), 4.56 (0.86H, d, J 
= 7.7, OCHH D2), 4.54 – 4.51 (2H, m, OCHH D1), 4.45 (1H, d, J = 7.7, OCHH D1), 
4.41 (1.86H, d, J = 7.7, OCHH D1 and D2), 3.75 (2.58H, s, CO2CH3 D2), 3.74 (3H, s, 
CO2CH3 D1), 3.62 – 3.43 (3.72H, m, CHHPh D1 and D2, CHiPr D1 and D2), 3.28 – 
3.20 (1.86H, m, CHHPh D1 and D2), 2.63 (1H, d, J = 10.5, NH D1), 2.24 (0.86H, d, J 
= 10.3, NH D2), 2.10 – 2.01 (1H, m, CHMe2 D1), 2.01 – 1.90 (0.86H, m, CHMe2 
D2), 1.00 (3H, d, J = 6.5, CH3 D1), 0.92 (3H, d, J = 6.5, CH3 D1), 0.91 (2.58H, d, J = 
6.8, CH3 D2), 0.89 (2.58H, d, J = 6.8, CH3 D2); δC (100 MHz, CDCl3) 176.2 (C=O, 
D2), 176.0 (C=O, D1), 135.6 (C, Ar, D2), 135.5 (C, Ar, D1), 129.1 (CH, Ar, D1 and 
D2), 128.9 (CH, Ar, D1 and D2), 127.7 (CH, Ar, D1), 127.7 (CH, Ar, D2), 94.3 (CH, 
D1), 92.1 (CH, D2), 78.2 (OCH2, D2), 78.0 (OCH2, D2), 77.6 (OCH2, D1), 77.3 
(OCH2, D1), 62.4 (C, D2), 62.3 (C, D1), 60.8 (CH
iPr, D2), 60.6 (CH
iPr, D1), 52.3 
(CO2CH3, D1), 52.2 (CO2CH3, D2), 34.7 (CH2Ph, D1), 34.1 (CH2Ph, D2), 32.5 
(CHMe2, D1), 32.3 (CHMe2, D2), 19.6 (CH3, D1), 19.3 (CH3, D2), 18.1 (CH3, D2), 
17.9 (CH3, D1); MS (ES
+) m/z 337 [M+H]+, 359 [M+Na]+; HRMS (ES+) calcd. for 
C17H24N2NaO5 [M+Na]
+: 359.1577; found: 359.1579.   
 
3-(Nitromethylene)oxetane (162)9 
This known compound was prepared according to a literature procedure.9  
To a stirred solution of 3-oxetanone (178 µL, 2.77 mmol) in nitromethane 
(3.2 mL) was added NEt3 (50 µL, 0.36 mmol).  The reaction mixture was 
stirred at rt for 20 min then concentrated in vacuo.  The residue was diluted with 
anhydrous CH2Cl2 (10 mL) then cooled to ˗78 C.  To this solution was added NEt3 
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(1.7 mL, 12.2 mmol), followed by MsCl (640 µL, 8.27 mmol) dropwise over 10 min.  
The reaction mixture was stirred at ˗78 C for 20 min then loaded directly onto a 
silica column.  Purification by column chromatography (50% Et2O in petroleum 
ether) provided 162 (104 mg, ~33%) as a pale yellow solid containing some 
impurities.  Product was taken through without further purification. 
 
tert-Butyl [3-(nitromethyl)oxetan-3-yl]glycinate (192) 
This novel compound was prepared using a modified 
literature procedure.91  A solution of 174 (144 mg, 1.10 
mmol) in anhydrous THF (2 mL) was added to a stirred solution of 162 (49 mg, 0.43 
mmol) in anhydrous THF (2 mL).  The reaction mixture was stirred at rt overnight 
then concentrated in vacuo.  Purification by column chromatography (75% Et2O in 
petroleum ether) provided 192 (72 mg, 69%) as white crystals.  M.p. 67 – 68 °C; Rf 
= 0.30 (80% Et2O in petroleum ether); IR (film) 3330, 2977, 1731, 1554, 1455, 
1436, 1369, 1238, 1155 cm-1; δH (400 MHz, CDCl3) 4.81 (2H, s, NO2CH2), 4.62 
(2H, d, J = 7.3, OCHH), 4.56 (2H, d, J = 7.3, OCHH), 3.42 (2H, d, J = 5.0, 
CH2CO2
tBu), 2.35 (1H, br s, NH), 1.46 (9H, s, CH3); δC (100 MHz, CDCl3) 171.0 
(C=O), 82.3 (C, tBu), 78.8 (CH2), 78.4 (2 x CH2), 59.6 (C, oxetane), 45.6 
(CH2CO2
tBu), 28.1 (CH3); MS (ES
+) m/z 247 [M+H]+, 269 [M+Na]+; HRMS (ES+) 
calcd. for C10H18N2NaO5 [M+Na]
+: 269.1108; found: 269.1108.   
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-valinate ((S)-193) 
This novel compound was prepared using a modified 
literature procedure.91  A solution of 179 (100 mg, 0.76 
mmol) in anhydrous THF (2 mL) was added to a stirred solution of 162 (44 mg, 0.38 
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mmol) in anhydrous THF (2 mL).  The reaction mixture was stirred at rt overnight 
then concentrated in vacuo.  Purification by column chromatography (75% Et2O in 
petroleum ether) provided (S)-193 (64 mg, 68%) as a yellow oil.  Rf = 0.19 (100% 
CH2Cl2); [α]   –19.4 (c 0.24, CHCl3); IR (film) 3333, 2962, 2878, 1730, 1555, 1467, 
1435, 1379, 1276, 1202 cm-1; δH (400 MHz, CDCl3) 4.85 (1H, d, J = 13.1, 
NO2CHH), 4.77 (1H, d, J = 13.1, NO2CHH), 4.60 (2H, d, J = 7.0, OCHH), 4.50 (1H, 
d, J = 7.0, OCHH), 4.46 (1H, d, J = 7.0, OCHH), 3.72 (3H, s, CO2CH3), 3.22 (1H, 
dd, J = 10.8, 6.0, CHiPr), 2.27 (1H, d, J = 10.8, NH), 1.98 – 1.85 (1H, m, CHMe2), 
0.92 (3H, d, J = 6.8, CH3), 0.89 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 175.9 
(C=O), 79.0 (CH2), 78.7 (CH2), 78.6 (CH2), 61.4 (CH
iPr), 59.5 (C), 52.3 (CO2CH3), 
32.2 (CHMe2), 19.4 (CH3), 18.1 (CH3); MS (ES
+) m/z 269 [M+Na]+; HRMS (ES+) 
calcd. for C10H18N2NaO5 [M+Na]
+: 269.1108; found: 269.1105. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-valinate ((S)-193) 
This novel compound was prepared as follows.  
Nitromethane (70 µL, 1.29 mmol), 3-oxetanone (108 µL, 
1.68 mmol) and NEt3 (36 µL, 0.26 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (6.4 mL) and cooled to ˗78 °C.  To this solution was added 
NEt3 (360 µL, 2.58 mmol), followed by MsCl (100 µL, 1.29 mmol) dropwise over 
10 min.  The reaction mixture was stirred at ˗78 °C for 40 min.  Meanwhile, to a 
stirred solution of L-valine methyl ester hydrochloride (434 mg, 2.59 mmol) in 
anhydrous CH2Cl2 (8 mL) was added NEt3 (360 µL, 2.58 mmol).  The mixture was 
stirred at rt for 10 min then added to the oxetane solution at ˗78 °C.  The reaction 
mixture was allowed to warm to rt, stirred for 23 h, then quenched with saturated 
aqueous NH4Cl solution (10 mL).  The mixture was extracted with CH2Cl2 (5 x 30 
33 
D 
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mL) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  Purification by repeat column chromatography (20  25% 
EtOAc in hexane; 0  2% MeOH in CH2Cl2) provided (S)-193 (149 mg, 47%) as a 
pale yellow oil.  Data as previously reported. 
 
Benzyl [3-(nitromethyl)oxetan-3-yl]-L-valinate (194) 
This novel compound was prepared as follows.  
Nitromethane (177 µL, 3.27 mmol), 3-oxetanone (273 µL, 
4.26 mmol) and NEt3 (91 µL, 0.65 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (16 mL) and cooled to –78 °C.  To this solution was added 
NEt3 (0.91 mL, 6.53 mmol), followed by MsCl (255 µL, 3.29 mmol) dropwise over 
10 min.  The reaction mixture was stirred at –78 °C for 40 min.  Meanwhile, to a 
stirred solution of L-valine benzyl ester p-toluenesulfonate salt (2.49 g, 6.56 mmol) 
in anhydrous CH2Cl2 (19 mL) was added NEt3 (0.91 mL, 6.53 mmol).  The mixture 
was stirred at rt for 10 min before it was added to the oxetane solution at –78 °C.  
The reaction mixture was allowed to warm to rt, stirred for 21 h, then quenched with 
saturated aqueous NH4Cl solution (30 mL).  The mixture was extracted with CH2Cl2 
(2 x 40 mL) and EtOAc (2 x 40 mL).  The combined organic extracts were dried 
over Na2SO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (15  40% EtOAc in heptane) provided 194 (876 mg, 83%) as a 
pale pink oil.  Rf = 0.33 (30% EtOAc in heptane); [α]   –4.5 (c 0.20, CHCl3); IR 
(KBr) 3338, 2963, 2877, 1732, 1560, 1498, 1457, 1379, 1268, 1184, 983, 738 cm-1; 
δH (400 MHz, CDCl3) 7.40 – 7.31 (5H, m, ArH), 5.17 (1H, d, J = 12.0, OCHHPh), 
5.11 (1H, d, J = 12.0, OCHHPh), 4.80 (1H, dd, J = 13.1, 0.9, NO2CHH), 4.72 (1H, 
dd, J = 13.1, 0.9, NO2CHH), 4.55 (1H, d, J = 7.1, OCHH), 4.53 (1H, d, J = 7.1, 
17 
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OCHH), 4.45 (1H, d, J = 7.1, OCHH), 4.35 (1H, d, J = 7.1, OCHH), 3.25 (1H, dd, J 
= 10.9, 5.9, CHiPr), 2.29 (1H, d, J = 10.9, NH), 2.00 – 1.88 (1H, m, CHMe2), 0.91 
(3H, d, J = 6.8, CH3), 0.86 (3H, d, J = 6.8, CH3); δC (175 MHz, CDCl3) 175.3 
(C=O), 135.4 (C, Ar), 128.9 (CH, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 78.9 (CH2), 
78.7 (CH2), 78.7 (CH2), 67.3 (OCH2Ph), 61.5 (CH
iPr), 59.6 (C), 32.2 (CHMe2), 19.4 
(CH3), 18.0 (CH3); MS (ES
+) m/z 323 [M+H]+; HRMS (ES+) calcd. for C16H23N2O5 
[M+H]+: 323.1602; found: 323.1606. 
 
Benzyl [3-(nitromethyl)oxetan-3-yl]-L-phenylalaninate (195) 
This novel compound was prepared as follows.  
Nitromethane (220 µL, 4.06 mmol), 3-oxetanone (339 µL, 
5.28 mmol) and NEt3 (113 µL, 0.81 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (20 mL) and cooled to –78 °C.  To this solution was added 
NEt3 (1.13 mL, 8.11 mmol), followed by MsCl (317 µL, 4.09 mmol) dropwise over 
10 min.  The reaction mixture was stirred at –78 °C for 35 min.  Meanwhile, to a 
stirred solution of L-phenylalanine benzyl ester hydrochloride (2.38 g, 8.16 mmol) in 
anhydrous CH2Cl2 (25 mL) was added NEt3 (1.13 mL, 8.11 mmol).  The mixture 
was stirred at rt for 10 min before it was added to the oxetane solution at –78 °C.  
The reaction mixture was allowed to warm to rt, stirred for 22 h, then quenched with 
saturated aqueous NH4Cl solution (30 mL).  The mixture was extracted with CH2Cl2 
(1 x 30 mL) and EtOAc (3 x 40 mL).  The combined organic extracts were dried 
over Na2SO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (15  40% EtOAc in heptane) gave a yellow solid.  
Recrystallisation (MeOH) provided 195 (1.10 g, 73%) as pale yellow crystals.  M.p. 
92 – 93 °C (MeOH); Rf = 0.25 (30% EtOAc in heptane); [α]    –9.6 (c 0.20, CHCl3); 
17 
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IR (KBr) 3335, 2957, 2880, 1732, 1603, 1556, 1497, 1455, 1379, 1275, 1175, 982, 
749 cm-1; δH (400 MHz, CDCl3) 7.37 – 7.33 (3H, m, ArH), 7.28 – 7.21 (5H, m, 
ArH), 7.13 – 7.09 (2H, m, ArH), 5.11 (1H, d, J = 12.0, OCHHPh), 5.05 (1H, d, J = 
12.0, OCHHPh), 4.75 (1H, dd, J = 13.1, 0.8, NO2CHH), 4.69 (1H, d, J = 13.1, 
NO2CHH), 4.47 (1H, d, J = 7.2, OCHH), 4.35 (1H, d, J = 7.3, OCHH), 4.33 (1H, d, 
J = 7.2, OCHH), 4.25 (1H, d, J = 7.3, OCHH), 3.77 – 3.70 (1H, m, CH), 2.97 (1H, 
dd, J = 13.4, 6.3, CHHPh), 2.87 (1H, dd, J = 13.4, 7.1, CHHPh), 2.37 (1H, d, J = 9.6, 
NH); δC (175 MHz, CDCl3) 174.5 (C=O), 136.6 (C, Ar), 135.2 (C, Ar), 129.6 (CH, 
Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 128.6 (CH, Ar), 127.2 (CH, Ar), 78.8 (CH2), 
78.7 (CH2), 78.6 (CH2), 67.5 (OCH2Ph), 59.6 (C), 57.7 (CH), 40.8 (CH2Ph); MS 
(ES+) m/z 371 [M+H]+; HRMS (ES+) calcd. for C20H23N2O5 [M+H]
+: 371.1607; 
found: 371.1607; CHN calcd. for C20H22N2O5: C, 64.73 H, 5.92 N, 7.53%; found: C, 
64.85 H, 5.99 N, 7.56%. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-serinate (196) 
This novel compound was prepared as follows.  
Nitromethane (70 µL, 1.29 mmol), 3-oxetanone (107 µL, 
1.67 mmol) and NEt3 (36 µL, 0.26 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (6.3 mL) and cooled to –78 °C.  To this solution was added 
NEt3 (357 µL, 2.56 mmol), followed by MsCl (99 µL, 1.28 mmol) dropwise over 10 
min.  The reaction mixture was stirred at –78 °C for 30 min.  Meanwhile, to a stirred 
solution of L-serine methyl ester hydrochloride (401 mg, 2.58 mmol) in anhydrous 
CH2Cl2 (10 mL) was added NEt3 (357 µL, 2.56 mmol).  The mixture was stirred at rt 
for 10 min before it was added to the oxetane solution at –78 °C.  The reaction 
mixture was allowed to warm to rt, stirred for 25 h, then quenched with saturated 
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aqueous NH4Cl solution (15 mL).  The mixture was extracted with CH2Cl2 (2 x 30 
mL) and EtOAc (2 x 30 mL).  The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo.  Purification by column chromatography 
(65  70% EtOAc in hexane) provided 196 (146 mg, 48%) as a colourless oil.  Rf = 
0.28 (80% EtOAc in petroleum ether); [α]   –23.3 (c 0.20, CHCl3); IR (film) 3346, 
2956, 2886, 1732, 1553, 1459, 1380, 1207, 1060 cm-1; δH (400 MHz, CDCl3) 4.85 
(1H, d, J = 13.2, NO2CHH), 4.80 (1H, d, J = 13.2, NO2CHH), 4.61 (2H, d, J = 7.3, 
OCHH), 4.53 (2H, d, J = 7.3, OCHH), 3.79 – 3.73 (4H, m, CH3, CHHOH), 3.65 – 
3.59 (2H, m, CHHOH, CH), 2.70 (2H, br s, OH, NH); δC (100 MHz, CDCl3) 173.6 
(C=O), 78.9 (CH2), 78.7 (CH2), 78.5 (CH2), 63.9 (CH2OH), 59.3 (C), 57.5 (CH), 
52.9 (CH3); MS (ES
+) m/z 257 [M+Na]+; HRMS (ES+) calcd. for C8H14N2NaO6 
[M+Na]+: 257.0744; found: 257.0746. 
 
Isopropyl [3-(nitromethyl)oxetan-3-yl]glycinate (197) 
This novel compound was prepared as follows.  
Nitromethane (220 µL, 4.06 mmol), 3-oxetanone (339 µL, 
5.28 mmol) and NEt3 (113 µL, 0.81 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (20 mL) and cooled to ˗78 °C.  To this solution was added 
NEt3 (1.13 mL, 8.11 mmol), followed by MsCl (320 µL, 4.13 mmol) dropwise over 
10 min.  The reaction mixture was stirred at ˗78 °C for 30 min.  Meanwhile, to a 
stirred solution of glycine isopropyl ester hydrochloride (1.25 g, 8.14 mmol) in 
anhydrous CH2Cl2 (25 mL) was added NEt3 (1.13 mL, 8.11 mmol).  The mixture 
was stirred at rt for 10 min before it was added to the oxetane solution at ˗78 °C.  
The reaction mixture was allowed to warm to rt, stirred for 22 h, then quenched with 
saturated aqueous NH4Cl solution (30 mL).  The mixture was extracted with CH2Cl2 
30 
D 
Chapter 3: Experimental 
 
171 
(1 x 30 mL) and EtOAc (4 x 30 mL).  The combined organic extracts were dried 
over Na2SO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (30  50% EtOAc in heptane) provided 197 (580 mg, 61%) as a 
pale pink oil.  Rf = 0.20 (40% EtOAc in heptane); IR (KBr) 3335, 2982, 2881, 1731, 
1556, 1469, 1384, 1207, 1108 cm-1; δH (400 MHz, CDCl3) 5.07 (1H, septet, J = 6.2, 
CH), 4.82 (2H, s, NO2CH2), 4.64 (2H, d, J = 7.3, OCHH), 4.58 (2H, d, J = 7.3, 
OCHH), 3.50 (2H, s, CH2CO2
iPr), 2.38 (1H, br s, NH), 1.27 (6H, d, J = 6.2, CH3); δC 
(175 MHz, CDCl3) 171.4 (C=O), 78.7 (CH2), 78.4 (2 x CH2), 69.4 (CH), 59.6 (C), 
45.2 (CH2CO2
iPr), 21.9 (CH3); MS (ES
+) m/z 233 [M+H]+; HRMS (ES+) calcd. for 
C9H17N2O5 [M+H]
+: 233.1137; found: 233.1139. 
 
Benzyl [3-(nitromethyl)oxetan-3-yl]glycinate (198) 
This novel compound was prepared as follows.  
Nitromethane (220 µL, 4.06 mmol), 3-oxetanone (340 µL, 
5.30 mmol) and NEt3 (113 µL, 0.81 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (20 mL) and cooled to –78 °C.  To this solution was added 
NEt3 (1.13 mL, 8.11 mmol), followed by MsCl (315 µL, 4.07 mmol) dropwise over 
10 min.  The reaction mixture was stirred at –78 °C for 40 min.  Meanwhile, to a 
stirred solution of glycine benzyl ester p-toluenesulfonate salt (2.75 g, 8.15 mmol) in 
anhydrous CH2Cl2 (25 mL) was added NEt3 (1.13 mL, 8.11 mmol).  The mixture 
was stirred at rt for 10 min before it was added to the oxetane solution at –78 °C.  
The reaction mixture was allowed to warm to rt, stirred for 21 h, then quenched with 
saturated aqueous NH4Cl solution (30 mL).  The mixture was extracted with CH2Cl2 
(4 x 75 mL) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  Purification by column chromatography (60  80% Et2O in 
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hexane) gave a yellow solid.  Recrystallisation (EtOH/hexane) provided 198 (728 
mg, 64%) as off-white crystals.  M.p. 77 – 79 °C (EtOH); Rf = 0.30 (50% EtOAc in 
petroleum ether); IR (film) 3342, 2962, 2885, 1736, 1550, 1498, 1456, 1436, 1380, 
1190, 1102, 976, 737, 696 cm-1; δH (400 MHz, CDCl3) 7.41 – 7.32 (5H, m, ArH), 
5.18 (2H, s, OCH2Ph), 4.82 (2H, s, NO2CH2), 4.61 (2H, d, J = 7.3, OCHH), 4.56 
(2H, d, J = 7.3, OCHH), 3.58 (2H, d, J = 5.3, CH2CO2Bn), 2.42 – 2.36 (1H, m, NH); 
δC (100 MHz, CDCl3) 171.7 (C=O), 135.2 (C, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 
128.6 (CH, Ar), 78.5 (CH2), 78.3 (2 x CH2), 67.3 (OCH2Ph), 59.5 (C), 44.9 
(CH2CO2Bn); MS (ES
+) m/z 281 [M+H]+, 303 [M+Na]+; HRMS (ES+) calcd. for 
C13H16N2NaO5 [M+Na]
+: 303.0951; found: 303.0957. 
 
Benzyl [3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycinate (199) 
This novel compound was prepared as follows.  (2-
Nitroethyl)benzene (196 mg, 1.30 mmol), 3-oxetanone (108 
µL, 1.68 mmol) and NEt3 (36 µL, 0.26 mmol) were stirred at 
rt for 90 min then diluted with anhydrous CH2Cl2 (6.4 mL) and cooled to –78 °C.  To 
this solution was added NEt3 (358 µL, 2.57 mmol), followed by MsCl (100 µL, 1.29 
mmol) dropwise.  The reaction mixture was stirred at –78 °C for 90 min.  
Meanwhile, to a stirred solution of glycine benzyl ester p-toluenesulfonate salt (965 
mg, 2.86 mmol) in anhydrous CH2Cl2 (9 mL) was added NEt3 (360 µL, 2.58 mmol).  
The mixture was stirred at rt for 10 min before it was added to the oxetane solution 
at –78 °C.  The reaction mixture was allowed to warm to rt overnight, then quenched 
with saturated aqueous NH4Cl solution (15 mL).  The mixture was extracted with 
CH2Cl2 (2 x 50 mL) and EtOAc (2 x 50 mL).  The combined organic extracts were 
dried over MgSO4, filtered and concentrated in vacuo.  Purification by repeat column 
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chromatography (35  100% EtOAc in hexane; 20  30% EtOAc in hexane) 
provided 199 (280 mg, 58%) as a pale yellow solid.  M.p. 53 – 54 °C; Rf = 0.34 
(40% EtOAc in hexane); IR (film) 3342, 2958, 2883, 1736, 1604, 1551, 1496, 1455, 
1367, 1189, 1083, 981, 737 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.19 (10H, m, ArH), 
5.20 (2H, s, OCH2Ph), 5.11 (1H, dd, J = 9.9, 4.4, CH), 4.61 (1H, d, J = 7.5, OCHH), 
4.59 (1H, d, J = 7.5, OCHH), 4.47 (2H, s, OCH2), 3.75 (1H, d, J = 17.6, 
CHHCO2Bn), 3.65 (1H, d, J = 17.6, CHHCO2Bn), 3.51 (1H, dd, J = 14.7, 9.9, 
CHHPh), 3.27 (1H, dd, J = 14.7, 4.4, CHHPh), 2.50 (1H, br s, NH); δC (100 MHz, 
acetone-d6) 172.6 (C=O), 137.2 (C, Ar), 137.1 (C, Ar), 129.9 (CH, Ar), 129.5 (CH, 
Ar), 129.3 (CH, Ar), 129.1 (CH, Ar), 129.0 (CH, Ar), 128.0 (CH, Ar), 92.8 (CH), 
77.5 (OCH2), 77.1 (OCH2), 67.1 (OCH2Ph), 63.1 (C), 45.2 (CH2CO2Bn), 35.1 
(CH2Ph); MS (ES
+) m/z 371 [M+H]+, 393 [M+Na]+; HRMS (ES+) calcd. for 
C20H23N2O5 [M+H]
+: 371.1601; found: 371.1602. 
 
Benzyl [[3-(1-nitro-2-phenylethyl)oxetan-3-yl]glycyl]glycinate (200) 
This novel compound was prepared as follows.  (2-
Nitroethyl)benzene (303 mg, 2.00 mmol), 3-
oxetanone (167 µL, 2.60 mmol) and NEt3 (56 µL, 
0.40 mmol) were stirred at rt for 90 min then diluted with anhydrous CH2Cl2 (12.5 
mL) and cooled to –78 °C.  To this solution was added NEt3 (559 µL, 4.01 mmol), 
followed by MsCl (156 µL, 2.01 mmol) dropwise.  The reaction mixture was stirred 
at –78 °C for 90 min.  Meanwhile, to a stirred solution of glycylglycine benzyl ester 
p-toluenesulfonate salt (1.74 g, 4.41 mmol) in anhydrous CH2Cl2 (10 mL) was added 
NEt3 (559 µL, 4.01 mmol).  The mixture was stirred at rt for 10 min before being 
added to the oxetane solution at –78 °C.  The reaction mixture was allowed to warm 
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to rt overnight, then quenched with saturated aqueous NH4Cl solution (20 mL).  The 
mixture was extracted with CH2Cl2 (3 x 50 mL) and EtOAc (1 x 50 mL).  The 
combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo.  Purification by repeat column chromatography (65  100% EtOAc in 
heptane; 45  80% EtOAc in heptane) provided 200 (549 mg, 64%) as a sticky 
yellow solid.  Rf = 0.23 (80% EtOAc in heptane); IR (KBr) 3379, 3342, 2956, 2887, 
1744, 1668, 1605, 1549, 1521, 1497, 1455, 1189, 1030, 736, 698 cm-1; δH (700 MHz, 
CDCl3) 7.39 – 7.28 (9H, m, ArH, CONH), 7.22 (2H, d, J = 7.3, ArH), 5.19 (2H, s, 
OCH2Ph), 5.17 (1H, dd, J = 10.3, 3.8, CH), 4.66 (1H, d, J = 7.7, OCHH), 4.61 (1H, 
d, J = 7.7, OCHH), 4.59 (1H, d, J = 8.0, OCHH), 4.53 (1H, d, J = 8.0, OCHH), 4.20 
(1H, dd, J = 18.4, 6.1, CHHCO2Bn), 4.06 (1H, dd, J = 18.4, 6.1, CHHCO2Bn), 3.66 
(1H, d, J = 17.2, NHCHHCO), 3.60 (1H, d, J = 17.2, NHCHHCO), 3.56 (1H, dd, J = 
14.8, 10.3, CHHPh), 3.28 (1H, dd, J = 14.8, 3.8, CHHPh), 2.51 (1H, br s, NH); δC 
(175 MHz, CDCl3) 171.3 (C=O), 169.7 (C=O), 135.2 (C, Ar), 135.2 (C, Ar), 129.3 
(CH, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.6 (CH, Ar), 127.9 
(CH, Ar), 93.3 (CH), 77.0 (OCH2), 76.6 (OCH2), 67.5 (OCH2Ph), 62.4 (C), 46.1 
(CH2CO2Bn), 41.2 (NHCH2CO), 34.8 (CH2Ph); MS (ES
+) m/z 428 [M+H]+, 450 
[M+Na]+; HRMS (ES+) calcd. for C22H26N3O6 [M+H]
+: 428.1816; found: 428.1812. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-valinate ((S)-193) 
This novel compound was prepared as follows.  3-Oxetanone 
(130 µL, 2.03 mmol), nitromethane (154 µL, 2.85 mmol) 
and NEt3 (57 µL, 0.41 mmol) were stirred at rt for 30 min then diluted with 
anhydrous CH2Cl2 (10 mL) and cooled to –78 °C.  To this solution was added NEt3 
(565 µL, 4.05 mmol), followed by MsCl (157 µL, 2.03 mmol) dropwise over 10 min.  
Chapter 3: Experimental 
 
175 
The reaction mixture was stirred at –78 °C for 40 min.  Meanwhile, to a stirred 
solution of L-valine methyl ester hydrochloride (681 mg, 4.06 mmol) in anhydrous 
CH2Cl2 (12.5 mL) was added NEt3 (565 µL, 4.05 mmol).  The mixture was stirred at 
rt for 10 min then added to the oxetane solution at –78 °C.  The reaction mixture was 
allowed to warm to rt, stirred for 20 h, then quenched with saturated aqueous NH4Cl 
solution (15 mL).  The mixture was extracted with CH2Cl2 (5 x 30 mL) and the 
combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo.  Purification by column chromatography (15  25% EtOAc in hexane) 
provided (S)-193 (323 mg, 65%) as a yellow oil.  Data as previously reported. 
 
Methyl [3-(nitromethyl)oxetan-3-yl]-L-valinate ((S)-193) 
This novel compound was prepared as follows.  3-Oxetanone 
(130 µL, 2.03 mmol), nitromethane (154 µL, 2.85 mmol) 
and NEt3 (57 µL, 0.41 mmol) were stirred at rt for 30 min then diluted with 
anhydrous CH2Cl2 (10 mL) and cooled to ˗78 °C.  To this solution was added NEt3 
(565 µL, 4.05 mmol), followed by MsCl (157 µL, 2.03 mmol) dropwise over 10 min.  
The reaction mixture was stirred at ˗78 °C for 40 min.  Meanwhile, to a stirred 
solution of L-valine methyl ester hydrochloride (409 mg, 2.44 mmol) in anhydrous 
CH2Cl2 (12.5 mL) was added NEt3 (339 µL, 2.43 mmol).  The mixture was stirred at 
rt for 10 min then added to the oxetane solution at ˗78 °C.  The reaction mixture was 
allowed to warm to rt, stirred for 20 h, then quenched with saturated aqueous NH4Cl 
solution (15 mL).  The mixture was extracted with CH2Cl2 (5 x 30 mL) and the 
combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo.  Purification by column chromatography (15  25% EtOAc in hexane) 
provided (S)-193 (202 mg, 40%) as a yellow oil.  Data as previously reported. 
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Methyl [3-(nitromethyl)oxetan-3-yl]-D-valinate ((R)-193) 
This novel compound was prepared as follows.  3-
Oxetanone (130 µL, 2.03 mmol), nitromethane (154 µL, 
2.85 mmol), and NEt3 (57 µL, 0.41 mmol) were stirred at rt for 30 min then diluted 
with anhydrous CH2Cl2 (10 mL) and cooled to –78 °C.  To this solution was added 
NEt3 (565 µL, 4.05 mmol), followed by MsCl (157 µL, 2.03 mmol) dropwise over 
10 min.  The reaction mixture was stirred at –78 °C for 40 min.  Meanwhile, to a 
stirred solution of D-valine methyl ester hydrochloride (682 mg, 4.07 mmol) in 
anhydrous CH2Cl2 (12.5 mL) was added NEt3 (565 µL, 4.05 mmol).  The mixture 
was stirred at rt for 10 min then added to the oxetane solution at –78 °C.  The 
reaction mixture was allowed to warm to rt, stirred for 20 h, then quenched with 
saturated aqueous NH4Cl solution (15 mL).  The mixture was extracted with CH2Cl2 
(5 x 30 mL) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  Purification by column chromatography (15  25% EtOAc 
in hexane) provided (R)-193 (337 mg, 68%) as a yellow oil.  Rf = 0.23 (40% EtOAc 
in hexane); [α]   +16.6 (c 0.22, CHCl3); IR (film) 3330, 2960, 2877, 1729, 1555, 
1466, 1434, 1379, 1275, 1201 cm-1; δH (400 MHz, CDCl3) 4.85 (1H, dd, J = 13.1, 
0.8, NO2CHH), 4.76 (1H, d, J = 13.1, NO2CHH), 4.60 (1H, d, J = 7.3, OCHH), 4.59 
(1H, d, J = 7.3, OCHH), 4.49 (1H, d, J = 7.3, OCHH), 4.45 (1H, d, J = 7.3, OCHH), 
3.71 (3H, s, CO2CH3), 3.21 (1H, dd, J = 8.5, 6.5, CH
iPr), 2.27 (1H, d, J = 8.5, NH), 
1.97 – 1.85 (1H, m, CHMe2), 0.91 (3H, d, J = 6.8, CH3), 0.88 (3H, d, J = 6.8, CH3); 
δC (100 MHz, CDCl3) 175.9 (C=O), 79.0 (OCH2), 78.7 (OCH2), 78.5 (NO2CH2), 
61.3 (CHiPr), 59.5 (C), 52.3 (CO2CH3), 32.1 (CHMe2), 19.4 (CH3), 18.1 (CH3); MS 
(ES+) m/z 247 [M+H]+, 269 [M+Na]+; HRMS (ES+) calcd. for C10H18N2NaO5 
[M+Na]+: 269.1108; found: 269.1101. 
25 
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Benzyl [3-(nitromethyl)oxetan-3-yl]-L-leucinate (203) 
This novel compound was prepared as follows.  3-Oxetanone 
(260 µL, 4.05 mmol), nitromethane (307 µL, 5.67 mmol) and 
NEt3 (113 µL, 0.81 mmol) were stirred at rt for 30 min then 
diluted with anhydrous CH2Cl2 (20 mL) and cooled to –78 °C.  To this solution was 
added NEt3 (1.13 mL, 8.11 mmol), followed by MsCl (314 µL, 4.06 mmol) dropwise 
over 10 min.  The reaction mixture was stirred at –78 °C for 40 min.  Meanwhile, to 
a stirred solution of L-leucine benzyl ester p-toluenesulfonate salt (3.19 g, 8.11 
mmol) in anhydrous CH2Cl2 (25 mL) was added NEt3 (1.13 mL, 8.11 mmol).  The 
mixture was stirred at rt for 10 min then added to the oxetane solution at –78 °C.  
The reaction mixture was allowed to warm to rt, stirred for 20 h, then quenched with 
saturated aqueous NH4Cl solution (30 mL).  The mixture was extracted with CH2Cl2 
(5 x 50 mL) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  Purification by column chromatography (15  30% EtOAc 
in hexane) provided 203 (798 mg, 59%) as a pale yellow oil.  Rf = 0.31 (30% EtOAc 
in hexane); [α]   +5.0 (c 0.16, CHCl3); IR (film) 3338, 2958, 2874, 1730, 1553, 1499, 
1457, 1379, 1268, 1169, 976, 737, 697 cm-1; δH (300 MHz, CDCl3) 7.42 – 7.31 (5H, 
m, ArH), 5.17 (1H, d, J = 12.1, OCHHPh), 5.08 (1H, d, J = 12.1, OCHHPh), 4.83 
(1H, dd, J = 12.8, 0.8, NO2CHH), 4.75 (1H, d, J = 12.8, NO2CHH), 4.58 (1H, d, J = 
7.2, OCHH), 4.53 (1H, d, J = 7.0, OCHH), 4.45 (1H, d, J = 7.2, OCHH), 4.26 (1H, 
d, J = 7.0, OCHH), 3.51 (1H, s, CHCO2Bn), 2.22 (1H, br s, NH), 1.74 – 1.57 (1H, m, 
CHMe2), 1.55 – 1.35 (2H, m, CH2iPr), 0.90 (3H, d, J = 6.8, CH3), 0.88 (3H, d, J = 
6.8, CH3); δC (75 MHz, CDCl3) 175.9 (C=O), 135.2 (C, Ar), 128.8 (CH, Ar), 128.8 
(CH, Ar), 79.1 (OCH2), 78.9 (OCH2), 78.3 (NO2CH2), 67.3 (OCH2Ph), 59.7 (C), 
54.5 (CHCO2Bn), 43.5 (CH2
iPr), 24.7 (CHMe2), 22.9 (CH3), 22.3 (CH3); MS (ES
+) 
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m/z 337 [M+H]+, 359 [M+Na]+; HRMS (ES+) calcd. for C17H24N2NaO5 [M+Na]
+: 
359.1577; found: 359.1564. 
 
Benzyl L-isoleucinate 4-methylbenzenesulfonate (263) 
This known compound was prepared according to a 
literature procedure.156  L-isoleucine (3.0 g, 22.9 
mmol) and p-toluenesulfonic acid monohydrate 
(4.78 g, 25.1 mmol) were added to a mixture of benzyl alcohol (29 mL) and toluene 
(43 mL).  The reaction mixture was heated under reflux for 16 h with a Dean-Stark 
trap before being cooled to rt and diluted with Et2O (30 mL).  The solution was 
cooled in an ice bath for 3 h and the precipitate formed was filtered under vacuum 
and washed with Et2O.  Recrystallisation (MeOH – Et2O) gave 263 (7.55 g, 84%) as 
a white solid.  Data has not been fully reported.  M.p. 150 – 151 °C (MeOH – Et2O); 
[α]   +3.89 (c 0.22, MeOH); IR (film) 2967, 1738, 1604, 1528, 1497, 1397, 1214, 
1175, 1125, 1037, 1013, 699, 678 cm-1; δH (300 MHz, MeOD) 7.71 (2H, d, J = 8.2, 
ArH), 7.44 – 7.34 (5H, m, ArH), 7.22 (2H, d, J = 8.2, ArH), 5.32 (1H, d, J = 12.1, 
OCHHPh), 5.21 (1H, d, J = 12.1, OCHHPh), 4.03 (1H, d, J = 4.0, CHCO2Bn), 2.36 
(3H, s, CH3, Ts), 2.02 – 1.89 (1H, m, EtCHMe), 1.52 – 1.37 (1H, m, CHHMe), 1.36 
– 1.20 (1H, m, CHHMe), 0.96 – 0.86 (6H, m, CH3), NH2, SO3H not observed; δC (75 
MHz, MeOD) 169.8 (C=O), 143.4 (C, Ar), 141.7 (C, Ar), 136.4 (C, Ar), 130.0 (CH, 
Ar), 129.8 (CH, Ar), 129.7 (CH, Ar), 126.9 (CH, Ar), 69.0 (OCH2Ph), 58.2 
(CHCO2Bn), 37.8 (EtCHMe), 26.6 (CH2Me), 21.3 (CH3, Ts), 14.8 (CH3), 11.9 
(CH3); MS (ES
+) m/z 222 [M free base+H]+, 244 [M free base+Na]+; HRMS (ES+) 
calcd. for C13H20NO2 [M+H]
+: 222.1489; found: 222.1486. 
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Benzyl [3-(nitromethyl)oxetan-3-yl]-L-isoleucinate (204) 
This novel compound was prepared as follows.  3-Oxetanone 
(260 µL, 4.05 mmol), nitromethane (307 µL, 5.67 mmol) and 
NEt3 (113 µL, 0.81 mmol) were stirred at rt for 30 min then 
diluted with anhydrous CH2Cl2 (20 mL) and cooled to –78 °C.  To this solution was 
added NEt3 (1.13 mL, 8.11 mmol), followed by MsCl (314 µL, 4.06 mmol) dropwise 
over 10 min.  The reaction mixture was stirred at –78 °C for 40 min.  Meanwhile, to 
a stirred solution of 263 (3.19 g, 8.11 mmol) in anhydrous CH2Cl2 (25 mL) was 
added NEt3 (1.13 mL, 8.11 mmol).  The mixture was stirred at rt for 10 min then 
added to the oxetane solution at –78 °C.  The reaction mixture was allowed to warm 
to rt, stirred for 20 h, then quenched with saturated aqueous NH4Cl solution (30 mL).  
The mixture was extracted with CH2Cl2 (5 x 50 mL) and the combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo.  Purification by 
column chromatography (10  25% EtOAc in hexane) provided 204 (704 mg, 52%) 
as a pale yellow oil.  Rf = 0.23 (30% EtOAc in hexane); [α]   –2.2 (c 0.24, CHCl3); 
IR (film) 3339, 2965, 2879, 1728, 1555, 1499, 1457, 1379, 1177, 1147, 979, 751, 
698 cm-1; δH (400 MHz, CDCl3) 7.41 – 7.32 (5H, m, ArH), 5.16 (1H, d, J = 12.1, 
OCHHPh), 5.12 (1H, d, J = 12.1, OCHHPh), 4.80 (1H, dd, J = 13.1, 0.8, NO2CHH), 
4.72 (1H, d, J = 13.1, NO2CHH), 4.55 (1H, d, J = 7.3, OCHH), 4.54 (1H, d, J = 7.3, 
OCHH), 4.45 (1H, d, J = 7.3, OCHH), 4.33 (1H, d, J = 7.3, OCHH), 3.31 (1H, dd, J 
= 11.0, 6.2, CHCO2Bn), 2.30 (1H, d, J = 11.0, NH), 1.72 – 1.61 (1H, m, EtCHMe), 
1.52 – 1.41 (1H, m, CHHMe), 1.13 – 1.01 (1H, m, CHHMe), 0.88 – 0.81 (6H, m, 
CH3); δC (100 MHz, CDCl3) 175.3 (C=O), 135.3 (C, Ar), 128.9 (CH, Ar), 128.8 
(CH, Ar), 78.9 (CH2), 78.7 (CH2), 78.5 (CH2), 67.2 (OCH2Ph), 60.6 (CHCO2Bn), 
59.6 (C), 39.0 (EtCHMe), 24.9 (CH2Me), 15.7 (CH3), 11.6 (CH3); MS (ES
+) m/z 337 
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[M+H]+, 359 [M+Na]+; HRMS (ES+) calcd. for C17H24N2NaO5 [M+Na]
+: 359.1577; 
found: 359.1576. 
 
Benzyl L-threoninate hydrochloride (264)157 
This known compound was prepared using a modified literature 
procedure.156,158  L-threonine (2.0 g, 16.8 mmol) and p-
toluenesulfonic acid monohydrate (3.51 g, 18.5 mmol) were 
added to a mixture of benzyl alcohol (21.3 mL) and toluene (32 mL).  The reaction 
mixture was heated under reflux for 16 h with a Dean-Stark trap before being cooled 
to rt and diluted with Et2O (25 mL).  Cooling of the solution in an ice bath gave no 
precipitate, so the toluene was removed in vacuo and the residue partitioned between 
EtOAc (100 mL) and water (100 mL).  The organic extracts were washed with water 
(4 x 100 mL) before NaHCO3 (3.5 g) was added to the combined aqueous phases.  
The aqueous was then extracted with EtOAc (5 x 100 mL) and the combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo.  To this was 
added HCl solution (4 M in dioxane, 17 mL) and the reaction mixture was stirred at 
rt for 3 h before it was concentrated in vacuo.  Addition of CH2Cl2 and Et2O formed 
a white precipitate, which was filtered under vacuum to give 264 (2.79 g, 68%) as a 
white solid.  Data in agreement with literature values.157  M.p. 125 – 126 °C (Et2O – 
CH2Cl2); [α]    –7.12 (c 0.28, MeOH); IR (film) 3337, 2975, 2875, 1742, 1596, 1490, 
1196, 1050, 913, 753, 700 cm-1; δH (400 MHz, DMSO-d6) 8.59 (3H, br s, NH2·HCl), 
7.45 – 7.31 (5H, m, ArH), 5.75 (1H, d, J = 5.0, OH), 5.26 – 5.19 (2H, m, OCH2Ph), 
4.21 – 4.13 (1H, m, CHMe), 3.98 (1H, d, J = 3.8, CHCO2Bn), 1.21 (3H, d, J = 6.5, 
CH3); δC (100 MHz, DMSO-d6) 168.1 (C=O), 135.3 (C, Ar), 128.5 (CH, Ar), 128.3 
(CH, Ar), 128.1 (CH, Ar), 67.0 (OCH2Ph), 65.3 (CHMe), 58.0 (CHCO2Bn), 20.0 
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(CH3); MS (ES
+) m/z 210 [M free base+H]+, 232 [M free base+Na]+; HRMS (ES+) 
calcd. for C11H16NO3 [M+H]
+: 210.1125; found: 210.1123. 
 
Benzyl [3-(nitromethyl)oxetan-3-yl]-L-threoninate (205)  
This novel compound was prepared as follows.  3-Oxetanone 
(260 µL, 4.05 mmol), nitromethane (307 µL, 5.67 mmol) 
and NEt3 (113 µL, 0.81 mmol) were stirred at rt for 30 min 
then diluted with anhydrous CH2Cl2 (20 mL) and cooled to –78 °C.  To this solution 
was added NEt3 (1.13 mL, 8.11 mmol), followed by MsCl (314 µL, 4.06 mmol) 
dropwise over 10 min.  The reaction mixture was stirred at –78 °C for 40 min.  
Meanwhile, to a stirred solution of 264 (1.99 g, 8.10 mmol) in anhydrous CH2Cl2 (25 
mL) was added NEt3 (1.13 mL, 8.11 mmol).  The mixture was stirred at rt for 10 min 
then added to the oxetane solution at –78 °C.  The reaction mixture was allowed to 
warm to rt, stirred for 20 h, then quenched with saturated aqueous NH4Cl solution 
(30 mL).  The mixture was extracted with CH2Cl2 (5 x 50 mL) and the combined 
organic extracts were dried over MgSO4, filtered and concentrated in vacuo.  
Purification by repeat column chromatography (30  50% EtOAc in hexane; 0  
2% MeOH in CH2Cl2; 70  85% Et2O in hexane) provided 205 (741 mg, 56%) as a 
pale yellow oil.  Rf = 0.22 (50% EtOAc in hexane); [α]   –7.7 (c 0.22, CHCl3); IR 
(film) 3347, 2925, 1729, 1552, 1499, 1457, 1378, 1265, 1173, 974, 736, 697 cm-1; δH 
(400 MHz, CDCl3) 7.41 – 7.33 (5H, m, ArH), 5.20 (1H, d, J = 12.1, OCHHPh), 5.15 
(1H, d, J = 12.1, OCHHPh), 4.82 (1H, d, J = 13.3, NO2CHH), 4.73 (1H, d, J = 13.3, 
NO2CHH), 4.57 – 4.52 (2H, m, OCHH), 4.45 (1H, d, J = 7.3, OCHH), 4.43 (1H, d, J 
= 7.3, OCHH), 3.84 – 3.76 (1H, m, CHMe), 3.27 (1H, dd, J = 10.6, 6.2, CHCO2Bn), 
2.87 (1H, d, J = 3.5, OH), 2.70 (1H, d, J = 10.6, NH), 1.18 (3H, d, J = 6.3, CH3); δC 
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(100 MHz, CDCl3) 173.7 (C=O), 134.8 (C, Ar), 129.0 (CH, Ar), 128.9 (CH, Ar), 
78.8 (CH2), 78.5 (CH2), 78.3 (CH2), 68.5 (CHMe), 67.8 (OCH2Ph), 62.1 
(CHCO2Bn), 59.2 (C), 19.2 (CH3); MS (ES
+) m/z 325 [M+H]+, 347 [M+Na]+; 
HRMS (ES+) calcd. for C15H20N2NaO6 [M+Na]
+: 347.1214; found: 347.1213. 
 
Benzyl [[3-(nitromethyl)oxetan-3-yl]glycyl]glycinate (206) 
This novel compound was prepared as follows.  3-
Oxetanone (303 µL, 4.72 mmol), nitromethane (358 
µL, 6.61 mmol) and NEt3 (132 µL, 0.95 mmol) were 
stirred at rt for 30 min then diluted with anhydrous CH2Cl2 (23.6 mL) and cooled to 
˗78 °C.  To this solution was added NEt3 (1.32 mL, 9.47 mmol), followed by MsCl 
(366 µL, 4.73 mmol) dropwise over 10 min.  The reaction mixture was stirred at ˗78 
°C for 2 h.  Meanwhile, to a stirred solution of glycylglycine benzyl ester p-
toluenesulfonate salt (3.73 g, 9.46 mmol) in anhydrous CH2Cl2 (29 mL) was added 
NEt3 (1.32 mL, 9.47 mmol).  The mixture was stirred at rt for 10 min then added to 
the oxetane solution at ˗78 °C.  The reaction mixture was allowed to warm to rt, 
stirred for 20 h, then quenched with saturated aqueous NH4Cl solution (30 mL).  The 
mixture was extracted with CH2Cl2 (5 x 60 mL) and the combined organic extracts 
were dried over MgSO4, filtered and concentrated in vacuo.  Purification by column 
chromatography (70  100% EtOAc in hexane) provided 206 (916 mg, 57%) as a 
pale yellow solid.  M.p. 82 – 84 °C; Rf = 0.26 (100% EtOAc); IR (film) 3359, 2969, 
2884, 1744, 1668, 1551, 1526, 1499, 1456, 1382, 1266, 1188, 979, 731, 697 cm-1; δH 
(400 MHz, CDCl3) 7.42 (1H, br t, J = 5.6, CONH), 7.39 – 7.31 (5H, m, ArH), 5.17 
(2H, s, OCH2Ph), 4.81 (2H, s, NO2CH2), 4.60 (2H, d, J = 7.4, OCHH), 4.54 (2H, d, J 
= 7.4, OCHH), 4.09 (2H, d, J = 5.6, CH2CO2Bn), 3.45 (2H, s, NHCH2CO), 2.47 (1H, 
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br s, NH); δC (100 MHz, CDCl3) 171.1 (C=O), 169.6 (C=O), 135.2 (C, Ar), 128.8 
(CH, Ar), 128.7 (CH, Ar), 128.5 (CH, Ar), 78.6 (NO2CH2), 77.8 (2 x OCH2), 67.4 
(OCH2Ph), 59.5 (C), 46.2 (NHCH2CO), 41.1 (CH2CO2Bn); MS (ES
+) m/z 360 
[M+Na]+; HRMS (ES+) calcd. for C15H19N3NaO6 [M+Na]
+: 360.1166; found: 
360.1174. 
 
Benzyl (tert-butoxycarbonyl)-L-valylglycinate (265)159 
This known compound was prepared according to a 
literature procedure.160  A stirred solution of glycine 
benzyl ester p-toluenesulfonate salt (4.61 g, 13.7 
mmol), N-(tert-butoxycarbonyl)-L-valine (3.07 g, 14.1 mmol), HOBt (317 mg, 2.06 
mmol) and NMM (4.83 mL, 43.9 mmol) in EtOH (137 mL) was cooled in an ice-
water bath before EDC.HCl (3.16 g, 16.5 mmol) was added.  The reaction mixture 
was stirred at rt for 64 h before water (800 mL) was added and the precipitate formed 
was filtered under vacuum.  The resultant white solid was dissolved in EtOAc, dried 
over MgSO4, filtered and concentrated in vacuo to afford 265 (4.29 g, 86%) as a 
cream solid.  Data in agreement with literature values.159  M.p. 81 – 82 °C; [α]    –
23.2 (c 0.24, MeOH); δH (400 MHz, CDCl3) 7.39 – 7.30 (5H, m, ArH), 6.64 (1H, br 
t, J = 5.2, NH), 5.17 (2H, s, OCH2Ph), 5.09 (1H, br d, J = 8.0, NH), 4.12 (1H, dd, J = 
18.3, 5.2, NHCHH), 4.08 – 3.97 (2H, m, NHCHH, CHiPr), 2.22 – 2.10 (1H, m, 
CHMe2), 1.43 (9H, s, CH3, Boc), 0.97 (3H, d, J = 6.8, CH3), 0.91 (3H, d, J = 6.8, 
CH3); δC (100 MHz, CDCl3) 172.1 (C=O), 169.7 (C=O), 156.0 (C=O), 135.2 (C, Ar), 
128.8 (CH, Ar), 128.7 (CH, Ar), 128.6 (CH, Ar), 80.1 (C), 67.4 (OCH2Ph), 59.9 
(CHiPr), 41.4 (NHCH2), 31.0 (CHMe2), 28.4 (CH3, Boc), 19.4 (CH3), 17.7 (CH3); 
MS (ES+) m/z 387 [M+Na]+. 
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Benzyl L-valylglycinate hydrochloride (266) 
This known compound was prepared using a modified 
literature procedure.161  265 (4.0 g, 11.0 mmol) was 
stirred in an HCl solution (4 M in dioxane, 22.0 mL, 88.0 
mmol) at rt for 2 h before it was concentrated in vacuo.  The resultant white solid 
was diluted with Et2O, filtered under vacuum and washed with Et2O to give 266 
(3.28 g, 99%) as a cream solid.  Data has not been fully reported.  M.p. 71 – 73 °C; 
[α]   +8.54 (c 0.24, MeOH); IR (film) 3207, 3036, 2935, 2880, 2634, 1745, 1671, 
1554, 1497, 1186, 1105, 736, 695 cm-1; δH (400 MHz, CDCl3) 8.60 (1H, br s, NH), 
8.16 (3H, br s, NH2·HCl), 7.31 – 7.27 (5H, m, ArH), 5.09 (2H, s, OCH2Ph), 4.30 
(1H, d, J = 4.5, CHiPr), 4.15 – 3.95 (2H, m, NHCH2), 2.39 – 2.29 (1H, m, CHMe2), 
1.06 (3H, d, J = 6.8, CH3), 1.02 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 169.8 
(C=O), 169.1 (C=O), 135.1 (C, Ar), 128.7 (CH, Ar), 128.6 (CH, Ar), 128.6 (CH, 
Ar), 67.5 (OCH2Ph), 58.6 (CH
iPr), 41.6 (NHCH2), 30.4 (CHMe2), 18.5 (CH3), 18.2 
(CH3); MS (ES
+) m/z 265 [M free base+H]+, 287 [M free base+Na]+; HRMS (ES+) 
calcd. for C14H21N2O3 [M+H]
+: 265.1547; found: 265.1546. 
 
Benzyl [[3-(nitromethyl)oxetan-3-yl]-L-valyl]glycinate (207) 
This novel compound was prepared as follows.  3-
Oxetanone (260 µL, 4.05 mmol), nitromethane (307 
µL, 5.67 mmol) and NEt3 (113 µL, 0.81 mmol) were 
stirred at rt for 30 min then diluted with anhydrous CH2Cl2 (20 mL) and cooled to –
78 °C.  To this solution was added NEt3 (1.13 mL, 8.11 mmol), followed by MsCl 
(314 µL, 4.06 mmol) dropwise over 10 min.  The reaction mixture was stirred at –78 
°C for 40 min.  Meanwhile, to a stirred solution of 266 (2.44 g, 8.11 mmol) in 
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anhydrous CH2Cl2 (25 mL) was added NEt3 (1.13 mL, 8.11 mmol).  The mixture 
was stirred at rt for 10 min then added to the oxetane solution at –78 °C.  The 
reaction mixture was allowed to warm to rt, stirred for 20 h, then quenched with 
saturated aqueous NH4Cl solution (30 mL).  The mixture was extracted with CH2Cl2 
(5 x 50 mL) and the combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  Purification by repeat column chromatography (40  50% 
EtOAc in hexane; 80  100% Et2O in hexane; 0  2% MeOH in CH2Cl2) provided 
207 (949 mg, 62%) as a pale yellow oil.  Rf = 0.31 (60% EtOAc in hexane); [α]   –
17.1 (c 0.22, CHCl3); IR (film) 3321, 2962, 2878, 1746, 1652, 1552, 1499, 1457, 
1380, 1278, 1187, 977, 738, 698 cm-1; δH (400 MHz, CDCl3) 7.40 – 7.30 (6H, m, 
ArH, CONH), 5.20 – 5.13 (2H, m, OCH2Ph), 4.85 (1H, d, J = 13.8, NO2CHH), 4.79 
(1H, dd, J = 13.8, 0.5, NO2CHH), 4.69 (1H, d, J = 7.3, OCHH), 4.59 (1H, d, J = 7.5, 
OCHH), 4.47 (1H, d, J = 7.3, OCHH), 4.45 (1H, d, J = 7.5, OCHH), 4.14 (1H, dd, J 
= 18.2, 6.3, NHCHH), 4.02 (1H, dd, J = 18.2, 5.5, NHCHH), 3.36 (1H, t, J = 4.0, 
CHiPr), 2.26 – 2.14 (2H, m, CHMe2, NH), 1.01 (3H, d, J = 6.8, CH3), 0.91 (3H, d, J 
= 7.0, CH3); δC (100 MHz, CDCl3) 174.3 (C=O), 169.7 (C=O), 135.2 (C, Ar), 128.8 
(CH, Ar), 128.7 (CH, Ar), 128.6 (CH, Ar), 79.5 (NO2CH2), 77.9 (OCH2), 77.5 
(OCH2), 67.4 (OCH2Ph), 62.4 (CH
iPr), 59.3 (C), 41.0 (NHCH2), 31.7 (CHMe2), 19.7 
(CH3), 17.6 (CH3); MS (ES
+) m/z 380 [M+H]+, 402 [M+Na]+; HRMS (ES+) calcd. 
for C18H25N3NaO6 [M+Na]
+: 402.1636; found: 402.1631. 
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9-Benzyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (209) 
This novel compound was prepared using a modified literature 
procedure.113  To a stirred solution of 169 (50 mg, 0.17 mmol) in 
anhydrous methanol (4.5 mL), samarium(II) iodide solution (0.085 
M in THF, 28.0 mL, 2.38 mmol) was added.  The reaction mixture was stirred at rt 
for 30 min then quenched with saturated aqueous NaHCO3 solution (30 mL) and 
extracted with CH2Cl2 (5 x 70 mL).  The combined organic extracts were dried over 
Na2SO4, filtered and concentrated in vacuo.  Purification by column chromatography 
(10  20% MeOH in EtOAc) provided 209 (13 mg, 33%) as a cream solid.  M.p. 
157 – 160 °C; Rf = 0.19 (10% MeOH in EtOAc); IR (film) 3297, 2948, 2874, 1657, 
1494, 1454, 1312, 977, 734, 700 cm-1; δH (400 MHz, CDCl3) 7.31 – 7.26 (2H, m, 
ArH), 7.24 – 7.19 (1H, m, ArH), 7.15 (2H, d, J = 7.0, ArH), 5.74 (1H, br s, NH), 
4.63 (1H, d, J = 7.3, OCHH), 4.58 (1H, d, J = 6.8, OCHH), 4.52 (1H, d, J = 6.8, 
OCHH), 4.41 (1H, d, J = 7.3, OCHH), 3.75 (1H, dt, J = 10.6, 3.0, CH), 3.55 (1H, d, 
J = 17.8, CHHNH), 3.49 (1H, d, J = 17.8, CHHNH), 3.03 (1H, dd, J = 13.6, 3.0, 
CHHPh), 2.70 (1H, dd, J = 13.6, 10.6, CHHPh), 2.17 (1H, br s, NH); δC (100 MHz, 
CDCl3) 168.4 (C=O), 136.5 (C, Ar), 129.4 (CH, Ar), 129.3 (CH, Ar), 127.4 (CH, 
Ar), 80.1 (OCH2), 77.9 (OCH2), 58.7 (CH), 58.3 (C), 45.8 (CH2NH), 38.1 (CH2Ph); 
MS (ES+) m/z 233 [M+H]+, 255 [M+Na]+; HRMS (ES+) calcd. for C13H17N2O2 
[M+H]+: 233.1285; found: 233.1284.  A crystal for X-ray analysis was grown using 
the solvent diffusion method (EtOAc/pentane). 
Crystal Data for C13H16N2O2, M = 232.28, orthorhombic, a = 12.8111 (17) Å, b = 
8.7861 (9) Å, c = 10.4514 (12) Å, U = 1176.4 (2) Å3, T = 150 (2) K, space group 
Pna2 (1), Z = 4, µ(MoKα) = 0.725 mm-1, 7966 reflections measured, 2322 unique 
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(Rint = 0.1297) which were used in all calculations.  The final wR2 was 0.1388 and R1 
was 0.0466 (>2 sigma (I)). 
 
9-Benzyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (209) 
This novel compound was prepared using a modified literature 
procedure.107  To a stirred solution of 199 (81 mg, 0.22 mmol) in 
glacial AcOH (3.6 mL), Zn (503 mg, 7.69 mmol) was added.  The 
reaction mixture was stirred vigorously at rt for 24 h then filtered through Celite®, 
washed with Et2O and concentrated in vacuo.  The residue was diluted with saturated 
aqueous NaHCO3 solution (15 mL) and extracted with EtOAc (3 x 20 mL).  The 
combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo.  Recrystallisation (EtOH) provided 209 (18 mg, 35%) as a pale orange solid.  
Data as previously reported. 
 
(S)-6-Isopropyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (210) 
This novel compound was prepared using a modified literature 
procedure.107  To a stirred solution of 194 (126 mg, 0.39 mmol) in 
glacial AcOH (6.5 mL) was added Zn (901 mg, 13.8 mmol).  The 
reaction mixture was stirred vigorously at rt for 67 h then filtered through Celite® 
and concentrated in vacuo.  The residue was diluted with saturated aqueous NaHCO3 
solution (15 mL) and extracted with EtOAc (4 x 20 mL).  The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo.  Purification by 
repeat column chromatography (0  15% MeOH in EtOAc + 0.5% NEt3; 0  5% 
MeOH in EtOAc + 0.5% NEt3), followed by recrystallisation (EtOAc-hexane) 
provided 210 (16 mg, 22%) as white flakes.  M.p. 153 – 154 °C (EtOAc – hexane); 
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Rf = 0.27 (10% MeOH in EtOAc); [α]    –107 (c 0.16, CHCl3); IR (film) 3255, 2968, 
2871, 2822, 1669, 1491, 1455, 1323 cm-1; δH (300 MHz, CDCl3) 6.75 (1H, br s, 
NHCO), 4.63 – 4.58 (2H, m, OCH2), 4.51 (1H, d, J = 7.1, OCHH), 4.45 (1H, d, J = 
7.1, OCHH), 3.65 (1H, dd, J = 11.5, 4.7, CHHNH), 3.49 – 3.40 (2H, m, CHHNH, 
CHiPr), 2.50 – 2.34 (1H, m, CHMe2), 1.82 (1H, br s, NH), 1.00 (3H, d, J = 7.2, 
CH3), 0.91 (3H, d, J = 6.8, CH3); δC (75 MHz, CDCl3) 171.3 (C=O), 82.2 (OCH2), 
80.1 (OCH2), 60.1 (CH
iPr), 55.4 (C), 49.1 (CH2NH), 30.2 (CHMe2), 19.2 (CH3), 
16.3 (CH3); MS (ES
+) m/z 185 [M+H]+, 207 [M+Na]+; HRMS (ES+) calcd. for 
C9H17N2O2 [M+H]
+: 185.1285; found: 185.1282. 
 
(S)-6-Isopropyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (210) 
This novel compound was prepared using a modified literature 
procedure.133  A suspension of (S)-193 (107 mg, 0.43 mmol) and 
10% Pd/C (53 mg) in MeOH (8 mL) was stirred under an 
atmosphere of hydrogen at rt for 17 h then filtered through Celite®, washed with 
MeOH and concentrated in vacuo.  Purification by column chromatography (0  
4% MeOH in CH2Cl2 + 0.5% NEt3), followed by recrystallisation (EtOAc-hexane) 
provided 210 as a cream solid (36 mg, 45%).  Data as previously reported. 
 
(S)-6-Benzyl-2-oxa-5,8-diazaspiro[3.5]nonan-7-one (211) 
This novel compound was prepared using a modified literature 
procedure.107  To a stirred solution of 195 (98 mg, 0.26 mmol) in 
glacial AcOH (4.5 mL) was added Zn (628 mg, 9.60 mmol).  The 
reaction mixture was stirred vigorously at rt for 67 h then filtered through Celite® 
and concentrated in vacuo.  The residue was diluted with saturated aqueous NaHCO3 
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solution (15 mL) and extracted with EtOAc (3 x 20 mL).  The combined organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo.  Purification by 
column chromatography (0  10% MeOH in EtOAc + 0.5% NEt3) provided 211 (42 
mg, 68%) as a white solid.  M.p. 156 – 158 °C; Rf = 0.30 (10% MeOH in EtOAc); 
[α]   –98.9 (c 0.18, CHCl3); IR (film) 3286, 3061, 2945, 2869, 1665, 1604, 1495, 
1455, 1314, 975, 734, 700 cm-1; δH (400 MHz, CDCl3) 7.37 – 7.32 (2H, m, ArH), 
7.31 – 7.25 (3H, m, ArH), 6.30 (1H, br s, NHCO), 4.57 (1H, d, J = 6.5, OCHH), 4.49 
(1H, d, J = 6.5, OCHH), 4.41 (1H, d, J = 7.0, OCHH), 4.38 (1H, d, J = 7.0, OCHH), 
3.72 (1H, dd, J = 10.0, 3.4, CH), 3.68 (1H, dd, J = 11.5, 4.0, CHHNH), 3.52 – 3.44 
(2H, m, CHHNH, CHHPh), 2.80 (1H, dd, J = 13.7, 10.0, CHHPh), 1.86 (1H, br s, 
NH); δC (100 MHz, CDCl3) 170.8 (C=O), 137.8 (C, Ar), 129.4 (CH, Ar), 129.0 (CH, 
Ar), 127.0 (CH, Ar), 81.8 (OCH2), 79.9 (OCH2), 56.3 (CH), 55.2 (C), 49.4 
(CH2NH), 38.5 (CH2Ph); MS (ES
+) m/z 233 [M+H]+, 255 [M+Na]+; HRMS (ES+) 
calcd. for C13H16N2NaO2 [M+Na]
+: 255.1104; found: 255.1106. 
 
Methyl [3-[1-[2-[[(benzyloxy)carbonyl]amino]acetamido]-2-phenylethyl]oxetan-
3-yl]-L-valinate (213a/b) 
This novel compound was prepared using 
modified literature procedures.113,154  To a stirred 
solution of 180a/b (137 mg, 0.41 mmol) in 
anhydrous MeOH (7.3 mL) was added samarium(II) iodide solution (0.1 M in THF, 
57.0 mL, 5.70 mmol).  The reaction mixture was stirred at rt for 20 min before 
saturated aqueous NaHCO3 solution (30 mL) was added and the solution extracted 
with CH2Cl2 (5 x 70 mL).  The combined organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo to give the crude amine.  To this was added 
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anhydrous CH2Cl2 (2.5 mL) and the resultant solution was added to a stirred mixture 
of Z-Gly-OH (79 mg, 0.38 mmol), DCC (85 mg, 0.41 mmol), HOBt (66 mg, 0.43 
mmol) and DIEA (70.9 µL, 0.41 mmol) in anhydrous CH2Cl2 (1.5 mL) at 0 °C.  The 
reaction mixture was stirred at 0 °C for 1 h, then at rt for 22 h, before it was filtered 
through Celite®, washed with CH2Cl2 and concentrated in vacuo.  Purification by 
repeat column chromatography (40  70% EtOAc in petroleum ether + 0.5% NEt3; 
50  55% EtOAc in petroleum ether + 0.5% NEt3) provided 213a/b (133 mg, 71%) 
as a colourless oil.  Both diastereomers were observed in a 1 : 1.3 ratio.  Rf = 0.29 
(70% EtOAc in petroleum ether); IR (film) 3321, 2958, 1724, 1662, 1502, 1497, 
1454, 1239, 1151, 1049, 980, 733, 699 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.16 
(23H, m, ArH), 6.95 (1.3H, br d, J = 8.5, CONH), 6.62 (1H, br d, J = 8.5, CONH), 
5.55 – 5.49 (1.3H, m, CbzNH), 5.45 – 5.39 (1H, m, CbzNH), 5.11 (4.6H, s, 
PhCH2O), 4.75 – 4.65 (2.3H, m, CHBn), 4.42 – 4.32 (3.3H, m, OCH2, OCHH), 4.29 
– 4.22 (2.6H, m, OCHH and OCHH), 4.19 (1.3H, d, J = 6.8, OCHH), 4.07 (1H, d, J 
= 7.3, OCHH), 4.01 (1H, d, J = 7.3, OCHH), 3.86 (1.3H, dd, J = 16.8, 5.5, 
NHCHH), 3.79 – 3.69 (10.2H, m, 2 x CO2CH3, NHCH2, NHCHH), 3.62 (1H, d, J = 
4.8, CHiPr), 3.55 (1.3H, d, J = 5.0, CHiPr), 2.94 – 2.72 (4.6H, m, CH2Ph), 2.26 – 
1.78 (4.6H, m, CHMe2, NH), 0.99 (3.9H, d, J = 6.7, CH3), 0.96 (3H, d, J = 6.7, CH3), 
0.90 (3.9H, d, J = 6.8, CH3), 0.89 (3H, d, J = 6.8, CH3); δC (150 MHz, CDCl3) 177.1 
(C=O), 176.9 (C=O), 169.3 (C=O), 168.9 (C=O), 156.7 (C=O), 137.8 (C, Ar), 137.3 
(C, Ar), 136.3 (C, Ar), 136.2 (C, Ar), 129.3 (CH, Ar), 128.7 (CH, Ar), 128.6 (CH, 
Ar), 128.4 (CH, Ar), 128.3 (CH, Ar), 128.2 (CH, Ar), 128.1 (CH, Ar), 126.9 (CH, 
Ar), 126.9 (CH, Ar), 79.4 (OCH2), 79.3 (OCH2), 79.0 (OCH2), 77.8 (OCH2), 67.3 
(PhCH2O), 67.2 (PhCH2O), 62.6 (C), 62.5 (C), 61.1 (CH
iPr), 60.1 (CHiPr), 56.4 
(CHBn), 55.9 (CHBn), 52.4 (CO2CH3), 52.3 (CO2CH3), 44.9 (NHCH2), 44.7 
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(NHCH2), 35.9 (CH2Ph), 35.5 (CH2Ph), 32.6 (CHMe2), 32.1 (CHMe2), 19.7 (CH3), 
19.7 (CH3), 18.1 (CH3), 18.0 (CH3); MS (ES
+) m/z 498 [M+H]+, 520 [M+Na]+; 
HRMS (ES+) calcd. for C27H36N3O6 [M+H]
+: 498.2599; found: 498.2594.  
  
Methyl [3-[(S)-1-[2-[[(benzyloxy)carbonyl]amino]acetamido]-2-
phenylethyl]oxetan-3-yl]-L-valinate (213a and 213b) 
These diastereomers were separated by 
preparative HPLC (Phenomonex Lux C2 column, 
20 µm silica, 50 mm diameter, 250 mm length), 
50 : 50 heptane : EtOH at 90 ml / min. to afford 
the less polar 213a (36 mg, 19%) as a yellow 
waxy solid.  Rf = 0.39 (70% EtOAc in heptane); 
[α]   +9.35 (c 0.26, CHCl3); IR (KBr) 3319, 2959, 2876, 1729, 1670, 1518, 1455, 
1245, 1050, 751 cm-1; δH (700 MHz, CDCl3) 7.30 – 7.11 (10H, m, ArH), 6.44 (1H, 
br d, J = 7.9, CONH), 5.22 (1H, br s, CbzNH), 5.04 (2H, s, PhCH2O), 4.68 – 4.64 
(1H, m, CHBn), 4.31 (2H, s, OCH2), 4.00 (1H, d, J = 6.9, OCHH), 3.94 (1H, d, J = 
6.9, OCHH), 3.71 (2H, d, J = 5.7, NHCH2), 3.70 (3H, s, CO2CH3), 3.55 (1H, d, J = 
4.8, CHiPr), 2.81 – 2.74 (1H, m, CHHPh), 2.71 (1H, dd, J = 13.9, 7.5, CHHPh), 1.97 
– 1.90 (1H, m, CHMe2), 0.90 (3H, d, J = 6.8, CH3), 0.82 (3H, d, J = 6.8, CH3), 
secondary NH not observed; δC (175 MHz, CDCl3) 176.9 (C=O), 168.9 (C=O), 
156.7 (C=O), 137.3 (C, Ar), 136.2 (C, Ar), 129.3 (CH, Ar), 128.8 (CH, Ar), 128.7 
(CH, Ar), 128.5 (CH, Ar), 128.3 (CH, Ar), 127.0 (CH, Ar), 79.3 (OCH2), 77.9 
(OCH2), 67.4 (PhCH2O), 62.6 (C), 60.2 (CH
iPr), 56.4 (CHBn), 52.3 (CO2CH3), 45.0 
(NHCH2), 36.1 (CH2Ph), 32.7 (CHMe2), 19.7 (CH3), 18.0 (CH3); MS (ES
+) m/z 498 
[M+H]+, 520 [M+Na]+; HRMS (ES+) calcd. for C27H36N3O6 [M+H]
+: 498.2599; 
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found: 498.2604.  And the more polar 213b (48 mg, 26%) as a yellow waxy solid.  
Rf = 0.34 (70% EtOAc in heptane); [α]   –22.3 (c 0.20, CHCl3); IR (KBr) 3323, 
2959, 2875, 1730, 1668, 1520, 1454, 1243, 1053, 982, 751 cm-1; δH (700 MHz, 
CDCl3) 7.30 – 7.11 (10H, m, ArH), 6.74 (1H, br d, J = 7.8, CONH), 5.35 (1H, br s, 
CbzNH), 5.05 (2H, s, PhCH2O), 4.63 (1H, dd, J = 14.3, 7.8, CHBn), 4.27 (1H, d, J = 
7.2, OCHH), 4.20 (1H, d, J = 6.8, OCHH), 4.16 (1H, d, J = 7.2, OCHH), 4.11 (1H, 
d, J = 6.8, OCHH), 3.81 (1H, dd, J = 16.6, 4.6, NHCHH), 3.70 (1H, dd, J = 16.6, 
5.3, NHCHH), 3.64 (3H, s, CO2CH3), 3.49 (1H, d, J = 5.1, CH
iPr), 2.83 (1H, dd, J = 
14.3, 5.7, CHHPh), 2.76 (1H, dd, J = 14.3, 7.8, CHHPh), 2.01 – 1.94 (1H, m, 
CHMe2), 1.77 (1H, br s, NH), 0.93 (3H, d, J = 6.8, CH3), 0.83 (3H, d, J = 7.0, CH3); 
δC (175 MHz, CDCl3) 177.1 (C=O), 169.3 (C=O), 156.7 (C=O), 137.7 (C, Ar), 136.4 
(C, Ar), 129.3 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.4 (CH, Ar), 128.2 
(CH, Ar), 127.0 (CH, Ar), 79.5 (OCH2), 79.0 (OCH2), 67.3 (PhCH2O), 62.7 (C), 
61.2 (CHiPr), 56.1 (CHBn), 52.4 (CO2CH3), 44.8 (NHCH2), 35.7 (CH2Ph), 32.1 
(CHMe2), 19.7 (CH3), 18.1 (CH3); MS (ES
+) m/z 498 [M+H]+, 520 [M+Na]+; HRMS 
(ES+) calcd. for C27H36N3O6 [M+H]
+: 498.2599; found: 498.2602.   
 
tert-Butyl [3-[1-[2-[[(benzyloxy)carbonyl]amino]acetamido]-2- 
phenylethyl]oxetan-3-yl]glycinate (214) 
This novel compound was prepared using 
modified literature procedures.113,154  To a stirred 
solution of 178 (165 mg, 0.49 mmol) in anhydrous 
MeOH (10 mL) was added samarium(II) iodide solution (0.1 M in THF, 68.8 mL, 
6.88 mmol).  The reaction mixture was stirred at rt for 20 min before saturated 
aqueous NaHCO3 solution (35 mL) was added and the solution extracted with 
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CH2Cl2 (5 x 80 mL).  The combined organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo to give the crude amine.  To this was added 
anhydrous CH2Cl2 (4 mL) and the resultant solution was added to a stirred mixture 
of Z-Gly-OH (94 mg, 0.45 mmol), DCC (103 mg, 0.50 mmol), HOBt (75 mg, 0.49 
mmol) and DIEA (85.4 µL, 0.49 mmol) in anhydrous CH2Cl2 (1.5 mL) at 0 °C.  The 
reaction mixture was stirred at 0 °C for 1 h, then at rt for 24 h, before it was filtered 
through Celite®, washed with CH2Cl2 and concentrated in vacuo.  Purification by 
column chromatography (45  80% EtOAc in petroleum ether + 0.5% NEt3) 
provided 214 (121 mg, 54%) as a white solid.  M.p. 132 – 133 °C; Rf = 0.32 (70% 
EtOAc in petroleum ether); IR (film) 3312, 2974, 1725, 1662, 1522, 1455, 1367, 
1235, 1154, 979, 737, 698 cm-1; δH (400 MHz, CDCl3) 7.31 – 7.10 (10H, m, ArH), 
6.61 (1H, d, J = 8.8, CONH), 5.39 – 5.33 (1H, m, CbzNH), 5.04 (2H, s, PhCH2O), 
4.68 – 4.60 (1H, m, CH), 4.35 – 4.27 (2H, m, OCH2), 4.18 (1H, d, J = 7.0, OCHH), 
4.09 (1H, d, J = 7.0, OCHH), 3.75 (1H, dd, J = 16.2, 5.8, CbzNHCHH), 3.66 (1H, 
dd, J = 16.2, 5.3, CbzNHCHH), 3.55 (1H, d, J = 17.6, CHHCO2
tBu), 3.47 (1H, d, J = 
17.6, CHHCO2
tBu), 2.79 – 2.64 (2H, m, CH2Ph), 1.89 (1H, br s, NH), 1.42 (9H, s, 
CH3); δC (150 MHz, CDCl3) 172.4 (C=O), 169.0 (C=O), 156.6 (C=O), 137.5 (C, Ar), 
136.3 (C, Ar), 129.1 (CH, Ar), 128.7 (CH, Ar), 128.7 (CH, Ar), 128.4 (CH, Ar), 
128.3 (CH, Ar), 126.9 (CH, Ar), 82.2 (C, tBu), 78.5 (OCH2), 78.0 (OCH2), 67.3 
(PhCH2O), 62.6 (C, oxetane), 55.6 (CH), 45.6 (CH2CO2
tBu), 44.7 (CbzNHCH2), 
35.8 (CH2Ph), 28.2 (CH3); MS (ES
+) m/z 498 [M+H]+, 520 [M+Na]+; HRMS (ES+) 
calcd. for C27H36N3O6 [M+H]
+: 498.2599; found: 498.2601.   
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Methyl [[3-[1-[2-[[(benzyloxy)carbonyl]amino]acetamido]-2-
phenylethyl]oxetan-3-yl]glycyl]glycinate (217) 
This novel compound was prepared using 
modified literature procedures.113,154  To a 
stirred solution of 200 (168 mg, 0.39 
mmol) in anhydrous MeOH (7.9 mL) was added samarium(II) iodide solution (0.1 M 
in THF, 55.0 mL, 5.50 mmol).  The reaction mixture was stirred at rt for 20 min 
before saturated aqueous NaHCO3 solution (35 mL) was added and the solution 
extracted with CH2Cl2 (5 x 70 mL).  The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo to give the crude amine.  To this was 
added anhydrous CH2Cl2 (2 mL) and the resultant solution was added to a stirred 
mixture of Z-Gly-OH (83 mg, 0.40 mmol), DCC (91 mg, 0.44 mmol), HOBt (67 mg, 
0.44 mmol) and DIEA (75.4 µL, 0.43 mmol) in anhydrous CH2Cl2 (2 mL) at 0 °C.  
The reaction mixture was stirred at 0 °C for 10 min, then at rt for 66 h, before it was 
filtered through Celite®, washed with CH2Cl2 and concentrated in vacuo.  
Purification by repeat column chromatography (0  9% MeOH in CH2Cl2 + 0.5% 
NEt3; 2  4% MeOH in EtOAc + 0.5% NEt3) provided 217 (90 mg, 45%) as a white 
solid.  M.p. 55 – 57 °C (Et2O); Rf = 0.24 (7% MeOH in EtOAc); IR (film) 3321, 
2952, 1721, 1659, 1530, 1454, 1440, 1234, 1182, 737, 700 cm-1; δH (400 MHz, 
CDCl3) 7.50 (1H, br s, NH), 7.40 – 7.14 (10H, m, ArH), 6.69 (1H, br d, J = 8.3, 
NH), 5.52 (1H, br t, J = 5.8. NH), 5.13 – 5.06 (2H, m, PhCH2O), 4.71 – 4.64 (1H, m, 
CH), 4.56 (1H, d, J = 7.5, OCHH), 4.39 – 4.29 (3H, m, OCHH, OCH2), 4.13 (1H, 
dd, J = 18.2, 5.5, CHH), 4.03 (1H, dd, J = 18.2, 5.3, CHH), 3.81 – 3.51 (7H, m, CH3, 
CH2, CH2), 2.83 (1H, dd, J = 14.1, 4.3, CHHPh), 2.72 (1H, dd, J = 14.1, 9.0, 
CHHPh), 2.10 (1H, br s, NH); δC (125 MHz, CDCl3) 172.4 (C=O), 171.1 (C=O), 
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169.7 (C=O), 157.0 (C=O), 137.4 (C, Ar), 136.3 (C, Ar), 129.0 (CH, Ar), 128.8 (CH, 
Ar), 128.7 (CH, Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 127.0 (CH, Ar), 78.3 (OCH2), 
77.7 (OCH2), 67.3 (PhCH2O), 63.4 (C), 55.7 (CH), 52.6 (CH3), 46.4 (CH2), 44.8 
(CH2), 40.9 (CH2), 35.6 (CH2Ph); MS (ES
+) m/z 535 [M+Na]+; HRMS (ES+) calcd. 
for C26H33N4O7 [M+H]
+: 513.2344; found: 513.2348. 
 
Benzyl [[3-[[2-[[(benzyloxy)carbonyl]amino]acetamido]methyl]oxetan-3-
yl]glycyl]glycinate (223) 
This novel compound was prepared using 
modified literature procedures.113,160  To a 
stirred solution of 206 (153 mg, 0.45 
mmol) in anhydrous tBuOH (10.6 mL) was added samarium(II) iodide solution (0.1 
M in THF, 63.5 mL, 6.35 mmol).  The reaction mixture was stirred at rt for 20 min 
before saturated aqueous NaHCO3 solution (40 mL) was added and the solution 
extracted with CH2Cl2 (5 x 75 mL).  The combined organic extracts were dried over 
MgSO4, filtered and concentrated in vacuo to give the crude amine.  To this was 
added Z-Gly-OH (97 mg, 0.46 mmol), HOBt (12 mg, 0.08 mmol), NMM (108 µL, 
0.98 mmol) and EtOH (4.5 mL).  The reaction mixture was cooled in an ice-water 
bath before EDC.HCl (103 mg, 0.54 mmol) was added.  The reaction mixture was 
stirred at rt for 18 h before water (25 mL) was added and the solution extracted with 
EtOAc (4 x 50 mL).  The combined organic extracts were dried over MgSO4, filtered 
and concentrated in vacuo.  Purification by column chromatography (4  9% 
MeOH in CH2Cl2) provided 223 (55 mg, 24%) as a colourless oil.  Rf = 0.24 (9% 
MeOH in CH2Cl2); IR (film) 3318, 2938, 2879, 1717, 1660, 1530, 1456, 1230, 1190, 
974, 740, 699 cm-1; δH (400 MHz, MeOD) 7.36 – 7.26 (10H, m, ArH), 5.15 (2H, s, 
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CO2CH2Ph), 5.07 (2H, s, PhCH2OCONH), 4.48 (2H, d, J = 6.8, OCHH), 4.41 (2H, 
d, J = 6.8, OCHH), 4.04 (2H, s, CH2CO2Bn), 3.77 (2H, s, CbzNHCH2), 3.59 (2H, s, 
CH2), 3.40 (2H, s, CH2), NHs not observed; δC (100 MHz, MeOD) 175.5 (C=O), 
173.0 (C=O), 171.3 (C=O), 159.1 (C=O), 138.1 (C, Ar), 137.1 (C, Ar), 129.6 (CH, 
Ar), 129.5 (CH, Ar), 129.3 (CH, Ar), 129.1 (CH, Ar), 128.9 (CH, Ar), 79.8 (2 x 
OCH2), 68.0 (CH2), 67.8 (CH2), 61.5 (C), 46.7 (CH2), 45.1 (CH2), 44.7 (CH2), 41.9 
(CH2CO2Bn); MS (ES
+) m/z 499 [M+H]+, 521 [M+Na]+; HRMS (ES+) calcd. for 
C25H30N4NaO7 [M+Na]
+: 521.2007; found: 521.1997. 
 
General Method A: Nitro reduction112 and amide coupling160 
To a stirred suspension of the nitro compound (1.0 molar equiv.) in THF/H2O (1:3, 
1.0 mL) was added In metal (4.0 molar equiv.), followed by 6 M HCl (6.0 molar 
equiv.).  The reaction mixture was stirred at rt for 90 min, then basified with 
saturated aqueous NaHCO3 solution (8 mL) and diluted with EtOAc (20 mL).  The 
solution was filtered through Celite® and extracted with EtOAc (3 x 20 mL).  The 
combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo to give the crude amine.  To this amine (1.0 molar equiv.) was added the Cbz 
protected amino acid (1.03 molar equiv.), HOBt (0.15 molar equiv.), NMM (2.2 
molar equiv.) in EtOH.  The reaction mixture was cooled in an ice-water bath before 
EDC.HCl (1.2 molar equiv.) was added.  The reaction mixture was stirred at rt for 18 
h before water (18 mL) was added and the solution extracted with EtOAc (4 x 30 
mL).  The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo.  Purification by column chromatography provided the 
product. 
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Benzyl [3-[[2-[[(benzyloxy)carbonyl]amino]acetamido]methyl]oxetan-3-yl]-L-
valinate (216) 
This novel compound was prepared as follows.  
194 (97 mg, 0.30 mmol), In metal (142 mg, 1.24 
mmol) and 6 M HCl (0.31 mL, 1.86 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-Gly-OH (68 mg, 0.33 mmol), HOBt (8 mg, 0.05 mmol), NMM (75 µL, 0.68 
mmol), EDC.HCl (70 mg, 0.37 mmol) in EtOH (3.1 mL).  Work-up, followed by 
purification by column chromatography (60  80% EtOAc in hexane) provided 216 
(71 mg, 49%) as a colourless oil.  Rf = 0.31 (80% EtOAc in petroleum ether); [α]  
+12.3 (c 0.22, CHCl3); IR (film) 3316, 2960, 2875, 1722, 1666, 1520, 1456, 1241, 
1152, 974, 737, 699 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.29 (10H, m, ArH), 6.50 
(1H, br s, CONH), 5.41 (1H, br s, CbzNH), 5.16 – 5.08 (4H, m, CO2CH2Ph and 
PhCH2OCONH), 4.37 (1H, d, J = 6.4, OCHH), 4.30 (1H, d, J = 6.5, OCHH), 4.23 
(1H, d, J = 6.5, OCHH), 4.18 (1H, d, J = 6.4, OCHH), 3.86 (2H, d, J = 5.5, 
CbzNHCH2), 3.78 (1H, dd, J = 14.0, 5.8, CHH), 3.41 (1H, dd, J = 14.0, 4.9, CHH), 
3.12 (1H, d, J = 5.3, CHiPr), 2.01 – 1.65 (2H, m, CHMe2, NH), 0.94 (3H, d, J = 6.8, 
CH3), 0.87 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 176.0 (C=O), 169.7 (C=O), 
156.7 (C=O), 136.2 (C, Ar), 135.3 (C, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.7 
(CH, Ar), 128.6 (CH, Ar), 128.3 (CH, Ar), 128.2 (CH, Ar), 79.7 (OCH2), 79.4 
(OCH2), 67.3 (CH2), 67.2 (CH2), 61.1 (CH
iPr), 59.4 (C), 44.7 (CbzNHCH2), 43.6 
(CH2), 32.0 (CHMe2), 19.5 (CH3), 17.9 (CH3); MS (ES
+) m/z 484 [M+H]+, 506 
[M+Na]+; HRMS (ES+) calcd. for C26H34N3O6 [M+H]
+: 484.2442; found: 484.2444. 
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Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-3-
phenylpropanamido]methyl]oxetan-3-yl]-L-valinate (225) 
This novel compound was prepared as follows.  
194 (101 mg, 0.31 mmol), In metal (145 mg, 1.26 
mmol) and 6 M HCl (0.31 mL, 1.86 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-L-Phe-OH (97 mg, 0.32 mmol), HOBt (9 mg, 0.06 mmol), NMM (75 µL, 0.68 
mmol), EDC.HCl (73 mg, 0.38 mmol) in EtOH (3.1 mL).  Work-up, followed by 
purification by column chromatography (40  50% EtOAc in hexane) provided 225 
(107 mg, 60%) as a colourless oil.  Rf = 0.26 (50% EtOAc in hexane); [α]    +15.5 (c 
0.20, CHCl3); IR (film) 3320, 2962, 2875, 1724, 1663, 1525, 1498, 1456, 1254, 
1179, 1152, 977, 747, 698 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.21 (13H, m, ArH), 
7.18 (2H, d, J = 7.5, ArH), 6.19 – 6.13 (1H, m, CONH), 5.43 – 5.36 (1H, m, 
CbzNH), 5.12 – 5.04 (4H, m, CO2CH2Ph and PhCH2OCONH), 4.43 – 4.35 (1H, m, 
CHBn), 4.28 (1H, d, J = 6.5, OCHH), 4.14 (1H, d, J = 6.5, OCHH), 4.06 (1H, d, J = 
6.5, OCHH), 4.02 (1H, d, J = 6.5, OCHH), 3.64 (1H, dd, J = 13.9, 5.4, NHCHH), 
3.33 (1H, dd, J = 13.9, 5.0, NHCHH), 3.15 (1H, dd, J = 13.8, 6.3, CHHPh), 3.04 – 
2.97 (2H, m, CHHPh, CHiPr), 1.92 – 1.78 (2H, m, CHMe2, NH), 0.86 (3H, d, J = 
6.8, CH3), 0.78 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 176.0 (C=O), 171.3 
(C=O), 155.9 (C=O), 136.6 (C, Ar), 136.3 (C, Ar), 135.3 (C, Ar), 129.4 (CH, Ar), 
128.9 (CH, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.6 (CH, Ar), 
128.3 (CH, Ar), 128.2 (CH, Ar), 127.2 (CH, Ar), 79.6 (OCH2), 79.6 (OCH2), 67.2 
(CH2), 67.2 (CH2), 61.0 (CH
iPr), 59.0 (C), 56.6 (CHBn), 43.7 (NHCH2), 38.8 
(CH2Ph), 32.0 (CHMe2), 19.5 (CH3), 18.0 (CH3); MS (ES
+) m/z 596 [M+Na]+; 
HRMS (ES+) calcd. for C33H39N3NaO6 [M+Na]
+: 596.2731; found: 596.2722. 
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Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-3-
phenylpropanamido]methyl]oxetan-3-yl]-L-isoleucinate (226) 
This novel compound was prepared as follows.  
204 (100 mg, 0.30 mmol), In metal (137 mg, 1.19 
mmol) and 6 M HCl (298 µL, 1.79 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-L-Phe-OH (95 mg, 0.32 mmol), HOBt (7 mg, 0.05 mmol), NMM (72 µL, 0.65 
mmol), EDC.HCl (70 mg, 0.37 mmol) in EtOH (3 mL).  Work-up, followed by 
purification by column chromatography (30  50% EtOAc in hexane) provided 226 
(102 mg, 58%) as a colourless oil.  Rf = 0.31 (50% EtOAc in hexane); [α]    +16.3 (c 
0.20, CHCl3); IR (film) 3313, 3033, 2963, 2876, 1724, 1663, 1523, 1498, 1456, 
1255, 1174, 976, 746, 698 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.20 (13H, m, ArH), 
7.18 (2H, d, J = 7.3, ArH), 6.17 – 6.12 (1H, m, CONH), 5.41 (1H, d, J = 7.5, 
CbzNH), 5.10 (1H, d, J = 12.3, CHH), 5.08 (2H, s, CH2), 5.07 (1H, d, J = 12.3, 
CHH), 4.43 – 4.36 (1H, m, CHBn), 4.28 (1H, d, J = 6.5, OCHH), 4.14 (1H, d, J = 
6.5, OCHH), 4.06 (1H, d, J = 6.5, OCHH), 4.01 (1H, d, J = 6.5, OCHH), 3.64 (1H, 
dd, J = 13.9, 5.4, NHCHH), 3.32 (1H, dd, J = 13.9, 4.9, NHCHH), 3.16 (1H, dd, J = 
13.7, 5.8, CHHPh), 3.05 (1H, d, J = 5.8, CHCO2Bn), 2.99 (1H, dd, J = 13.7, 7.8, 
CHHPh), 1.83 (1H, br s, NH), 1.64 – 1.54 (1H, m, EtCHMe), 1.39 – 1.28 (1H, m, 
CHHMe), 1.04 – 0.90 (1H, m, CHHMe), 0.83 – 0.78 (6H, m, CH3); δC (100 MHz, 
CDCl3) 176.0 (C=O), 171.3 (C=O), 155.9 (C=O), 136.6 (C, Ar), 136.3 (C, Ar), 135.2 
(C, Ar), 129.4 (CH, Ar), 128.9 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.7 
(CH, Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 127.2 (CH, Ar), 79.7 (OCH2), 79.6 
(OCH2), 67.2 (2 x OCH2Ph), 60.2 (CHCO2Bn), 59.0 (C), 56.5 (CHBn), 43.7 
(NHCH2), 38.9 (CH2Ph), 38.8 (EtCHMe), 24.9 (CH2Me), 15.9 (CH3), 11.6 (CH3); 
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MS (ES+) m/z 588 [M+H]+, 610 [M+Na]+; HRMS (ES+) calcd. for C34H42N3O6 
[M+H]+: 588.3068; found: 588.3050. 
 
Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]propanamido]methyl]oxetan-3-
yl]-L-valinate (227) 
This novel compound was prepared as follows.  
194 (101 mg, 0.31 mmol), In metal (146 mg, 1.27 
mmol) and 6 M HCl (0.31 mL, 1.86 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-L-Ala-OH (72 mg, 0.32 mmol), HOBt (8 mg, 0.05 mmol), NMM (75 µL, 0.68 
mmol), EDC.HCl (71 mg, 0.37 mmol) in EtOH (3.1 mL).  Work-up, followed by 
purification by column chromatography (50  70% EtOAc in hexane) provided 227 
(69 mg, 44%) as a colourless oil.  Rf = 0.31 (70% EtOAc in hexane); [α]   +9.4 (c 
0.16, CHCl3); IR (film) 3327, 2962, 2876, 1721, 1663, 1521, 1499, 1456, 1239, 
1178, 1153, 974, 737, 697 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.28 (10H, m, ArH), 
6.48 (1H, br s, CONH), 5.31 (1H, br s, CbzNH), 5.14 (1H, d, J = 12.1, CO2CHHPh), 
5.11 (1H, d, J = 12.1, CO2CHHPh), 5.10 (2H, s, PhCH2OCONH), 4.35 (1H, d, J = 
6.5, OCHH), 4.28 (1H, d, J = 6.5, OCHH), 4.25 – 4.19 (2H, m, OCHH, CHMe), 4.17 
(1H, d, J = 6.5, OCHH), 3.75 (1H, dd, J = 13.9, 5.8, NHCHH), 3.39 (1H, dd, J = 
13.9, 4.9, NHCHH), 3.13 (1H, d, J = 5.5, CHiPr), 2.03 – 1.89 (2H, m, CHMe2, NH), 
1.38 (3H, d, J = 7.0, CH3, Ala), 0.94 (3H, d, J = 6.8, CH3, Val), 0.87 (3H, d, J = 6.8, 
CH3, Val); δC (100 MHz, CDCl3) 176.1 (C=O), 173.0 (C=O), 156.0 (C=O), 136.3 
(C, Ar), 135.3 (C, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.7 (CH, 
Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 79.7 (OCH2), 79.4 (OCH2), 67.2 (CH2), 67.1 
(CH2), 61.1 (CH
iPr), 59.5 (C), 50.9 (CHMe), 43.7 (NHCH2), 32.0 (CHMe2), 19.6 
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(CH3, Val), 18.8 (CH3, Ala), 18.0 (CH3, Val); MS (ES
+) m/z 520 [M+Na]+; HRMS 
(ES+) calcd. for C27H35N3NaO6 [M+Na]
+: 520.2418; found: 520.2420. 
 
Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-3-
methylbutanamido]methyl]oxetan-3-yl]-L-valinate (228) 
This novel compound was prepared as follows.  
194 (102 mg, 0.32 mmol), In metal (144 mg, 1.25 
mmol) and 6 M HCl (0.31 mL, 1.86 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-L-Val-OH (82 mg, 0.33 mmol), HOBt (8 mg, 0.05 mmol), NMM (75 µL, 0.68 
mmol), EDC.HCl (73 mg, 0.38 mmol) in EtOH (3.1 mL).  Work-up, followed by 
purification by column chromatography (35  50% EtOAc in hexane) provided 228 
(78 mg, 47%) as a white oily solid. Rf = 0.24 (50% EtOAc in hexane); [α]    +20.5 (c 
0.20, CHCl3); IR (film) 3311, 2963, 2876, 1723, 1659, 1521, 1498, 1456, 1233, 
1177, 1152, 1027, 976, 737, 696 cm-1; δH (400 MHz, CDCl3) 7.39 – 7.28 (10H, m, 
ArH), 6.46 – 6.41 (1H, m, CONH), 5.39 (1H, d, J = 8.3, CbzNH), 5.14 (1H, d, J = 
12.1, OCHHPh), 5.11 (1H, d, J = 12.1, OCHHPh), 5.10 (2H, s, PhCH2OCONH), 
4.35 (1H, d, J = 6.5, OCHH), 4.29 (1H, d, J = 6.5, OCHH), 4.22 (1H, d, J = 6.5, 
OCHH), 4.17 (1H, d, J = 6.5, OCHH), 3.99 (1H, dd, J = 8.3, 6.0, CHiPr, Z-Val), 3.74 
(1H, dd, J = 13.8, 5.5, NHCHH), 3.42 (1H, dd, J = 13.8, 5.0, NHCHH), 3.13 (1H, d, 
J = 5.3, CHiPr, Val-OBn), 2.22 – 2.09 (1H, m, CHMe2, Z-Val), 2.07 – 1.90 (2H, m, 
CHMe2, Val-OBn, and NH), 0.98 – 0.93 (6H, m, CH3), 0.91 (3H, d, J = 7.0, CH3), 
0.87 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 176.1 (C=O), 171.8 (C=O), 156.5 
(C=O), 136.4 (C, Ar), 135.3 (C, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, 
Ar), 128.7 (CH, Ar), 128.3 (CH, Ar), 128.2 (CH, Ar), 79.7 (OCH2), 79.5 (OCH2), 
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67.2 (CH2), 67.2 (CH2), 61.1 (CH
iPr, Val-OBn), 60.8 (CHiPr, Z-Val), 59.4 (C), 43.7 
(NHCH2), 32.0 (CHMe2, Val-OBn), 31.0 (CHMe2, Z-Val), 19.6 (CH3), 19.3 (CH3), 
18.0 (CH3), 17.9 (CH3); MS (ES
+) m/z 526 [M+H]+, 548 [M+Na]+; HRMS (ES+) 
calcd. for C29H39N4NaO6 [M+Na]
+: 548.2731; found: 548.2724. 
 
Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-4-
methylpentanamido]methyl]oxetan-3-yl]-L-isoleucinate (229) 
This novel compound was prepared as follows.  
204 (104 mg, 0.31 mmol), In metal (145 mg, 1.26 
mmol) and 6 M HCl (0.31 mL, 1.86 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-L-Leu-OH (98 mg, 0.33 mmol), HOBt (8 mg, 0.05 mmol), NMM (75 µL, 0.68 
mmol), EDC.HCl (73 mg, 0.38 mmol) in EtOH (3.1 mL).  Work-up, followed by 
purification by repeat column chromatography (30   45% EtOAc in hexane; 2  
4% MeOH in CH2Cl2) provided 229 (92 mg, 54%) as a colourless oil.  Rf = 0.37 
(50% EtOAc in hexane); [α]  +9.1 (c 0.20, CHCl3); IR (film) 3314, 3034, 2960, 
2875, 1724, 1718, 1660, 1529, 1456, 1237, 1172, 975, 737, 697 cm-1; δH (400 MHz, 
CDCl3) 7.39 – 7.28 (10H, m, ArH), 6.58 – 6.52 (1H, m, CONH), 5.23 (1H, d, J = 
7.8, CbzNH), 5.12 (2H, s, CO2CH2Ph), 5.09 (2H, s, PhCH2OCONH), 4.35 (1H, d, J 
= 6.3, OCHH), 4.29 (1H, d, J = 6.3, OCHH), 4.23 – 4.14 (3H, m, OCHH, CHCH2), 
3.74 (1H, dd, J = 14.0, 5.7, NHCHH), 3.39 (1H, dd, J = 14.0, 5.0, NHCHH), 3.20 
(1H, d, J = 5.5, CHCO2Bn), 2.03 (1H, br s, NH), 1.75 – 1.60 (3H, m, CHHiPr, 
CHMe2, EtCHMe), 1.55 – 1.37 (2H, m, CHHiPr, CHHMe), 1.17 – 1.04 (1H, m, 
CHHMe), 0.97 – 0.81 (12H, m, CH3); δC (100 MHz, CDCl3) 176.1 (C=O), 172.9 
(C=O), 156.2 (C=O), 136.3 (C, Ar), 135.3 (C, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 
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128.7 (CH, Ar), 128.6 (CH, Ar), 128.3 (CH, Ar), 128.2 (CH, Ar), 79.8 (OCH2), 79.4 
(OCH2), 67.2 (2 x OCH2Ph), 60.3 (CHCO2Bn), 59.5 (C), 53.8 (CHCH2), 43.7 
(NHCH2), 41.7 (CH2
iPr), 39.0 (EtCHMe), 24.9 (CH2Me), 24.9 (CHMe2), 23.0 (CH3), 
22.1 (CH3), 16.0 (CH3), 11.7 (CH3); MS (ES
+) m/z 554 [M+H]+, 576 [M+Na]+; 
HRMS (ES+) calcd. for C31H44N3O6 [M+H]
+: 554.3225; found: 554.3210. 
 
Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-3-(1H-indol-3-
yl)propanamido]methyl]oxetan-3-yl]-L-valinate (230) 
This novel compound was prepared as follows.  
194 (100 mg, 0.31 mmol), In metal (147 mg, 
1.28 mmol) and 6 M HCl (0.31 mL, 1.86 
mmol) were reacted according to General 
Method A.  The crude amine was further reacted with Z-L-Trp-OH (109 mg, 0.32 
mmol), HOBt (8 mg, 0.05 mmol), NMM (75 µL, 0.68 mmol), EDC.HCl (72 mg, 
0.38 mmol) in EtOH (3.1 mL).  Work-up, followed by purification by column 
chromatography (50  70% EtOAc in hexane) provided 230 (38 mg, 20%) as oily 
white crystals.  M.p. 65 – 67 °C; Rf = 0.35 (70% EtOAc in hexane); [α]   +17.8 (c 
0.16, CHCl3); IR (film) 3318, 2961, 2875, 1718, 1665, 1508, 1504, 1457, 1233, 
1215, 1181, 1153, 974, 740, 698 cm-1; δH (400 MHz, CDCl3) 8.27 (1H, br s, indole 
NH), 7.66 (1H, d, J = 7.5, ArH), 7.39 – 7.28 (11H, m, ArH), 7.17 (1H, t, J = 7.3, 
ArH), 7.11 (1H, t, J = 7.3, ArH), 7.01 (1H, s, ArH), 6.11 – 6.05 (1H, m, CONH), 
5.53 (1H, d, J = 7.0, CbzNH), 5.13 (1H, d, J = 12.3, PhCHHOCONH), 5.09 (1H, d, J 
= 12.3, PhCHHOCONH), 5.04 (2H, s, CO2CH2Ph), 4.56 – 4.48 (1H, m, CHCH2), 
4.20 (1H, d, J = 6.5, OCHH), 4.00 (1H, d, J = 6.5, OCHH), 3.94 (1H, d, J = 6.5, 
OCHH), 3.86 (1H, d, J = 6.5, OCHH), 3.53 – 3.45 (1H, m, NHCHH), 3.42 – 3.33 
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(2H, m, NHCHH, CHCHH), 3.14 (1H, dd, J = 14.3, 7.9, CHCHH), 2.81 (1H, d, J = 
4.5, CHiPr), 1.81 – 1.64 (2H, m, CHMe2, NH), 0.74 (3H, d, J = 6.5, CH3), 0.64 (3H, 
d, J = 6.5, CH3); δC (100 MHz, CDCl3) 175.9 (C=O), 171.9 (C=O), 156.0 (C=O), 
136.4 (C, Ar), 135.3 (C, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.7 (CH, Ar), 128.6 
(CH, Ar), 128.3 (CH, Ar), 128.2 (CH, Ar), 127.3 (C, Ar), 123.2 (CH, Ar), 122.5 
(CH, Ar), 120.0 (CH, Ar), 119.0 (CH, Ar), 111.4 (CH, Ar), 110.5 (C, Ar), 79.6 
(OCH2), 79.4 (OCH2), 67.1 (2 x OCH2Ph), 60.8 (CH
iPr), 58.6 (C), 55.7 (CHCH2), 
43.6 (NHCH2), 31.8 (CHMe2), 28.8 (CHCH2), 19.3 (CH3), 17.9 (CH3), quarternary 
aryl carbon not observed; MS (ES+) m/z 613 [M+H]+, 635 [M+Na]+; HRMS (ES+) 
calcd. for C35H40N4NaO6 [M+Na]
+: 635.2840; found: 635.2839. 
 
Benzyl [3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-4-
(methylthio)butanamido]methyl]oxetan-3-yl]-L-valinate (231) 
This novel compound was prepared as follows.  
194 (101 mg, 0.31 mmol), In metal (145 mg, 1.26 
mmol) and 6 M HCl (0.31 mL, 1.86 mmol) were 
reacted according to General Method A.  The crude amine was further reacted with 
Z-L-Met-OH (92 mg, 0.32 mmol), HOBt (8 mg, 0.05 mmol), NMM (75 µL, 0.68 
mmol), EDC.HCl (72 mg, 0.38 mmol) in EtOH (3.10 mL).  Work-up, followed by 
purification by repeat column chromatography (40  50% EtOAc in heptane, then 2 
 4% MeOH in CH2Cl2) provided 231 (65 mg, 37%) as a colourless oil.  Rf = 0.33 
(60% EtOAc in hexane); [α]   +8.54 (c 0.24, CHCl3); IR (film) 3307, 2960, 2875, 
1724, 1663, 1526, 1498, 1456, 1238, 1180, 1151, 1052, 975, 741, 698 cm-1; δH (400 
MHz, CDCl3) 7.40 – 7.29 (10H, m, ArH), 6.63 – 6.57 (1H, m, CONH), 5.53 (1H, br 
d, J = 7.3, CbzNH), 5.16 – 5.09 (4H, m, CO2CH2Ph and PhCH2OCONH), 4.38 – 
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4.31 (2H, m, OCHH, CHCH2), 4.29 (1H, d, J = 6.5, OCHH), 4.21 (1H, d, J = 6.5, 
OCHH), 4.16 (1H, d, J = 6.5, OCHH), 3.75 (1H, dd, J = 13.9, 5.7, NHCHH), 3.43 
(1H, dd, J = 13.9, 5.0, NHCHH), 3.14 (1H, d, J = 5.3, CHiPr), 2.62 – 2.47 (2H, m, 
CH2), 2.16 – 1.91 (4H, m, CH2, CHMe2, NH), 2.09 (3H, s, SCH3), 0.94 (3H, d, J = 
6.8, CH3), 0.87 (3H, d, J = 6.8, CH3); δC (100 MHz, CDCl3) 176.1 (C=O), 171.8 
(C=O), 156.2 (C=O), 136.3 (C, Ar), 135.3 (C, Ar), 128.8 (CH, Ar), 128.8 (CH, Ar), 
128.7 (CH, Ar), 128.7 (CH, Ar), 128.4 (CH, Ar), 128.2 (CH, Ar), 79.6 (OCH2), 79.4 
(OCH2), 67.2 (2 x CH2), 61.1 (CH
iPr), 59.5 (C), 54.2 (CHCH2), 43.9 (NHCH2), 32.0 
(CHMe2), 31.7 (CH2), 30.2 (CH2), 19.6 (CH3), 18.0 (CH3), 15.3 (SCH3); MS (ES
+) 
m/z 558 [M+H]+, 580 [M+Na]+; HRMS (ES+) calcd. for C29H39N3NaO6S [M+Na]
+: 
580.2452; found: 580.2456. 
 
Benzyl [[3-[[(S)-2-[[(benzyloxy)carbonyl]amino]-3-
phenylpropanamido]methyl]oxetan-3-yl]-L-valyl]glycinate (235) 
This novel compound was prepared as 
follows.  207 (102 mg, 0.27 mmol), In 
metal (123 mg, 1.07 mmol) and 6 M HCl 
(0.27 mL, 1.62 mmol) were reacted according to General Method A.  The crude 
amine was further reacted with Z-L-Phe-OH (84 mg, 0.28 mmol), HOBt (6 mg, 0.04 
mmol), NMM (65 µL, 0.59 mmol), EDC.HCl (62 mg, 0.32 mmol) in EtOH (2.7 
mL).  Work-up, followed by purification by repeat column chromatography (65  
80% EtOAc in hexane; 0  6% MeOH in CH2Cl2) provided 235 (33 mg, 19%) as a 
colourless oil.  Rf = 0.27 (80% EtOAc in hexane); [α]   +19.0 (c 0.16, CHCl3); IR 
(film) 3305, 2959, 2875, 1715, 1654, 1518, 1497, 1455, 1240, 1188, 970, 733, 696 
cm-1; δH (400 MHz, CDCl3) 7.50 (1H, br s, NH), 7.37 – 7.19 (13H, m, ArH), 7.17 – 
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7.14 (2H, m, ArH), 6.85 (1H, br s, NH), 5.48 (1H, d, J = 8.3, CbzNH), 5.16 – 5.09 
(2H, m, CO2CH2Ph), 5.06 – 4.99 (2H, m, PhCH2OCONH), 4.41 (1H, d, J = 6.8, 
OCHH), 4.39 – 4.26 (4H, m, OCHH, OCHH, CHBn, CHH), 4.20 (1H, d, J = 6.8, 
OCHH), 3.87 (1H, dd, J = 13.9, 7.5, CHH), 3.80 (1H, dd, J = 18.3, 3.8, CHH), 3.30 
(1H, dd, J = 13.9, 4.3, CHH), 3.23 (1H, d, J = 3.8, CHiPr), 3.07 (1H, dd, J = 13.8, 
7.0, CHHPh), 3.00 (1H, dd, J = 13.8, 7.3, CHHPh), 2.12 – 2.00 (1H, m, CHMe2), 
1.79 (1H, br s, NH), 0.98 (3H, d, J = 6.8, CH3), 0.89 (3H, d, J = 6.8, CH3); δC (100 
MHz, CDCl3) 175.0 (C=O), 172.4 (C=O), 171.3 (C=O), 156.3 (C=O), 136.6 (C, Ar), 
136.3 (C, Ar), 135.0 (C, Ar), 129.4 (CH, Ar), 128.8 (CH, Ar), 128.7 (CH, Ar), 128.7 
(CH, Ar), 128.4 (CH, Ar), 128.1 (CH, Ar), 127.1 (CH, Ar), 79.2 (OCH2), 78.5 
(OCH2), 67.5 (CO2CH2Ph), 67.1 (PhCH2OCONH), 62.6 (CH
iPr), 60.6 (C), 56.3 
(CHBn), 45.0 (CH2), 41.0 (CH2), 38.1 (CH2Ph), 31.8 (CHMe2), 19.7 (CH3), 18.0 
(CH3); MS (ES
+) m/z 631 [M+H]+, 653 [M+Na]+; HRMS (ES+) calcd. for 
C35H42N4NaO7 [M+Na]
+: 653.2946; found: 653.2929. 
 
Benzyl [2-[[1-(3-hydroxyoxetan-3-yl)-2-phenylethyl]amino]-2-
oxoethyl]carbamate (236) 
This novel compound was prepared using modified 
literature procedures.133,160  A suspension of 166 (302 mg, 
1.35 mmol) and 10% Pd/C (151 mg) in anhydrous MeOH 
(13.4 mL) was stirred under an atmosphere of hydrogen at rt for 22 h before it was 
filtered through Celite®, washed with MeOH and concentrated in vacuo to give the 
crude amine.  To this was added Z-Gly-OH (291 mg, 1.39 mmol), HOBt (31 mg, 
0.20 mmol), NMM (325 µL, 2.95 mmol) and EtOH (13.4 mL).  The reaction mixture 
was cooled in an ice-water bath before EDC.HCl (309 mg, 1.61 mmol) was added.  
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The reaction mixture was stirred at rt for 17 h before water (30 mL) was added and 
the precipitate formed was filtered under vacuum then washed with water and dried 
to afford 236 (336 mg, 65%) as a white solid.  M.p. 144 – 146 °C; Rf = 0.31 (100% 
EtOAc); IR (film) 3311, 3264, 2963, 2894, 1686, 1648, 1538, 1495, 1455, 1436, 
1258, 1139, 951, 749, 695 cm-1; δH (400 MHz, MeOD) 7.38 – 7.13 (10H, m, ArH), 
5.09 (2H, s, PhCH2O), 4.58 – 4.52 (2H, m, OCHH, CH), 4.47 (1H, d, J = 6.8, 
OCHH), 4.37 (1H, d, J = 7.0, OCHH), 4.30 (1H, d, J = 7.0, OCHH), 3.72 (1H, d, J = 
16.8, NHCHH), 3.63 (1H, d, J = 16.8, NHCHH), 2.90 (1H, dd, J = 13.8, 5.3, 
CHHPh), 2.70 (1H, dd, J = 13.8, 9.5, CHHPh); δC (75 MHz, MeOD) 172.3 (C=O), 
158.9 (C=O), 139.7 (C, Ar), 138.1 (C, Ar), 130.2 (CH, Ar), 129.5 (CH, Ar), 129.4 
(CH, Ar), 129.0 (CH, Ar), 128.9 (CH, Ar), 127.4 (CH, Ar), 83.5 (OCH2), 82.9 
(OCH2), 76.6 (C), 67.8 (PhCH2O), 57.1 (CH), 44.8 (NHCH2), 35.8 (CH2Ph); MS 
(ES+) m/z 407 [M+Na]+; HRMS (ES+) calcd. for C21H24N2NaO5 [M+Na]
+: 407.1577; 
found: 407.1575. 
 
Benzyl [2-[[2-[[1-(3-hydroxyoxetan-3-yl)-2-phenylethyl]amino]-2-
oxoethyl]amino]-2-oxoethyl]carbamate (238) 
This novel compound was prepared using 
modified literature procedures.133,160  A suspension 
of 166 (97 mg, 0.43 mmol) and 10% Pd/C (50 mg) 
in anhydrous MeOH (4.35 mL) was stirred under an atmosphere of hydrogen at rt for 
20 h before it was filtered through Celite®, washed with MeOH and concentrated in 
vacuo to give the crude amine.  To this was added Z-Gly-Gly-OH (119 mg, 0.45 
mmol), HOBt (11 mg, 0.07 mmol), NMM (105 µL, 0.95 mmol) and EtOH (11 mL).  
The reaction mixture was cooled in an ice-water bath before EDC.HCl (102 mg, 0.53 
Chapter 3: Experimental 
 
208 
mmol) was added.  The reaction mixture was stirred at rt for 20 h before water (20 
mL) was added and the solution was extracted with EtOAc (4 x 40 mL).  The 
combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo.  Purification by column chromatography (0  6% MeOH in EtOAc) 
provided 238 (142 mg, 74%) as a waxy white solid.  M.p. 61 – 62 °C; Rf = 0.20 (5% 
MeOH in EtOAc); IR (film) 3295, 2953, 2877, 1674, 1654, 1532, 1454, 1242, 1050, 
970, 737, 699 cm-1; δH (300 MHz, MeOD) 7.40 – 7.13 (10H, m, ArH), 5.15 (1H, d, J 
= 12.4, PhCHHO), 5.10 (1H, d, J = 12.4, PhCHHO), 4.60 (1H, d, J = 6.9, OCHH), 
4.54 (1H, dd, J = 9.8, 4.9, CH), 4.48 (1H, d, J = 6.9, OCHH), 4.40 (1H, d, J = 7.0, 
OCHH), 4.34 (1H, d, J = 7.0, OCHH), 3.86 (1H, d, J = 16.8, CONHCHH), 3.78 (2H, 
s, CbzNHCH2), 3.70 (1H, d, J = 16.8, CONHCHH), 2.92 (1H, dd, J = 13.8, 4.9, 
CHHPh), 2.74 (1H, dd, J = 13.8, 9.8, CHHPh), OH and NHs not observed; δC (100 
MHz, MeOD) 172.7 (C=O), 171.6 (C=O), 159.2 (C=O), 139.7 (C, Ar), 137.9 (C, 
Ar), 130.2 (CH, Ar), 129.5 (CH, Ar), 129.4 (CH, Ar), 129.1 (CH, Ar), 128.9 (CH, 
Ar), 127.4 (CH, Ar), 83.2 (OCH2), 82.9 (OCH2), 76.7 (C), 68.0 (PhCH2O), 57.2 
(CH), 45.1 (CbzNHCH2), 43.3 (CONHCH2), 35.6 (CH2Ph); MS (ES
+) m/z 464 
[M+Na]+; HRMS (ES+) calcd. for C23H27N3NaO6 [M+Na]
+: 464.1792; found: 
464.1796. 
 
[[3-(Aminomethyl)oxetan-3-yl]-L-valyl]glycine (249) 
This novel compound was prepared using a modified 
literature procedure.133  A suspension of 207 (47 mg, 
0.12 mmol) and 10% Pd/C (24 mg, 50% by wt) in 
MeOH (1.32 mL) was stirred under an atmosphere of hydrogen at rt for 16 h.  The 
mixture was filtered through Celite®, washed with MeOH and concentrated in vacuo.  
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The resultant solid was centrifuged in cold EtOH to give 249 (23 mg, 72%) as a 
white solid.  M.p. 183 – 185 °C (dec); [α]   –49.5 (c 0.20, MeOH); IR (film) 3314, 
2941, 2874, 2600, 1650, 1555, 1545, 1473, 1380 cm-1; δH (400 MHz, DMSO-d6) 
8.10 – 8.05 (1H, m, CONH), 4.46 (1H, d, J = 6.5, OCHH), 4.31 (1H, d, J = 6.8, 
OCHH), 4.27 – 4.23 (2H, m, OCHH), 3.60 (1H, dd, J = 16.7, 6.8, CHHCO2H), 3.33 
(1H, dd, J = 16.7, 4.5, CHHCO2H), 3.24 (1H, d, J = 13.3, NH2CHH), 3.09 (1H, d, J 
= 13.3, NH2CHH), 2.88 (1H, d, J = 5.5, CH
iPr), 1.87 – 1.75 (1H, m, CHMe2), 0.94 – 
0.87 (6H, m, CH3), NH, NH2 and CO2H not observed; δC (100 MHz, DMSO-d6) 
174.1 (C=O), 173.1 (C=O), 78.4 (OCH2), 78.1 (OCH2), 62.7 (CH
iPr), 58.6 (C), 43.0 
(CH2), 42.9 (CH2), 31.3 (CHMe2), 19.4 (CH3), 18.6 (CH3); MS (ES
+) m/z 260 
[M+H]+, 282 [M+Na]+; HRMS (ES+) calcd. for C11H22N3O4 [M+H]
+: 260.1605; 
found: 260.1612. 
 
General Method B: Deprotection134 
A suspension of the protected oxetane tripeptide and 10% Pd/C (20% by wt) in 
MeOH was stirred under an atmosphere of hydrogen at rt for 18 h then filtered 
through Celite®, washed with MeOH and concentrated in vacuo to give the product. 
 
[3-[(2-Aminoacetamido)methyl]oxetan-3-yl]-L-valine (250) 
This novel compound was prepared as follows.  216 
(73 mg, 0.15 mmol) and 10% Pd/C (15 mg) in MeOH 
(3 mL) were reacted according to General Method B 
to give 250 (33 mg, 84%) as a cream oily solid.  [α]   +12.3 (c 0.20, MeOH); IR 
(film) 3266, 3077, 2963, 2879, 1682, 1568, 1557, 1470, 1436, 1393 cm-1; δH (500 
MHz, D2O) 4.68 (1H, d, J = 7.3, OCHH), 4.62 (1H, d, J = 7.3, OCHH), 4.50 (1H, d, 
25 
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J = 7.3, OCHH), 4.43 (1H, d, J = 7.3, OCHH), 3.86 (2H, s, NH2CH2), 3.79 (1H, d, J 
= 14.3, CONHCHH), 3.65 (1H, d, J = 14.3, CONHCHH), 3.13 (1H, d, J = 5.2, 
CHiPr), 1.98 – 1.87 (1H, m, CHMe2), 0.95 (3H, d, J = 7.6, CH3), 0.94 (3H, d, J = 
7.6, CH3), NH2, NHs and CO2H not observed; δC (125 MHz, D2O) 181.2 (C=O), 
167.9 (C=O), 79.0 (OCH2), 78.8 (OCH2), 64.2 (CH
iPr), 59.9 (C), 43.3 (CONHCH2), 
40.5 (NH2CH2), 31.3 (CHMe2), 18.3 (CH3), 18.2 (CH3); MS (ES
+) m/z 260 [M+H]+, 
282 [M+Na]+; HRMS (ES+) calcd. for C11H22N3O4 [M+H]
+: 260.1605; found: 
260.1605. 
 
[3-[((S)-2-Amino-3-phenylpropanamido)methyl]oxetan-3-yl]-L-valine (251) 
This novel compound was prepared as follows.  225 
(89 mg, 0.16 mmol) and 10% Pd/C (18 mg) in MeOH 
(3.1 mL) were reacted according to General Method 
B to give 251 (52 mg, 96%) as a pale yellow solid.  M.p. 165 – 167 °C (dec); [α]  
+41.3 (c 0.18, MeOH); IR (film) 3045, 2958, 2890, 1666, 1559, 1512, 1455, 1436, 
1390, 974, 742, 697 cm-1; δH (500 MHz, DMSO-d6) 8.23 – 8.19 (1H, m, CONH), 
7.31 – 7.27 (2H, m, ArH), 7.25 – 7.20 (3H, m, ArH), 4.35 (1H, d, J = 6.2, OCHH), 
4.29 (1H, d, J = 6.3, OCHH), 4.17 (1H, d, J = 6.3, OCHH), 4.13 (1H, d, J = 6.2, 
OCHH), 3.67 – 3.63 (1H, m, CHBn), 3.49 – 3.40 (2H, m, NHCH2), 3.06 (1H, d, J = 
5.7, CHiPr), 3.02 (1H, dd, J = 13.6, 5.2, CHHPh), 2.75 (1H, dd, J = 13.6, 8.0, 
CHHPh), 1.87 – 1.79 (1H, m, CHMe2), 0.88 (3H, d, J = 6.8, CH3), 0.83 (3H, d, J = 
6.8, CH3), NH2, NH and CO2H not observed; δC (125 MHz, DMSO-d6) 177.1 (C=O), 
172.8 (C=O), 137.4 (C, Ar), 129.4 (CH, Ar), 128.3 (CH, Ar), 126.5 (CH, Ar), 78.4 
(OCH2), 78.2 (OCH2), 60.7 (CH
iPr), 59.7 (C), 55.3 (CHBn), 43.4 (NHCH2), 38.9 
26 
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(CH2Ph), 31.1 (CHMe2), 19.4 (CH3), 18.0 (CH3); MS (ES
+) m/z 350 [M+H]+, 372 
[M+Na]+; HRMS (ES+) calcd. for C18H28N3O4 [M+H]
+: 350.2074; found: 350.2070. 
 
[3-[((S)-2-Amino-3-phenylpropanamido)methyl]oxetan-3-yl]-L-isoleucine (252) 
This novel compound was prepared as follows.  226 
(91 mg, 0.15 mmol) and 10% Pd/C (18 mg) in MeOH 
(3.1 mL) were reacted according to General Method B 
to give 252 (54 mg, 96%) as a pale orange solid.  M.p. 162 – 164 °C (dec); [α]   
+43.2 (c 0.18, MeOH); IR (film) 3313, 3030, 2958, 2874, 1670, 1560, 1555, 1497, 
1453, 1437, 1387, 972, 742, 696 cm-1; δH (500 MHz, DMSO-d6) 8.20 (1H, br t, J = 
5.4, CONH), 7.31 – 7.26 (2H, m, ArH), 7.25 – 7.18 (3H, m, ArH), 4.34 (1H, d, J = 
6.2, OCHH), 4.31 (1H, d, J = 6.3, OCHH), 4.18 (1H, d, J = 6.3, OCHH), 4.13 (1H, 
d, J = 6.2, OCHH), 3.61 (1H, dd, J = 7.8, 5.4, CHBn), 3.48 – 3.40 (2H, m, NHCH2), 
3.10 (1H, d, J = 5.5, CHCO2H), 3.00 (1H, dd, J = 13.6, 5.4, CHHPh), 2.74 (1H, dd, J 
= 13.6, 7.8, CHHPh), 1.59 – 1.44 (2H, m, EtCHMe, CHHMe), 1.12 – 1.01 (1H, m, 
CHHMe), 0.87 – 0.79 (6H, m, CH3), NH2, NH and CO2H not observed; δC (125 
MHz, DMSO-d6) 177.2 (C=O), 173.2 (C=O), 137.6 (C, Ar), 129.3 (CH, Ar), 128.2 
(CH, Ar), 126.4 (CH, Ar), 78.5 (OCH2), 78.2 (OCH2), 60.1 (CHCO2H), 59.8 (C), 
55.4 (CHBn), 43.4 (NHCH2), 39.7 (CH2Ph), 38.1 (EtCHMe), 24.5 (CH2Me), 15.7 
(CH3), 11.6 (CH3); MS (ES
+) m/z 364 [M+H]+, 386 [M+Na]+; HRMS (ES+) calcd. 
for C19H30N3O4 [M+H]
+: 364.2231; found: 364.2228.  A crystal for X-ray analysis 
was grown from methanol. 
Crystal Data for C19H29N3O4 (M =366.65): triclinic, space group P1 (no. 1), a = 
8.4127(4) Å, b = 9.5002(5) Å, c = 13.3202(8) Å, α = 96.096(5)°, β = 104.312(5)°, 
γ = 90.121(4)°, V = 1025.27(10) Å3, Z = 2, T = 150(2) K, μ(CuKα) = 0.683 mm-1, 
26 
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Dcalc = 1.188 g/mm3, 19052 reflections measured (6.89 ≤ 2Θ ≤ 158.46), 8088 
unique (Rint = 0.0470, Rsigma = 0.0526) which were used in all calculations. The final 
R1 was 0.0506 (I > 2σ(I)) and wR2 was 0.1426 (all data). 
 
[3-[((S)-2-Aminopropanamido)methyl]oxetan-3-yl]-L-valine (253) 
This novel compound was prepared as follows.  227 
(53 mg, 0.11 mmol) and 10% Pd/C (11 mg) in MeOH 
(2.13 mL) were reacted according to General Method 
B to give 253 (29 mg, 100%) as a cream solid.  M.p. 113 – 114 °C; [α]   +31.5 (c 
0.16, MeOH); IR (film) 3245, 2960, 2876, 1672, 1558, 1539, 1468, 1393 cm-1; δH 
(400 MHz, D2O) 4.65 (1H, d, J = 7.0, OCHH), 4.60 (1H, d, J = 7.3, OCHH), 4.48 
(1H, d, J = 7.3, OCHH), 4.40 (1H, d, J = 7.0, OCHH), 4.03 (1H, q, J = 7.0, CHMe), 
3.75 (1H, d, J = 14.3, NHCHH), 3.59 (1H, d, J = 14.3, NHCHH), 3.07 (1H, d, J = 
5.3, CHiPr), 1.95 – 1.83 (1H, m, CHMe2), 1.52 (3H, d, J = 7.0, CH3, Ala), 0.93 (6H, 
d, J = 6.8, CH3, Val), NH2, NHs and CO2H not observed; δC (100 MHz, D2O) 182.3 
(C=O), 172.6 (C=O), 79.4 (OCH2), 79.2 (OCH2), 64.1 (CH
iPr), 59.7 (C), 49.4 
(CHMe), 43.6 (NHCH2), 31.5 (CHMe2), 18.5 (CH3, Va;), 18.2 (CH3, Val), 17.0 
(CH3, Ala); MS (ES
+) m/z 274 [M+H]+, 296 [M+Na]+; HRMS (ES+) calcd. for 
C12H24N3O4 [M+H]
+: 274.1761; found: 274.1769. 
 
[3-[((S)-2-Amino-3-methylbutanamido)methyl]oxetan-3-yl]-L-valine (254) 
This novel compound was prepared as follows.  228 
(61 mg, 0.12 mmol) and 10% Pd/C (12 mg) in MeOH 
(2.32 mL) were reacted according to General Method 
B to give 254 (33 mg, 94%) as a cream solid.  M.p. 102 – 103 °C; [α]   +56.6 (c 0.16, 
25 
D 
25 
D 
Chapter 3: Experimental 
 
213 
MeOH); IR (film) 3244, 2960, 2875, 1680, 1555, 1540, 1467, 1393 cm-1; δH (400 
MHz, D2O) 4.66 (1H, d, J = 7.0, OCHH), 4.61 (1H, d, J = 7.3, OCHH), 4.48 (1H, d, 
J = 7.3, OCHH), 4.42 (1H, d, J = 7.0, OCHH), 3.77 (1H, d, J = 14.3, NHCHH), 3.75 
(1H, d, J = 6.0, CHiPr, H-Val), 3.61 (1H, d, J = 14.3, NHCHH), 3.09 (1H, d, J = 5.3, 
CHiPr, Val-OH), 2.28 – 2.15 (1H, m, CHMe2, H-Val), 1.95 – 1.83 (1H, m, CHMe2, 
Val-OH), 1.04 (3H, d, J = 7.0, CH3, H-Val), 1.03 (3H, d, J = 7.0, CH3, H-Val), 0.93 
(6H, d, J = 6.8, CH3, Val-OH), NH2, NHs and CO2H not observed; δC (100 MHz, 
D2O) 182.3 (C=O), 171.1 (C=O), 79.3 (OCH2), 79.1 (OCH2), 64.1 (CH
iPr, Val-OH), 
59.7 (C), 59.1 (CHiPr, H-Val), 43.8 (NHCH2), 31.5 (CHMe2, Val-OH), 30.0 
(CHMe2, H-Val), 18.5 (CH3, Val-OH), 18.2 (CH3, Val-OH), 17.8 (CH3, H-Val), 16.9 
(CH3, H-Val); MS (ES
+) m/z 302 [M+H]+, 324 [M+Na]+; HRMS (ES+) calcd. for 
C14H28N3O4 [M+H]
+: 302.2074; found: 302.2066. 
 
[3-[((S)-2-Amino-4-methylpentanamido)methyl]oxetan-3-yl]-L-isoleucine (255) 
This novel compound was prepared as follows.  229 
(90 mg, 0.16 mmol) and 10% Pd/C (18 mg) in MeOH 
(3.25 mL) were reacted according to General Method 
B to give 255 (53 mg, 99%) as a pale cream/orange solid.  M.p. 130 – 132 °C (dec); 
[α]   +36.6 (c 0.18, MeOH); IR (film) 3200, 2960, 2875, 1673, 1557, 1550, 1466, 
1391 cm-1; δH (500 MHz, D2O) 4.70 (1H, d, J = 7.4, OCHH), 4.64 (1H, d, J = 7.6, 
OCHH), 4.52 (1H, d, J = 7.6, OCHH), 4.45 (1H, d, J = 7.4, OCHH), 4.05 (1H, t, J = 
7.3, NH2CH), 3.77 (1H, d, J = 14.5, NHCHH), 3.66 (1H, d, J = 14.5, NHCHH), 3.32 
(1H, d, J = 4.6, CHCO2H), 1.81 – 1.65 (4H, m, CH2iPr, EtCHMe, CHMe2), 1.57 – 
1.48 (1H, m, CHHMe), 1.25 – 1.15 (1H, m, CHHMe), 0.98 (3H, d, J = 6.5, CH3), 
0.96 (3H, d, J = 6.5, CH3), 0.93 – 0.89 (6H, m, CH3), NH2, NHs and CO2H not 
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observed; δC (125 MHz, D2O) 179.9 (C=O), 171.5 (C=O), 78.3 (OCH2), 78.0 
(OCH2), 63.0 (CHCO2H), 60.4 (C), 52.1 (NH2CH), 43.2 (NHCH2), 39.8 (CH2
iPr), 
38.2 (EtCHMe), 25.5 (CH2Me), 23.9 (CHMe2), 21.7 (CH3), 20.9 (CH3), 14.8 (CH3), 
11.2 (CH3); MS (ES
+) m/z 330 [M+H]+, 352 [M+Na]+; HRMS (ES+) calcd. for 
C16H31N3NaO4 [M+Na]
+: 352.2207; found: 352.2208.  A crystal for X-ray analysis 
was grown from methanol. 
Crystal Data for C16H31N3O4 (M =329.44): triclinic, space group P1 (no. 1), a = 
8.5557(2) Å, b = 14.0932(5) Å, c = 16.3070(4) Å, α = 77.134(3)°, β = 81.935(2)°, 
γ = 80.958(2)°, V = 1881.70(9) Å3, Z = 4, T = 150(2) K, μ(CuKα) = 0.679 mm-1, 
Dcalc = 1.163 g/mm3, 34050 reflections measured (6.488 ≤ 2Θ ≤ 156.87), 14895 
unique (Rint = 0.0468, Rsigma = 0.0504) which were used in all calculations. The final 
R1 was 0.0644 (I > 2σ(I)) and wR2 was 0.1836 (all data). 
 
2-Amino-N-[1-(3-hydroxyoxetan-3-yl)-2-phenylethyl]acetamide (256) 
This novel compound was prepared as follows.  236 (50 mg, 
0.13 mmol) and 10% Pd/C (10 mg) in MeOH (2.6 mL) were 
reacted according to General Method B.  Purification by 
column chromatography (10  15% MeOH in CH2Cl2 + 0.5% NH3(aq)) provided 256 
(24 mg, 74%) as a colourless oil.  Rf = 0.25 (20% MeOH in CH2Cl2 + 0.5% NH3(aq)); 
IR (film) 3294, 3030, 2915, 2872, 1651, 1528, 1497, 1456, 1368, 1228, 967, 752, 
697 cm-1; δH (400 MHz, MeOD) 7.28 – 7.23 (4H, m, ArH), 7.21 – 7.15 (1H, m, 
ArH), 4.60 – 4.55 (2H, m, CH, OCHH), 4.49 (1H, d, J = 6.8, OCHH), 4.41 (1H, d, J 
= 7.0, OCHH), 4.35 (1H, d, J = 7.0, OCHH), 3.29 – 3.13 (2H, m, NH2CH2), 2.94 
(1H, dd, J = 13.8, 5.0, CHHPh), 2.71 (1H, dd, J = 13.8, 9.8, CHHPh), NH2, NH and 
OH not observed; δC (100 MHz, MeOD) 174.2 (C=O), 139.8 (C, Ar), 130.3 (CH, 
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Ar), 129.4 (CH, Ar), 127.5 (CH, Ar), 83.4 (OCH2), 83.0 (OCH2), 76.7 (C), 57.0 
(CH), 44.3 (NH2CH2), 35.8 (CH2Ph); MS (ES
+) m/z 251 [M+H]+, 273 [M+Na]+; 
HRMS (ES+) calcd. for C13H19N2O3 [M+H]
+: 251.1390; found: 251.1389. 
 
2-Amino-N-[2-[[1-(3-hydroxyoxetan-3-yl)-2-phenylethyl]amino]-2-
oxoethyl]acetamide (257) 
 This novel compound was prepared as follows.  238 
(64 mg, 0.14 mmol) and 10% Pd/C (13 mg) in MeOH 
(2.9 mL) were reacted according to General Method 
B.  Purification by column chromatography (20  25% MeOH in CH2Cl2 + 0.5% 
NH3(aq)) provided 257 (36 mg, 81%) as a colourless oil.  Rf = 0.33 (30% MeOH in 
CH2Cl2 + 0.5% NH3(aq)); IR (film) 3294, 3063, 2948, 2875, 1652, 1604, 1532, 1496, 
1454, 1363, 1219, 971, 753, 700 cm-1; δH (400 MHz, MeOD) 7.26 (4H, d, J = 4.3, 
ArH), 7.21 – 7.15 (1H, m, ArH), 4.60 – 4.55 (2H, m, CH, OCHH), 4.49 (1H, d, J = 
7.0, OCHH), 4.39 (1H, d, J = 7.0, OCHH), 4.34 (1H, d, J = 7.0, OCHH), 3.85 (1H, 
d, J = 16.6, CONHCHH), 3.74 (1H, d, J = 16.6, CONHCHH), 3.29 (2H, s, NH2CH2), 
2.92 (1H, dd, J = 13.9, 5.0, CHHPh), 2.71 (1H, dd, J = 13.9, 9.7, CHHPh), NH2, 
NHs and OH not observed; δC (100 MHz, MeOD) 175.8 (C=O), 171.6 (C=O), 139.8 
(C, Ar), 130.2 (CH, Ar), 129.4 (CH, Ar), 127.4 (CH, Ar), 83.4 (OCH2), 82.9 
(OCH2), 76.7 (C), 57.1 (CH), 45.0 (NH2CH2), 43.1 (CONHCH2), 35.7 (CH2Ph); MS 
(ES+) m/z 308 [M+H]+, 330 [M+Na]+; HRMS (ES+) calcd. for C15H21N3NaO4 
[M+Na]+: 330.1424; found: 330.1433. 
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Appendix I – Chiral HPLC analysis of (R)-193 and (S)-193 
(HPLC OD-H, 95 : 5 hexane : iPrOH, flow rate = 0.30 µL/min, λ = 254 nm) 
 
 
 
Chiral HPLC trace of the racemic mixture of (R)- and (S)-193. 
 
 
 +  
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Chiral HPLC trace of enantiomerically pure (S)-193. 
 
 
 
Chiral HPLC trace of enantiomerically pure (R)-193. 
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Appendix II – NOESY and ROESY spectra of 253 and 254 
 
 
ROESY spectrum of 253. 
 
NOESY spectrum of 253. 
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ROESY spectrum of 254. 
 
NOESY spectrum of 254. 
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Appendix III – 1H and DEPT Spectra of 255 
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1H NMR of 255. 
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DEPT spectrum of 255. 
 
